



STIC Search Report

EIC 3700

STIC Database Tracking Number: 198305

TO: James Swiger, III
Location: RND 6C04
Art Unit: 3733
Tuesday, August 15, 2006

Case Serial Number: 10/670142

From: Edward Hart
Location: EIC-3700
Randolph – 8B21
Phone: 571-272-2512

edward.hart@uspto.gov

Search Notes

Examiner Swiger, III,

Attached are the results for the above search you requested.

I searched HCAPLUS, including the foreign patents database WPIX.

If you feel that the results are not on target please feel free to contact me so that I may refine your search.

Sincerely,
Edward Hart
Technical Information Specialist
EIC –3700 8B21
U.S. Patent & Trademark Office
Phone: 571-272-2512
edward.hart@uspto.gov



RUSH
SEARCH REQUEST FORM

Access DB# 198305

Scientific and Technical Information Center

Requester's Full Name: James Swiger Examiner #: 81582 Date: 8/10/06
Art Unit: 3733 Phone Number 302-5557 Serial Number: 10/670,142
Mail Box and Bldg/Room Location: 6C04 Results Format Preferred (circle): PAPER DISK, E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Filamentous embolization device with expansible elements.

Inventors (please provide full names): George Greene, Gregory Cruise, Michael Constant
Brian Cox

Earliest Priority Filing Date: 10/4/1999

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

This is a cont. of 10/157,621

and a CIP of 3 others.

(* Restricted)

flexible, filamentous
wire elastic
loop, 3-D

* embolizing element

hydrophilic polymer (in part) (27)

hydrophilic polymeric
linkage element (31)

stretch resistant
non-releasably fixed (56)

expansible embolizing
element.



EDUARDO C. ROBERT
SUPERVISORY PATENT EXAMINER

Please Rush!

STAFF USE ONLY

Type of Search

Vendors and cost where applicable

=> file hcaplus, medline, embase, biosis, scisearch
 FILE 'HCAPLUS' ENTERED AT 09:19:11 ON 15 AUG 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 09:19:11 ON 15 AUG 2006

FILE 'EMBASE' ENTERED AT 09:19:11 ON 15 AUG 2006
 Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 09:19:11 ON 15 AUG 2006
 Copyright (c) 2006 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 09:19:11 ON 15 AUG 2006
 Copyright (c) 2006 The Thomson Corporation

=> d his

(FILE 'HOME' ENTERED AT 09:10:02 ON 15 AUG 2006)
 SET COST OFF

FILE 'HCAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:10:29 ON
 15 AUG 2006

		E GREENE G/AU
L1	449	S E3,E17,E23-24
		E GREENE GEORGE/AU
L2	22	S E3,E19-20
		E CRUISE G/AU
L3	57	S E3-E7
		E CONSTANT M/AU
L4	121	S E3,E23-24
		E COX B/AU
L5	2042	S E3,E14
		E COX BRIAN/AU
L6	385	S E3,E12-E13
		E TRAN T/AU
L7	1048	S E3
		E TRAN TERRANCE/AU
L8	1	S E3
L9	4110	S L1-L8
L10	23	S L9 AND (FILAMENT? OR EXPANSILE OR EMBOLIZATION)

Inventor's

FILE 'HCAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:19:11 ON
 15 AUG 2006

=> d ibib abs 110 tot

L10 ANSWER 1 OF 23 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:76526 HCAPLUS
 DOCUMENT NUMBER: 138:127010
 TITLE: Methods, polymeric materials and apparatus for
 deterring or preventing endoleaks following
 endovascular graft implantation
 INVENTOR(S): Rosenbluth, Robert F.; Cox, Brian J.;
 Lenker, Jay A.
 PATENT ASSIGNEE(S): Microvention, Inc., USA
 SOURCE: PCT Int. Appl., 42 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003007785	A2	20030130	WO 2002-US22242	20020712
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2004537353	T2	20041216	JP 2003-513399	20020712
PRIORITY APPLN. INFO.:			US 2001-906415	A 20010716
			WO 2002-US22242	W 20020712

AB Methods and apparatus for treating or preventing endoleaks after an endovascular graft (e.g., a stent, tubular graft, stent-graft, coated stent, covered stent, intravascular flow modifier or other endovascular implant that affects, limits or prevents blood flow into a vascular defect such as an aneurysm, arterio-venous fistula, arterio-venous malformation, vessel wall perforation, etc.) has been implanted in the vasculature of a human or veterinary patient. An **expansile** polymeric material, such as a swellable polymer (e.g., a hydrogel), a flexible or elastomeric polymer foam (e.g. silicone, polyurethane, etc.) or a carrier member (e.g. a coil, **filament**, wire, etc.) that carries a quantity of such **expansile** polymer is delivered into a perigraft space (i.e., space between the endovascular graft and the surrounding blood vessel wall) such that the polymeric material expands in situ to substantially fill the perigraft space or a portion thereof. The **expansile** polymeric material is delivered into the perigraft space through a catheter and/or cannula that is placed prior to, during or after the implantation of the endovascular graft. The invention includes an injector apparatus that is usable to deliver the **expansile** polymeric material through the wall of a previously implanted graft. After delivery into the perigraft space, the expanded polymeric material expands so as to fill all or an intended portion of the perigraft space in a manner that substantially prevents addnl. blood from leaking or flowing into such perigraft space. One type of blood-absorbing, porous, **expansile** polymeric material usable in this invention is a super-**expansile** hydrogel.

L10 ANSWER 2 OF 23 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:63661 HCAPLUS
 TITLE: Device and method for controlling injection of liquid embolic composition
 INVENTOR(S): Cragg, Andrew H.; Walker, Blair D.; Perl, John, II;
 Jones, Michael; **Greene, George Robert**;
 Wallace, George; Greff, Richard J.
 PATENT ASSIGNEE(S): Micro Therapeutics, Inc., USA
 SOURCE: U.S., Cont.-in-part of Ser. No. US 1997-953149, filed
 on 17 Oct 1997, now patented, Pa
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6511468	B1	20030128	US 1999-387274	19990831
JP 2001520085	T2	20011030	JP 2000-516716	19980923
JP 2003508107	T2	20030304	JP 2001-519825	20000807
US 2003040733	A1	20030227	US 2002-242469	20020913
US 2003225391	A1	20031204	US 2003-361851	20030211
US 6964657	B2	20051115		

PRIORITY APPLN. INFO.:
 US 1997-953149 A2 19971017
 WO 1998-US3344 W 19980923
 US 1999-387274 A 19990831
 US 2000-573154 A1 20000519
 WO 2000-US40603 W 20000807

AB A liquid embolic delivery system is provided for trapping an injected liquid embolic composition to prevent the liquid embolic from solidifying or otherwise passing outside of an **embolization** area. The delivery system includes a catheter for delivery of a liquid embolic composition and a containment member positioned at a distal end of the catheter which is shaped to trap the liquid embolic composition delivered through the lumen of the catheter. The containment member is formed as a brush, nest, sponge, swab, flexible sack, or other shape into and around which the liquid embolic composition is injected. The liquid embolic composition is trapped or meshes with the containment member during solidification containing the liquid embolic and preventing the embolic composition from passing into the blood stream.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 23 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:716008 HCAPLUS

DOCUMENT NUMBER: 137:237799

TITLE: Hydrogels that undergo volumetric expansion in response to changes in their environment and their methods of manufacture and use

INVENTOR(S): **Cruise, Gregory M.; Constant, Michael J.**

PATENT ASSIGNEE(S): Microvention, Inc., USA

SOURCE: PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002071994	A1	20020919	WO 2002-US5988	20020228
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,			

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2002176880 A1 20021128 US 2001-804935 20010313
 US 6878384 B2 20050412
 CA 2439925 AA 20020919 CA 2002-2439925 20020228
 EP 1372553 A1 20040102 EP 2002-750563 20020228
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 BR 2002008034 A 20040225 BR 2002-8034 20020228
 JP 2004528880 T2 20040924 JP 2002-570954 20020228
 CN 1617694 A 20050518 CN 2002-806384 20020228
 US 2005196426 A1 20050908 US 2005-90806 20050324
 PRIORITY APPLN. INFO.: US 2001-804935 A 20010313
 WO 2002-US5988 W 20020228

AB Hydrogels that expand volumetrically in response to a change in their environment (e.g., a change in pH or temperature) and their methods of manufacture and use. Generally, the hydrogels are prepared by forming a liquid reaction mixture that contains (a) monomer(s) and/or polymer(s) at least portion(s) of which are sensitive to environmental changes (e.g., changes in pH or temperature), (b) a crosslinker and (c) a polymerization initiator. If desired, a porosigen may be incorporated into the liquid reaction mixture to create pores. After the hydrogel is formed, the porosigen is removed to create pores in the hydrogel. The hydrogel may also be treated to cause it to assume a non-expanded volume in which it remains until a change in its environment causes it to expand. These hydrogels may be prepared in many forms including pellets, **filaments**, and particles. Biomedical uses of these hydrogels include applications wherein the hydrogel is implanted in the body of a patient and an environmental condition at the implantation site causes the hydrogel to expand *in situ*. A hydrogel was prepared by the polymerization of acrylamide, sodium acrylate, and N,N-methylene-bis-acrylamide. The hydrogel can be used for **embolization** of aneurysm.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 23 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:616378 HCAPLUS
 DOCUMENT NUMBER: 137:175033
 TITLE: Radiation cross-linked polymer hydrogels
 INVENTOR(S): **Cruise, Gregory M.**
 PATENT ASSIGNEE(S): Microvention, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 6 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002111392	A1	20020815	US 2001-783762	20010214
US 6537569	B2	20030325		
CA 2437870	AA	20020822	CA 2002-2437870	20020213
WO 2002064189	A2	20020822	WO 2002-US4166	20020213
WO 2002064189	A3	20021205		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1365704 A2 20031203 EP 2002-723139 20020213
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2002007249 A 20040309 BR 2002-7249 20020213

CN 1496241 A 20040512 CN 2002-804996 20020213

JP 2004520134 T2 20040708 JP 2002-563981 20020213

PRIORITY APPLN. INFO.: US 2001-783762 A 20010214

WO 2002-US4166 W 20020213

AB Radiation-crosslinked, biodegradable, synthetic hydrogels and their use in various applications, including certain medical applications wherein the hydrogel(s) are implanted on or in the body of a human or animal patient are described. Radiation-crosslinked, biodegradable, synthetic hydrogels of this invention may be prepared by irradiating monomers (e.g., ethylenically unsatd. hydrocarbons such as acrylic monomers and methacrylic monomers) or polymers, some or which are biodegradable or which contain biodegradable units or subunits. Specific medical applications of these radiation-crosslinked, biodegradable, synthetic hydrogels include applications wherein the hydrogel is used for hemostasis, tissue augmentation, tissue engineering, **embolization**, closure of vascular punctures or wounds and other medical applications. For example, a biodegradable PEG hydrogel was prepared from monomethoxypoly(ethylene glycol) (mPEG)-succinic acid-mPEG macromer. The mPEG dimer (17.05 g) was dissolved in 82.5 g of 50 mM sodium phosphate pH 5, the macromer solution was placed into syringes and the syringes were irradiated with 30 kGy of electron beam radiation.

L10 ANSWER 5 OF 23 MEDLINE on STN

ACCESSION NUMBER: 95238447 MEDLINE

DOCUMENT NUMBER: PubMed ID: 7721855

TITLE: Neurofilament protein heterotetramers as assembly intermediates.

AUTHOR: Cohlberg J A; Hajarian H; **Tran T**; Alipourjeddi P; Noveen A

CORPORATE SOURCE: Department of Chemistry and Biochemistry, California State University, Long Beach 90840, USA.

SOURCE: The Journal of biological chemistry, (1995 Apr 21) Vol. 270, No. 16, pp. 9334-9.

Journal code: 2985121R. ISSN: 0021-9258.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199505

ENTRY DATE: Entered STN: 5 Jun 1995

Last Updated on STN: 5 Jun 1995

Entered Medline: 23 May 1995

AB Evidence is presented for the existence of a soluble heterotetramer containing the low and middle molecular weight neurofilament (NF) proteins, NF-L and NF-M, and one containing the low and high molecular weight proteins, NF-L and NF-H, and for their role in **filament** assembly. When a mixture of either pair of proteins was renatured in 2 M urea, 20 mM Tris, pH 7.2, a new band representing a complex was observed

in native gel electrophoresis. No new band was observed with a mixture of NF-M and NF-H. Two-dimensional gel electrophoresis showed that treatment of the complexes with SDS caused them to dissociate into their constituent polypeptide chains. Native neurofilaments dissociated in 2 M urea into a mixture of LM and LH complexes. Titration of NF-L with NF-M indicated that complex formation was complete at an approximately equimolar ratio of the two proteins. The LM complex had a sedimentation coefficient, $s_{20,w}$, of 4.4 S, consistent with a tetrameric structure. Dialysis of a solution of the LM complex against 50 mM 4-morpholineethanesulfonic acid, 0.17 M NaCl, pH 6.25, led to the formation of 10-nm **filaments** in good yield. These results suggest that NF protein heterooligomers are intermediates in NF assembly and disassembly.

L10 ANSWER 6 OF 23 MEDLINE on STN
 ACCESSION NUMBER: 83268435 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 6876007
 TITLE: [Nonsurgical treatment of pulmonary arteriovenous aneurysms].
 Le traitement non chirurgical des anevrysmes arterio-veineux pulmonaires.
 AUTHOR: Remy J; Lemaitre L; Harry G; **Constant M**;
 Saint-Michel J; Wallaert B
 SOURCE: Journal de radiologie, (1983 Apr) Vol. 64, No. 4, pp. 263-74.
 Journal code: 7906266. ISSN: 0221-0363.
 PUB. COUNTRY: France
 DOCUMENT TYPE: (CASE REPORTS)
 Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: French
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 198309
 ENTRY DATE: Entered STN: 19 Mar 1990
 Last Updated on STN: 19 Mar 1990
 Entered Medline: 23 Sep 1983
 AB Four patients with single or multiple pulmonary arteriovenous aneurysms, including three with Rendu-Osler's disease, were treated by occlusion with metallic spirals of the supplying pedicles during angiography. Results are compared with those of 16 cases treated by the same method and reported in the literature. The technique and its therapeutic indications are discussed based on these 20 cases and a review of documented data concerning 502 other cases with these aneurysms.

L10 ANSWER 7 OF 23 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 ACCESSION NUMBER: 95341121 EMBASE
 DOCUMENT NUMBER: 1995341121
 TITLE: Spontaneous rupture of renal artery: Diagnosis by Doppler ultrasound and treatment by coil **embolization**.
 AUTHOR: Beale T.J.; Aref F.; **Tran T**.
 CORPORATE SOURCE: Department of Radiology, Central Middlesex Hospital, Acton Lane, Park Royal, London NW10 7NS, United Kingdom
 SOURCE: Journal of Interventional Radiology, (1995) Vol. 10, No. 3, pp. 99-102.
 ISSN: 0268-0882 CODEN: JIRAE8
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 014 Radiology
 018 Cardiovascular Diseases and Cardiovascular Surgery
 028 Urology and Nephrology

LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 5 Dec 1995
 Last Updated on STN: 5 Dec 1995

AB We report the case of a 27-year-old man who presented with renal colic. The diagnosis of spontaneous rupture of an intrarenal artery was made with Doppler ultrasound and successfully treated with coil **embolization**. This rare condition has an associated high mortality and is usually treated surgically. The diagnosis by Doppler ultrasound and subsequent treatment by coil **embolization** to our knowledge has not been described in the literature.

L10 ANSWER 8 OF 23 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 95133949 EMBASE
 DOCUMENT NUMBER: 1995133949
 TITLE: Neurofilament protein heterotetramers as assembly intermediates.
 AUTHOR: Cohlberg J.A.; Hajarian H.; **Tran T.**; Alipourjeddi P.; Noveen A.
 CORPORATE SOURCE: Dept. of Chemistry and Biochemistry, California State University, 1250 Bellflower Blvd., Long Beach, CA 90840, United States
 SOURCE: Journal of Biological Chemistry, (1995) Vol. 270, No. 16, pp. 9334-9339. .
 ISSN: 0021-9258 CODEN: JBCHA3
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 029 Clinical Biochemistry
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 16 May 1995
 Last Updated on STN: 16 May 1995

AB Evidence is presented for the existence of a soluble heterotetramer containing the low and middle molecular weight neurofilament (NF) proteins, NF-L and NF-M, and one containing the low and high molecular weight proteins, NF-L and NF-H, and for their role in **filament** assembly. When a mixture of either pair of proteins was renatured in 2 M urea, 20 mM Tris, pH 7.2, a new band representing a complex was observed in native gel electrophoresis. No new band was observed with a mixture of NF-M and NF-H. Two-dimensional gel electrophoresis showed that treatment of the complexes with SDS caused them to dissociate into their constituent polypeptide chains. Native neurofilaments dissociated in 2 M urea into a mixture of LM and LH complexes. Titration of NY-L with NF-M indicated that complex formation was complete at an approximately equimolar ratio of the two proteins. The LM complex had a sedimentation coefficient, $s(20,w)$, of 4.4 S, consistent with a tetrameric structure. Dialysis of a solution of the LM complex against 50 mM 4- morpholineethanesulfonic acid, 0.17 M NaCl, pH 6.25, led to the formation of 10-nm **filaments** in good yield. These results suggest that NF protein heterooligomers are intermediates in NF assembly and disassembly.

L10 ANSWER 9 OF 23 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 ACCESSION NUMBER: 2006:398224 BIOSIS
 DOCUMENT NUMBER: PREV200600398538
 TITLE: Vascular **embolization** with an expansible implant.
 AUTHOR(S): Greene,, George R. [Inventor]; Rosenbluth, Robert F. [Inventor]; **Cox, Brian J.** [Inventor]
 CORPORATE SOURCE: Costa Mesa, CA USA

ASSIGNEE: Microvention, Inc.
 PATENT INFORMATION: US 07029487 20060418
 SOURCE: Official Gazette of the United States Patent and Trademark
 Office Patents, (APR 18 2006)
 CODEN: OGUPE7. ISSN: 0098-1133.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 ENTRY DATE: Entered STN: 9 Aug 2006
 Last Updated on STN: 9 Aug 2006

AB A vascular implant formed of a compressible foam material has a compressed configuration from which it is expansible into a configuration substantially conforming to the shape and size of a vascular site to be embolized. Preferably, the implant is formed of a hydrophilic, macroporous foam material, having an initial configuration of a scaled-down model of the vascular site, from which it is compressible into the compressed configuration. The implant is made by scanning the vascular site to create a digitized scan data set; using the scan data set to create a three-dimensional digitized virtual model of the vascular site; using the virtual model to create a scaled-down physical mold of the vascular site; and using the mold to create a vascular implant in the form of a scaled-down model of the vascular site. To embolize a vascular site, the implant is compressed and passed through a microcatheter, the distal end of which has been passed into a vascular site. Upon entering the vascular site, the implant expands in situ substantially to fill the vascular site. A retention element is contained within the microcatheter and has a distal end detachably connected to the implant. A flexible, tubular deployment element is used to pass the implant and the retention element through the microcatheter, and then to separate the implant from the retention element when the implant has been passed out of the microcatheter and into the vascular site.

L10 ANSWER 10 OF 23 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2006:356343 BIOSIS
 DOCUMENT NUMBER: PREV200600362284
 TITLE: Method of manufacturing **expansile filamentous embolization** devices.
 AUTHOR(S): Greene,, George R. [Inventor]; **Cruise, Gregory M.** [Inventor]; **Constant, Michael** [Inventor]; **Cox, Brian J.** [Inventor]; **Tran, Terrance** [Inventor]
 CORPORATE SOURCE: Costa Mesa, CA USA
 ASSIGNEE: Microvention Inc.
 PATENT INFORMATION: US 07014645 20060321
 SOURCE: Official Gazette of the United States Patent and Trademark
 Office Patents, (MAR 21 2006)
 CODEN: OGUPE7. ISSN: 0098-1133.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 ENTRY DATE: Entered STN: 19 Jul 2006
 Last Updated on STN: 19 Jul 2006

AB An **embolization** device for occluding a body cavity includes one or more elongated, expansible, hydrophilic embolizing elements non-releasably carried along the length of an elongated **filamentous** carrier that is preferably made of a very thin, highly flexible **filament** or microcoil of nickel/titanium alloy. At least one **expansile** embolizing element is non-releasably attached to the carrier. A first embodiment includes a plurality of embolizing elements fixed to the carrier at spaced-apart intervals along

its length. In second, third and fourth embodiments, an elongate, continuous, coaxial embolizing element is non-releasably fixed to the exterior surface of the carrier, extending along a substantial portion of the length of the carrier proximally from a distal tip, and optionally includes a luminal reservoir for delivery of therapeutic agents. Exemplary methods for making these devices include skewering and molding the embolizing elements. In any of the embodiments, the embolizing elements may be made of a hydrophilic, macro-porous, polymeric, hydrogel foam material. In the second, third and fourth embodiments, the elongate embolizing element is preferably made of a porous, environmentally-sensitive, **expansile** hydrogel, which can optionally be made biodegradable and/or bioresorbable, having a rate of expansion that changes in response to a change in an environmental parameter, such as the pH or temperature of the environment.

L10 ANSWER 11 OF 23 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2006:134677 BIOSIS
 DOCUMENT NUMBER: PREV200600145111
 TITLE: Hydrogels that undergo volumetric expansion in response to changes in their environment and their methods of manufacture and use.
 AUTHOR(S): **Cruise, Gregory M.** [Inventor]; **Constant, Michael J.** [Inventor]
 CORPORATE SOURCE: Rancho Santa Margarita, CA USA
 ASSIGNEE: MicroVention, Inc.
 PATENT INFORMATION: US 06878384 20050412
 SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (APR 12 2005)
 CODEN: OGUPE7. ISSN: 0098-1133.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 ENTRY DATE: Entered STN: 22 Feb 2006
 Last Updated on STN: 22 Feb 2006

AB Hydrogels that expand volumetrically in response to a change in their environment (e.g., a change in pH or temperature) and their methods of manufacture and use. Generally, the hydrogels are prepared by forming a liquid reaction mixture that contains a) monomer(s) and/or polymer(s) at least portion(s) of which are sensitive to environmental changes (e.g., changes in pH or temperature), b) a crosslinker and c) a polymerization initiator. If desired, a porosigen may be incorporated into the liquid reaction mixture to create pores. After the hydrogel is formed, the porosigen is removed to create pores in the hydrogel. The hydrogel may also be treated to cause it to assume a non-expanded volume in which it remains until a change in its environment causes it to expand. These hydrogels may be prepared in many forms including pellets, **filaments**, and particles. Biomedical uses of these hydrogels include applications wherein the hydrogel is implanted in the body of a patient and an environmental condition at the implantation site causes the hydrogel to expand in situ.

L10 ANSWER 12 OF 23 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2004:151538 BIOSIS
 DOCUMENT NUMBER: PREV200400154543
 TITLE: Mechanism for the deployment of endovascular implants.
 AUTHOR(S): Ferrera, David A. [Inventor, Reprint Author]; **Greene, George R. Jr.** [Inventor]; **Cox, Brian J.** [Inventor]; Rosenbluth, Robert F. [Inventor]

CORPORATE SOURCE: ASSIGNEE: MicroVention, Inc.
 PATENT INFORMATION: US 6689141 20040210
 SOURCE: Official Gazette of the United States Patent and Trademark
 Office Patents, (Feb 10 2004) Vol. 1279, No. 2.
<http://www.uspto.gov/web/menu/patdata.html>. e-file.
 ISSN: 0098-1133 (ISSN print).

DOCUMENT TYPE: Patent
 LANGUAGE: English
 ENTRY DATE: Entered STN: 17 Mar 2004
 Last Updated on STN: 17 Mar 2004

AB A mechanism for the deployment of a **filamentous** endovascular device includes a flexible deployment tube having an open proximal end, and a coupling element attached to the proximal end of the endovascular device. The deployment tube includes a distal section terminating in an open distal end, with a lumen defined between the proximal and distal ends. A retention sleeve is fixed around the distal section and includes a distal extension extending a short distance past the distal end of the deployment tube. The endovascular device is attached to the distal end of the deployment tube by fixing the retention sleeve around the coupling element, so that the coupling element is releasably held within the distal extension of the deployment tube. In use, the deployment tube, with the implant attached to its distal end, is passed intravascularly through a microcatheter to a target vascular site until the endovascular device is located within the site. To detach the endovascular device from the deployment tube, a liquid is injected through the lumen of the deployment tube so as to apply pressure to the upstream side of the coupling element, which is thus pushed out of the retention sleeve by the fluid pressure. The coupling element may include an internal or peripheral purge passage that allows air to be purged from the microcatheter prior to the intravascular passage of the endovascular device.

L10 ANSWER 13 OF 23 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:400129 BIOSIS
 DOCUMENT NUMBER: PREV200300400129
 TITLE: **Filamentous** embolic device with **expansile** elements.

AUTHOR(S): **Greene, George R. Jr.** [Inventor, Reprint Author];
Cruise, Gregory M. [Inventor]; **Constant, Michael** [Inventor]; **Cox, Brian J.** [Inventor]

CORPORATE SOURCE: Mission Viejo, CA, USA
 ASSIGNEE: Microvention, Inc., Aliso Viejo, CA, USA

PATENT INFORMATION: US 6602261 20030805
 SOURCE: Official Gazette of the United States Patent and Trademark
 Office Patents, (Aug 5 2003) Vol. 1273, No. 1.
<http://www.uspto.gov/web/menu/patdata.html>. e-file.
 ISSN: 0098-1133 (ISSN print).

DOCUMENT TYPE: Patent
 LANGUAGE: English
 ENTRY DATE: Entered STN: 27 Aug 2003
 Last Updated on STN: 27 Aug 2003

AB An **embolization** device includes one or more expansible, hydrophilic embolizing elements non-releasably carried along the length of a **filamentous** carrier that is preferably made of a very thin, highly flexible **filament** or microcoil of nickel/titanium alloy. At least one **expansile** embolizing element is non-releasably attached to the carrier. A first embodiment includes a plurality of embolizing elements fixed to the carrier at spaced-apart intervals along its length. In a second embodiment, an elongate, continuous, coaxial

embolizing element is non-releasably fixed to the exterior surface of the carrier, extending along a substantial portion of the length of the carrier proximally from a distal tip. In either of the embodiments, the embolizing elements may be made of a hydrophilic, macroporous, polymeric, hydrogel foam material. In the second embodiment, the elongate embolizing element is preferably made of a porous, environmentally-sensitive, **expansile** hydrogel that expands, after a predetermined time delay, in response to a change in an environmental parameter, such as pH or temperature.

L10 ANSWER 14 OF 23 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:196958 BIOSIS
 DOCUMENT NUMBER: PREV200300196958
 TITLE: Radiation cross-linked hydrogels.
 AUTHOR(S): **Cruise, Gregory M.** [Inventor, Reprint Author]
 CORPORATE SOURCE: Rancho Santa Margarita, CA, USA
 ASSIGNEE: MicroVention, Inc.
 PATENT INFORMATION: US 6537569 20030325
 SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Mar 25 2003) Vol. 1268, No. 4.
<http://www.uspto.gov/web/menu/patdata.html>. e-file.
 ISSN: 0098-1133 (ISSN print).
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 ENTRY DATE: Entered STN: 16 Apr 2003
 Last Updated on STN: 16 Apr 2003

AB Radiation-crosslinked, biodegradable, synthetic hydrogels and their use in various applications, including certain medical applications wherein the hydrogel(s) are implanted on or in the body of a human or animal patient. Radiation-crosslinked, biodegradable, synthetic hydrogels of this invention may be prepared by irradiating monomers (e.g., ethylenically unsaturated hydrocarbons such as acrylic monomers and methacrylic monomers) or polymers, some or which are biodegradable or which contain biodegradable units or subunits. Specific medical applications of these radiation-crosslinked, biodegradable, synthetic hydrogels include applications wherein the hydrogel is used for hemostasis, tissue augmentation, tissue engineering, **embolization**, closure of vascular punctures or wounds and other medical applications.

L10 ANSWER 15 OF 23 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:85838 BIOSIS
 DOCUMENT NUMBER: PREV200300085838
 TITLE: Vascular **embolization** with an expansible implant.
 AUTHOR(S): **Greene, George R. Jr.** [Inventor, Reprint Author];
 Rosenbluth, Robert F. [Inventor]; **Cox, Brian J.** [Inventor]
 CORPORATE SOURCE: ASSIGNEE: MicroVention, Aliso Viejo, CA, USA
 PATENT INFORMATION: US 6500190 20021231
 SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Dec 31 2002) Vol. 1265, No. 5.
<http://www.uspto.gov/web/menu/patdata.html>. e-file.
 ISSN: 0098-1133 (ISSN print).
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 ENTRY DATE: Entered STN: 6 Feb 2003
 Last Updated on STN: 6 Feb 2003

AB A vascular implant formed of a compressible foam material has a compressed

configuration from which it is expansible into a configuration substantially conforming to the shape and size of a vascular site to be embodied. Preferably, the implant is formed of a hydrophobic, macro porous foam material, having an initial configuration of a scaled-down model of the vascular site, from which it is compressible into the compressed configuration. The implant is made by scanning the vascular site to create a digitized scan data set; using the scan data set to create a three-dimensional digitized virtual model of the vascular site; using the virtual model to create a scaled-down physical mold of the vascular site; and using the mold to create a vascular implant in the form of a scaled-down model of the vascular site. To embolism a vascular site, the implant is compressed and passed through a micro catheter, the distal end of which has been passed into a vascular site. Upon entering the vascular site, the implant expands in situ substantially to fill the vascular site. A retention element is contained within the micro catheter and has a distal end detachably connected to the implant. A flexible, tubular deployment element is used to pass the implant and the retention element through the micro catheter, and then to separate the implant from the retention element when the implant has been passed out of the micro catheter and into the vascular site.

L10 ANSWER 16 OF 23 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:314032 BIOSIS
 DOCUMENT NUMBER: PREV200200314032
 TITLE: Apparatus and method for vascular **embolization**.
 AUTHOR(S): Rosenbluth, Robert F. [Inventor, Reprint author]; **Cox, Brian J.** [Inventor]; Green, George R., Jr. [Inventor]
 CORPORATE SOURCE: Laguna Niguel, CA, USA
 ASSIGNEE: MicroVention, Inc.
 PATENT INFORMATION: US 6375669 20020423
 SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Apr. 23, 2002) Vol. 1257, No. 4.
<http://www.uspto.gov/web/menu/patdata.html>. e-file.
 CODEN: OGUPE7. ISSN: 0098-1133.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 ENTRY DATE: Entered STN: 29 May 2002
 Last Updated on STN: 29 May 2002

AB Apparatus for vascular **embolization**, deployable through a microcatheter, includes a flexible, elongate deployment tube dimensioned for insertion through the microcatheter, and a **filamentous** embolic device releasably attached to the distal end of the tube. The embolic device is controllably transformable from a soft, compliant state to a rigid or semi-rigid state. The embolic device may include a polymeric material that is transformable by contact with vascular blood or with a liquid that is cooler than vascular blood, or it may include a metallic material that is transformable by electrolytic corrosion. The embolic device may be a continuous **filamentous** polymeric extrusion; an elongate microcoil filled with polymeric material; an elongate, multi-segmented chain including polymeric interconnecting portions; or an elongate chain of metal segments that are fused together by electrolytic corrosion. An aneurysm is embolized with this apparatus by deploying a microcatheter so that its distal end is adjacent the aneurysm; deploying the embolic device through the microcatheter and into the aneurysm so that the embolic device forms a web-like mass in the aneurysm; and transforming the embolic device from its soft, compliant state to its rigid or semi-rigid state. The embolic device is advantageously deployed by releasably attaching it to a flexible, elongate

deployment tube that is passed through the microcatheter, and then detaching the embolic device from the tube when the embolic device is suitably situated.

L10 ANSWER 17 OF 23 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2001:561229 BIOSIS
DOCUMENT NUMBER: PREV200100561229
TITLE: Methods for embolizing a target vascular site.
AUTHOR(S): **Greene, George R., Jr.** [Inventor, Reprint author]; **Rosenbluth, Robert F.** [Inventor]; **Cox, Brian J.** [Inventor]
CORPORATE SOURCE: Costa Mesa, CA, USA
ASSIGNEE: MicroVention, Inc.
PATENT INFORMATION: US 6299619 20011009
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Oct. 9, 2001) Vol. 1251, No. 2. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 5 Dec 2001
Last Updated on STN: 25 Feb 2002

AB An **embolization** device includes a plurality of highly-expandible embolizing elements disposed at spaced intervals along a **filamentous** carrier. In a preferred embodiment, the carrier is a suitable length of very thin, highly flexible **filament** of nickel/titanium alloy. The embolizing elements are separated from each other on the carrier by radiopaque spacers in the form of highly flexible microcoils made of platinum or platinum/tungsten alloy. In a preferred embodiment, the embolizing elements are made of a hydrophilic, macroporous, polymeric, hydrogen foam material. The device is particularly suited for embolizing a vascular site such as an aneurysm. The **embolization** bodies have an initial configuration in the form of small, substantially cylindrical "micropellets" of small enough outside diameter to fit within a microcatheter. The bodies are hydrophilically expandible into an expanded configuration in which they substantially conform to and fill the vascular site while connected to the carrier. A method for embolizing a vascular site using this device includes the steps of: (a) passing a microcatheter intravascularly so that its distal end is in a vascular site; (b) providing a vascular **embolization** device comprising a plurality of highly expandible embolizing elements carried on a **filamentous** carrier and separated from each other on the carrier by microcoil spacers; (c) passing the **embolization** device through the microcatheter so that it emerges from the distal end of the microcatheter into the vascular site; and (d) expanding the embolizing elements in situ substantially to fill the vascular site while retaining the embolizing elements on the carrier. Preferably, the method also includes the step of deploying a vaso-occlusive device in the vascular site, or an intravascular device in a blood vessel adjacent the vascular site, before **embolization** device is passed through the microcatheter.

L10 ANSWER 18 OF 23 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2001:542166 BIOSIS
DOCUMENT NUMBER: PREV200100542166
TITLE: **Filamentous** embolic device with expandible elements.
AUTHOR(S): **Greene, George R., Jr.** [Inventor, Reprint

author]; Rosenbluth, Robert F. [Inventor]; **Cox, Brian J.** [Inventor]
 CORPORATE SOURCE: Costa Mesa, CA, USA
 ASSIGNEE: MicroVention, Inc.
 PATENT INFORMATION: US 6238403 20010529
 SOURCE: Official Gazette of the United States Patent and Trademark
 Office Patents, (May 29, 2001) Vol. 1246, No. 5. e-file.
 CODEN: OGUPE7. ISSN: 0098-1133.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 ENTRY DATE: Entered STN: 21 Nov 2001
 Last Updated on STN: 25 Feb 2002

AB An **embolization** device includes a plurality of highly-expandible embolizing elements disposed at spaced intervals along a **filamentous** carrier. In a preferred embodiment, the carrier is a suitable length of very thin, highly flexible **filament** of nickel/titanium alloy. The embolizing elements are separated from each other on the carrier by radiopaque spacers in the form of highly flexible microcoils made of platinum or platinum/tungsten alloy. In a preferred embodiment, the embolizing elements are made of a hydrophilic, macroporous, polymeric, hydrogel foam material. The device is particularly suited for embolizing a vascular site such as an aneurysm. The **embolization** bodies have an initial configuration in the form of small, substantially cylindrical "micropellets" of small enough outside diameter to fit within a microcatheter. The bodies are hydrophilically expandible into an expanded configuration in which they substantially conform to and fill the vascular site while connected to the carrier. A method for embolizing a vascular site using this device includes the steps of: (a) passing a microcatheter intravascularly so that its distal end is in a vascular site; (b) providing a vascular **embolization** device comprising a plurality of highly expandible embolizing elements carried on a **filamentous** carrier and separated from each other on the carrier by microcoil spacers; (c) passing the **embolization** device through the microcatheter so that it emerges from the distal end of the microcatheter into the vascular site; and (d) expanding the embolizing elements in situ substantially to fill the vascular site.

L10 ANSWER 19 OF 23 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2001:280800 BIOSIS
 DOCUMENT NUMBER: PREV200100280800
 TITLE: Vascular **embolization** with an expandible implant.
 AUTHOR(S): Greene, George R. [Inventor]; Rosenbluth, Robert F. [Inventor]; **Cox, Brian J.** [Inventor]
 CORPORATE SOURCE: ASSIGNEE: MicroVention, Inc.
 PATENT INFORMATION: US 6165193 20001226
 SOURCE: Official Gazette of the United States Patent and Trademark
 Office Patents, (Dec. 26, 2000) Vol. 1241, No. 4. e-file.
 CODEN: OGUPE7. ISSN: 0098-1133.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 ENTRY DATE: Entered STN: 13 Jun 2001
 Last Updated on STN: 19 Feb 2002

AB A vascular implant formed of a compressible foam material has a compressed configuration from which it is expandible into a configuration substantially conforming to the shape and size of a vascular site to be embolized. Preferably, the implant is formed of a hydrophilic, macroporous foam material, having an initial configuration of a

scaled-down model of the vascular site, from which it is compressible into the compressed configuration. The implant is made by scanning the vascular site to create a digitized scan data set; using the scan data set to create a three-dimensional digitized virtual model of the vascular site; using the virtual model to create a scaled-down physical mold of the vascular site; and using the mold to create a vascular implant in the form of a scaled-down model of the vascular site. To embolize a vascular site, the implant is compressed and passed through a microcatheter, the distal end of which has been passed into a vascular site. Upon entering the vascular site, the implant expands in situ substantially to fill the vascular site. A retention element is contained within the microcatheter and has a distal end detachably connected to the implant. A flexible, tubular deployment element is used to pass the implant and the retention element through the microcatheter, and then to separate the implant from the retention element when the implant has been passed out of the microcatheter and into the vascular site.

L10 ANSWER 20 OF 23 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2000:332935 BIOSIS

DOCUMENT NUMBER: PREV200000332935

TITLE: Apparatus and method for vascular **embolization**.

AUTHOR(S): Rosenbluth, Robert F. [Inventor, Reprint author]; Cox, Brian J. [Inventor]; Greene, George R. [Inventor]

CORPORATE SOURCE: Laguna Niguel, CA, USA

ASSIGNEE: MicroVention, Inc., Aliso Viejo, CA, USA

PATENT INFORMATION: US 6015424 20000118

SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Jan. 18, 2000) Vol. 1230, No. 3. e-file. CODEN: OGUPE7. ISSN: 0098-1133.

DOCUMENT TYPE: Patent

LANGUAGE: English

ENTRY DATE: Entered STN: 2 Aug 2000

Last Updated on STN: 7 Jan 2002

AB Apparatus for vascular **embolization**, deployable through a microcatheter, includes a flexible, elongate deployment tube dimensioned for insertion through the microcatheter, and a **filamentous** embolic device releasably attached to the distal end of the tube. The embolic device is controllably transformable from a soft, compliant state to a rigid or semi-rigid state. The embolic device may include a polymeric material that is transformable by contact with vascular blood or with a liquid that is cooler than vascular blood, or it may include a metallic material that is transformable by electrolytic corrosion. The embolic device may be a continuous **filamentous** polymeric extrusion; an elongate microcoil filled with polymeric material; an elongate, multi-segmented chain including polymeric interconnecting portions; or an elongate chain of metal segments that are fused together by electrolytic corrosion. An aneurysm is embolized with this apparatus by deploying a microcatheter so that its distal end is adjacent the aneurysm; deploying the embolic device through the microcatheter and into the aneurysm so that the embolic device forms a web-like mass in the aneurysm; and transforming the embolic device from its soft, compliant state to its rigid or semi-rigid state. The embolic device is advantageously deployed by releasably attaching it to a flexible, elongate deployment tube that is passed through the microcatheter, and then detaching the embolic device from the tube when the embolic device is suitably situated.

L10 ANSWER 21 OF 23 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on

STN

ACCESSION NUMBER: 1995:50987 BIOSIS
 DOCUMENT NUMBER: PREV199598065287
 TITLE: Formation of assembly intermediates from truncated neurofilament proteins and further characterization of heterotetramers.
 AUTHOR(S): Ansari, A. [Reprint author]; **Tran, T.**; Haley, D.; Darby, P.; Cohlberg, J. A.
 CORPORATE SOURCE: Dep. Chem. and Biochem., Calif. State Univ., Long Beach, CA 90840, USA
 SOURCE: Molecular Biology of the Cell, (1994) Vol. 5, No. SUPPL., pp. 51A.
 Meeting Info.: Thirty-fourth Annual Meeting of the American Society for Cell Biology. San Francisco, California, USA. December 10-14, 1994.
 CODEN: MBCEEV. ISSN: 1059-1524.
 DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 Conference; (Meeting Poster)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 31 Jan 1995
 Last Updated on STN: 31 Jan 1995

L10 ANSWER 22 OF 23 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:625674 SCISEARCH
 THE GENUINE ARTICLE: 577TM
 TITLE: Perplexing papules and plaques
 AUTHOR: **Tran T**; Morgan J; Morgan M B (Reprint)
 CORPORATE SOURCE: 16124 Chastain Rd, Odessa, FL 33556 USA (Reprint); Univ S Florida, Tampa, FL 33620 USA; Bay Area Dermatopathol, Tampa, FL USA
 COUNTRY OF AUTHOR: USA
 SOURCE: AMERICAN JOURNAL OF DERMATOPATHOLOGY, (AUG 2002) Vol. 24, No. 4, pp. 374-376.
 ISSN: 0193-1091.
 PUBLISHER: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA.
 DOCUMENT TYPE: Article; Journal
 LANGUAGE: English
 REFERENCE COUNT: 3
 ENTRY DATE: Entered STN: 16 Aug 2002
 Last Updated on STN: 16 Aug 2002

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Dermatologic diseases are capable of presenting in a variety of clinical and pathologic guises. We present the clinicopathologic features of an unusual case misinterpreted initially as a dermal hypersensitivity reaction that was later deemed to be the cholesterol emboli syndrome. Salient histologic features of this case were the presence of numerous dermal eosinophils and the diagnostic finding of an intravascular cholesterol embolus. The presence of dermal eosinophilia should prompt a search for cholesterol emboli in the appropriate context.

L10 ANSWER 23 OF 23 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1995:263238 SCISEARCH
 THE GENUINE ARTICLE: QU089
 TITLE: NEUROFILAMENT PROTEIN HETEROTETRAMERS AS ASSEMBLY INTERMEDIATES

AUTHOR: COHLBERG J A (Reprint); HAJARIAN H; **TRAN T**;
 ALIPOURJEDDI P; NOVEEN A
 CORPORATE SOURCE: CALIF STATE UNIV LONG BEACH, DEPT CHEM & BIOCHEM, 1250
 BELLFLOWER BLVD, LONG BEACH, CA 90840 (Reprint)
 COUNTRY OF AUTHOR: USA
 SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (21 APR 1995) Vol. 270,
 No. 16, pp. 9334-9339.
 ISSN: 0021-9258.
 PUBLISHER: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650
 ROCKVILLE PIKE, BETHESDA, MD 20814.
 DOCUMENT TYPE: Article; Journal
 FILE SEGMENT: LIFE
 LANGUAGE: English
 REFERENCE COUNT: 55
 ENTRY DATE: Entered STN: 1995
 Last Updated on STN: 1995

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Evidence is presented for the existence of a soluble heterotetramer containing the low and middle molecular weight neurofilament (NF) proteins, NF-L and NF-M, and one containing the low and high molecular weight proteins, NF-L and NF-H, and for their role in **filament** assembly. When a mixture of either pair of proteins was renatured in 2 M urea, 20 mM Tris, pH 7.2, a new band representing a complex was observed in native gel electrophoresis. No new band was observed with a mixture of NF-M and NF-H. Two-dimensional gel electrophoresis showed that treatment of the complexes with SDS caused them to dissociate into their constituent polypeptide chains. Native neurofilaments dissociated in 2 M urea into a mixture of LM and LH complexes. Titration of NF-L with NF-M indicated that complex formation was complete at an approximately equimolar ratio of the two proteins. The LM complex had a sedimentation coefficient, $s(20,w)$, of 4.4 S, consistent with a tetrameric structure. Dialysis of a solution of the LM complex against 50 mM. 4-morpholineethanesulfonic acid, 0.17 M NaCl, pH 6.25, led to the formation of 10-nm **filaments** in good yield. These results suggest that NF protein heterooligomers are intermediates in NF assembly and disassembly.

=> => file wpix, japio

FILE 'WPIX' ENTERED AT 09:26:23 ON 15 AUG 2006
 COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'JAPIO' ENTERED AT 09:26:23 ON 15 AUG 2006
 COPYRIGHT (C) 2006 Japanese Patent Office (JPO)- JAPIO

=> d stat que

L11 38 SEA ("GREENE G"/AU OR "GREENE G R"/AU)
 L12 13 SEA ("CRUISE G"/AU OR "CRUISE G M"/AU)
 L13 18 SEA "CONSTANT M"/AU
 L14 101 SEA ("COX B"/AU OR "COX B J"/AU)
 L15 1 SEA "COX BRIAN"/AU
 L16 113 SEA "TRAN T"/AU
 L17 253 SEA (L11 OR L12 OR L13 OR L14 OR L15 OR L16)
 L18 20 SEA L17 AND (FILAMENT? OR EXPANSILE OR EMBOLIZATION)

Tran T's

=> d ibib abs l18 tot

L18 ANSWER 1 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2006-492530 [50] WPIX

CROSS REFERENCE: 2001-343247 [36]; 2002-691223 [74]; 2003-266113 [26];
 2004-339065 [31]
 DOC. NO. NON-CPI: N2006-397580
 DOC. NO. CPI: C2006-154124
 TITLE: **Embolization** device manufacturing method for
 treatment of vascular aneurysms, involves coaxially
 encapsulating portion of length of **filamentous**
 carrier in **expansile** hydrophilic polymer.
 DERWENT CLASS: A32 A96 D22 P31
 INVENTOR(S): **CONSTANT, M; COX, B J; CRUISE, G**
M; GREENE, G R; TRAN, T
 PATENT ASSIGNEE(S): (MICR-N) MICROVENTION INC
 COUNTRY COUNT: 1
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2006149299	A1	20060706	(200650)*		29

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2006149299	A1 CIP of	US 1999-410970	19991004
	CIP of	US 2000-542145	20000404
	CIP of	US 2001-867340	20010529
	Div ex	US 2002-157621	20020529
		US 2006-350357	20060208

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 2006149299	A1 CIP of	US 6238403
	CIP of	US 6299619
	CIP of	US 6602261
	Div ex	US 7014645

PRIORITY APPLN. INFO: US 2002-157621 20020529; US
 1999-410970 19991004; US
 2000-542145 20000404; US
 2001-867340 20010529; US
 2006-350357 20060208

AN 2006-492530 [50] WPIX
 CR 2001-343247 [36]; 2002-691223 [74]; 2003-266113 [26]; 2004-339065 [31]
 AB US2006149299 A UPAB: 20060804

NOVELTY - The method involves providing elongated flexible
filamentous carrier, and coaxially encapsulating portion of the
 length of the carrier in an **expansile** hydrophilic polymer set in
 softened state.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for
 method for delivering therapeutic agent to patient.

USE - For manufacturing **embolization** device used for
 treatment of vascular aneurysms, arteriovenous malformation and
 arteriovenous fistulas, tumor and other soft tissue voids. The device is
 also used for occluding body cavity and blood vessel for therapeutic
 benefit of patient, and fallopian tubes for the purpose of sterilization,
 and also for occlusive repair of cardiac defects such as patent foramen
 ovale, patent ductus arteriosus and left-atrial-appendage and

atrial-septal defects.

ADVANTAGE - Vascular **embolization** device can be deployed within cavity or vascular site with excellent locational control and with a lower risk of vascular rupture, tissue damage or migration. The device effects a conformal fit within the site that promotes effective **embolization** of body cavities having different size and configuration.

DESCRIPTION OF DRAWING(S) - The figure shows a schematic view of vascular **embolization** device.

vascular **embolization** device 10

micropellets 12

spacers 16

microcoil segment 18

hydrogel linkage element 24

Dwg.1/44

L18 ANSWER 2 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 2005-074475 [08] WPIX

CROSS REFERENCE: 2003-479465 [45]

DOC. NO. NON-CPI: N2005-064215

DOC. NO. CPI: C2005-025500

TITLE: Preventing leakage into a perigraft space between endovascular graft and adjacent portion of blood vessel wall, by introducing device comprising **expansile** polymeric material into perigraft space, and allowing polymeric material to expand.

DERWENT CLASS: A96 D22 P32

INVENTOR(S): COX, B J; LENKER, J A; ROSENBLUTH, R F

PATENT ASSIGNEE(S): (MICR-N) MICROVENTION INC

COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2005004660	A1	20050106	(200508)*		19

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2005004660	A1 Div ex	US 2001-906415	20010716
		US 2003-726135	20031201

PRIORITY APPLN. INFO: US 2001-906415 20010716; US
2003-726135 20031201

AN 2005-074475 [08] WPIX

CR 2003-479465 [45]

AB US2005004660 A UPAB: 20050202

NOVELTY - Preventing leakage into a perigraft space between an endovascular graft and an adjacent portion of blood vessel wall, includes introducing a device comprising **expansile** polymeric material in non-expanded state through a cannula and into the perigraft space, and allowing the polymeric material to expand to its expanded state within the perigraft space so that the device fills the perigraft space.

DETAILED DESCRIPTION - Preventing leakage into a perigraft space between an endovascular graft that has been implanted in the lumen of blood vessel of human or veterinary patient and an adjacent portion of blood vessel wall, includes providing a device having a solid member

comprising **expansile** polymeric material (30) that is initially in a non-expanded state (where a quantity of polymeric material occupies a first volume) and is subsequently expandable to an expanded state (where the quantity of polymeric material occupies a second volume larger than the first volume and absorbs blood); inserting a cannula (22B) into a perigraft space between the endovascular graft and blood vessel wall; introducing the device through the cannula and into the perigraft space while the **expansile** polymeric material is in its non-expanded state; and allowing the polymeric material to expand to its expanded state within the perigraft space so that the device fills the perigraft space.

USE - The method is used for preventing leakage into a perigraft space between an endovascular graft and an adjacent portion of blood vessel wall. It may be performed after an endoleak has been detected for treating the endoleak and/or before an endoleak has been detected for preventing an endoleak from occurring (claimed).

ADVANTAGE - The expanded mass of polymeric material in the perigraft space prevents additional blood from leaking or flowing into such perigraft space.

DESCRIPTION OF DRAWING(S) - The figure is a diagram showing a method of treating endoleak.

Cannula 22B

Expansile polymeric material 30

Infrarenal aorta A

Abdominal aortic aneurysm AN

Dwg.3/7

L18 ANSWER 3 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2004-728044 [71] WPIX
 CROSS REFERENCE: 2002-394528 [42]; 2003-311315 [30]
 DOC. NO. NON-CPI: N2004-576592
 DOC. NO. CPI: C2004-255812
 TITLE: Deployment mechanism to deploy **filamentous** endovascular device in vascular site, has coupling element releasably held in non-fluidtight engagement in retention sleeve near distal end of deployment tube to be separable from the sleeve.
 DERWENT CLASS: A96 P31 S05
 INVENTOR(S): COX, B; FITZ, M; LEI, C L; SCHAEFER, D
 PATENT ASSIGNEE(S): (COXB-I) COX B; (FITZ-I) FITZ M; (LEIC-I) LEI C L; (MICR-N) MICROVENTION INC
 COUNTRY COUNT: 108
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2004204701	A1	20041014	(200471)*		22
WO 2005077281	A1	20050825	(200556)	EN	
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IS IT KE LS LT LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2004204701	A1 CIP of	US 2000-692248	20001018
	CIP of	US 2002-143724	20020510
		US 2004-774299	20040206
WO 2005077281	A1	WO 2005-US1930	20050121

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 2004204701	A1 CIP of	US 6607538
	CIP of	US 6689141

PRIORITY APPLN. INFO: US 2004-774299 20040206; US
 2000-692248 20001018; US
 2002-143724 20020510

AN 2004-728044 [71] WPIX
 CR 2002-394528 [42]; 2003-311315 [30]
 AB US2004204701 A UPAB: 20050902

NOVELTY - A deployment mechanism comprises a coupling element attached to a proximal end of an endovascular device and releasably held in a non-fluidtight engagement within a retention sleeve near the distal end of a deployment tube to be separable from the retention sleeve in response to fluid pressure applied to the coupling element through the lumen and the distal end of the deployment tube.

DETAILED DESCRIPTION - A deployment mechanism for deploying a **filamentous** endovascular device (16) having a proximal end, comprises an elongate, flexible, hollow deployment tube having an open proximal end, a distal section (10c) terminating in an open distal end, and a lumen defined between the proximal and distal ends; a retention sleeve (12) fixed to the distal section of the deployment tube and extending a short distance distally past the distal end of the deployment tube; and a coupling element (14) attached to the proximal end of the endovascular device and releasably held in a non-fluidtight engagement within the retention sleeve near the distal end of the deployment tube to be separable from the retention sleeve in response to fluid pressure applied to the coupling element through the lumen and the distal end of the deployment tube.

USE - For deployment of a **filamentous** endovascular device, e.g. embolic implant such as microcoil (24) in targeted vascular site by purging air from the lumen, introducing the endovascular device to the vascular site, and injecting a liquid into the proximal end of the lumen at at least 30 kg/cm² (claimed).

ADVANTAGE - The coupling mechanism provides a secure attachment of the embolic implant to a deployment instrument during the deployment, while allowing for the easy and reliable detachment of the embolic implant once it is properly situated with respect to the target site. It allows improved control of the implant during deployment and allows the implant to be easily repositioned before detachment. It is readily adapted for use with a wide variety of endovascular devices, without adding to the cost.

DESCRIPTION OF DRAWING(S) - The figure shows a longitudinal cross-sectional view of the deployment mechanism.

Distal section 10c
 Retention sleeve 12
 Coupling element 14
 Endovascular device 16

Microcoil 24

Liquid 30

Dwg.4/26

L18 ANSWER 4 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2004-339065 [31] WPIX
 CROSS REFERENCE: 2001-343247 [36]; 2002-691223 [74]; 2003-266113 [26];
 2006-492530 [50]
 DOC. NO. NON-CPI: N2004-271032
 DOC. NO. CPI: C2004-128684
 TITLE: Manufacture of body cavity occlusion device for
 delivering therapeutic agent to patient involves
 coaxially encapsulating portion of carrier in expansible,
 hydrophilic polymer.
 DERWENT CLASS: A96 B07 D22 P34
 INVENTOR(S): CONSTANT, M; COX, B J; CRUISE, G
 M; GREENE, G R; TRAN, T
 PATENT ASSIGNEE(S): (CONS-I) CONSTANT M; (COXB-I) COX B J; (CRUI-I) CRUISE G
 M; (GREE-I) GREENE G R; (TRAN-I) TRAN T
 COUNTRY COUNT: 1
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2004059370	A1	20040325	(200431)*		29

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2004059370	A1 CIP of	US 1999-410970	19991004
	CIP of	US 2000-542145	20000404
	CIP of	US 2001-867340	20010529
	Cont of	US 2002-157621	20020529
		US 2003-670142	20030924

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 2004059370	A1 CIP of	US 6238403
	CIP of	US 6299619
	CIP of	US 6602261

PRIORITY APPLN. INFO: US 2002-157621 20020529; US
 1999-410970 19991004; US
 2000-542145 20000404; US
 2001-867340 20010529; US
 2003-670142 20030924

AN 2004-339065 [31] WPIX
 CR 2001-343247 [36]; 2002-691223 [74]; 2003-266113 [26]; 2006-492530 [50]
 AB US2004059370 A UPAB: 20060804

NOVELTY - A body cavity occlusion device (10) is manufactured by providing
 an elongated, flexible, **filamentous** carrier; and coaxially
 encapsulating a portion of the length of the carrier in an expansible,
 hydrophilic polymer.

USE - The invention is used for manufacture of body cavity occlusion
 device for delivering a therapeutic agent to a patient by disposing the
 agent in the axial reservoir of the device; and embolizing a body cavity
 of the patient with the device (claimed).

ADVANTAGE - The invented method can fill aneurysms and other body

cavities of a target range of sizes, configurations and neck widths with an occlusive and/or thrombogenic medium with a minimal risk of inadvertent tissue damage, aneurysm rupture or blood vessel wall damage. It also allows for the precise locational deployment of the medium while minimizing the potential for migration away from the target location.

DESCRIPTION OF DRAWING(S) - The figure is an elevational view of a vascular **embolization** device.

Device(12) Micropellet 10

Spacers 16

Segment 18

Retention member 20

Dwg.1/43

L18 ANSWER 5 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2004-225901 [21] WPIX
 CROSS REFERENCE: 2002-643005 [69]; 2003-229183 [22]; 2003-625320 [59]
 DOC. NO. NON-CPI: N2004-178545
 TITLE: Micro coil vaso-occlusive device for closing blood vessel by embolizing targeted site in blood vessel, has micro coil formed into minimum energy state secondary configuration that has curved segments or circular loops defining multiple axes.
 DERWENT CLASS: P32
 INVENTOR(S): ALMAZAN, H; COX, B J; FERRERA, D A;
 GREENE, G R; SCHAEFER, D
 PATENT ASSIGNEE(S): (ALMA-I) ALMAZAN H; (COXB-I) COX B J; (FERR-I) FERRERA D A; (GREE-I) GREENE G R; (SCHA-I) SCHAEFER D
 COUNTRY COUNT: 1
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2004045554	A1	20040311	(200421)*		9

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2004045554	A1 Cont of	US 2000-671021	20000926
		US 2003-638813	20030811

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 2004045554	A1 Cont of	US 6605101

PRIORITY APPLN. INFO: US 2000-671021 20000926; US
 2003-638813 20030811

AN 2004-225901 [21] WPIX
 CR 2002-643005 [69]; 2003-229183 [22]; 2003-625320 [59]
 AB US2004045554 A UPAB: 20040326

NOVELTY - The device (10) has a micro coil formed into a minimum energy state secondary configuration comprising of several curved segments or circular loops (14a,14b) defining multiple axes (16).

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for embolizing an aneurysm using the micro coil vaso-occlusive device.

USE - For occluding blood vessel by embolizing a targeted site, e.g. aneurysm, in the blood vessel

ADVANTAGE - Provides a micro coil vaso-occlusive device with a minimum energy state secondary configuration that is not conducive to coin-stacking, thereby minimizing the degree of compaction that is experienced. Engages the surrounding aneurysm wall surface, thereby minimizing shifting or tumbling due to blood flow dynamics. Ensures increased coverage of aneurysm neck due to presence of loops across the neck, and yet the probability of any part of the device intruding into the parent artery is reduced. Provides smoother deployment and exhibits greater resistance to coil compaction, thereby increasing positional stability in the face of pulsatile blood flow. Achieves stability with lower overall friction between the device and the aneurysm wall. Includes random distribution of loops throughout the aneurysm that allows the device to maintain a complex shape inside the aneurysm, yielding improved **embolization**.

DESCRIPTION OF DRAWING(S) - The figure shows the perspective view of the micro coil vaso-occlusive device.

Micro coil vaso-occlusive device 10

Curved segments or circular loops 14a,14b

Multiple axes 16

Dwg.1/7

L18 ANSWER 6 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 2004-088970 [09] WPIX

DOC. NO. NON-CPI: N2004-071213

DOC. NO. CPI: C2004-036288

TITLE: **Embolization** device for repairing vascular dysfunction, comprising resilient material thread, and surface irregularities formed on surface of material thread.

DERWENT CLASS: A96 B04 D22 P31 P34

INVENTOR(S): **COX, B J**; FERRERA, D; GREENC, G R; GREEN, G R

PATENT ASSIGNEE(S): (COXB-I) COX B J; (FERR-I) FERRERA D; (GREE-I) GREENC G R; (MICR-N) MICROVENTION INC

COUNTRY COUNT: 104

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2003199887	A1	20031023	(200409)*		13
WO 2003090837	A1	20031106	(200409)	EN	
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS					
LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK					
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR					
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL					
PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU					
ZA ZM ZW					
AU 2003230791	A1	20031110	(200442)		
EP 1501580	A1	20050202	(200510)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV					
MC MK NL PT RO SE SI SK TR					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2003199887	A1	US 2002-128917	20020423
WO 2003090837	A1	WO 2003-US10178	20030402
AU 2003230791	A1	AU 2003-230791	20030402

EP 1501580	A1	EP 2003-723886	20030402
		WO 2003-US10178	20030402

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003230791	A1 Based on	WO 2003090837
EP 1501580	A1 Based on	WO 2003090837

PRIORITY APPLN. INFO: US 2002-128917 20020423

AN 2004-088970 [09] WPIX

AB US2003199887 A UPAB: 20040205

NOVELTY - An **embolization** device (22) comprises a resilient material thread having a first relaxed shape forming a space-filling body, and a second stretched shape forming a linear body, and at least one surface irregularity formed on surface of the material thread.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of repairing vascular dysfunction by accessing site of vascular dysfunction in vivo, delivering **embolization** device into the vascular dysfunction, and promoting tissue in-growth with the **embolization** device.

USE - For repairing vascular dysfunction, e.g. vascular aneurysm (10), or imparting therapeutic effect on tissue in vivo.

ADVANTAGE - The device enables a user to treat aneurysm formed through the patient's body from a remote location.

DESCRIPTION OF DRAWING(S) - The figure is a perspective view of a porous **embolization** device.

Aneurysm 10

Neck portion 12

Blood vessel 14

Delivery device 20

Embolization device 22

Dwg. 2/15

L18 ANSWER 7 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 2003-479465 [45] WPIX

CROSS REFERENCE: 2005-074475 [08]

DOC. NO. NON-CPI: N2003-381097

DOC. NO. CPI: C2003-128073

TITLE: Method for preventing leakage into perigraft space, by providing **expansile** polymeric material to absorb blood, inserting cannula and allowing polymeric material to expand to its expanded state to fill perigraft space.

DERWENT CLASS: A96 B07 C07 D22 P31 P32 P34

INVENTOR(S): COX, B J; LENKER, J A; ROSENBLUTH, R F

PATENT ASSIGNEE(S): (MICR-N) MICROVENTION INC

COUNTRY COUNT: 101

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2003014075	A1	20030116	(200345)*		20
WO 2003007785	A2	20030130	(200345)	EN	
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU					
MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK					
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR					

KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
 RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW
 EP 1416859 A2 20040512 (200431) EN
 R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC
 MK NL PT RO SE SI SK TR
 AU 2002318325 A1 20030303 (200452)
 JP 2004537353 W 20041216 (200482) 68
 AU 2002318325 A8 20051027 (200624)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2003014075	A1	US 2001-906415	20010716
WO 2003007785	A2	WO 2002-US22242	20020712
EP 1416859	A2	EP 2002-748152	20020712
		WO 2002-US22242	20020712
AU 2002318325	A1	AU 2002-318325	20020712
JP 2004537353	W	WO 2002-US22242	20020712
		JP 2003-513399	20020712
AU 2002318325	A8	AU 2002-318325	20020712

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1416859	A2 Based on	WO 2003007785
AU 2002318325	A1 Based on	WO 2003007785
JP 2004537353	W Based on	WO 2003007785
AU 2002318325	A8 Based on	WO 2003007785

PRIORITY APPLN. INFO: US 2001-906415 20010716

AN 2003-479465 [45] WPIX

CR 2005-074475 [08]

AB US2003014075 A UPAB: 20060410

NOVELTY - Method for preventing leakage into perigraft space, involves providing **expansile** polymeric material (EPM) to absorb blood, inserting cannula, introducing EPM in non-expanded state through cannula and allowing EPM to expand to its expanded state to fill perigraft space. EPM which is initially in non-expanded state occupies volume-I and then expands to expanded state and occupies volume-II.

DETAILED DESCRIPTION - A method for preventing leakage into a perigraft space between an endovascular graft (10) that has been implanted in the lumen of a blood vessel and an adjacent portion of the blood vessel wall, involves providing an **expansile** polymeric material (EPM) to absorb blood, inserting a cannula (22) into a perigraft space between the endovascular graft and the blood vessel wall, introducing the EPM in non-expanded state through the cannula and into the perigraft space and allowing EPM to expand to expanded state within the perigraft space for substantially filling the perigraft space. EPM which is initially in a non-expanded state occupies a volume-I and expands to an expanded state and occupies a volume-II larger than the volume-I.

An INDEPENDENT CLAIM is included for a system for preventing or treating endoleaks.

USE - For treating or preventing endoleaks after an endovascular graft.

ADVANTAGE - The expanded mass of polymeric material in the perigraft space prevents additional blood from leaking or flowing into perigraft space. The expanded and/or cured states of the **expansile**

material in perigraft space allows the permeation of blood or blood fluid, promotes cellular growth and post implantation biological processes.

DESCRIPTION OF DRAWING(S) - The figure shows the method for treating an endoleak that has occurred in a bifurcated aorto-illiac endovascular graft.

endovascular graft 10
cannula 22
Dwg.1D/7

L18 ANSWER 8 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-311315 [30] WPIX
CROSS REFERENCE: 2002-394528 [42]; 2004-728044 [71]
DOC. NO. NON-CPI: N2003-247777
DOC. NO. CPI: C2003-081528
TITLE: Deployment device for endovascular implant e.g. microcoil, comprises flexible, hollow deployment tube, retention sleeve, and coupling element.
DERWENT CLASS: B07 D22 P31 P32 P34
INVENTOR(S): COX, B; FERRERA, D A; GREENE, G R;
ROSENBKUTH, R F; FITZ, M; LEI, C L; COX, B J;
ROSENBLUTH, R F
PATENT ASSIGNEE(S): (MICR-N) MICROVENTION INC; (COXB-I) COX B J; (FERR-I) FERRERA D A; (GREE-I) GREENE G R; (ROSE-I) ROSENBLUTH R F
COUNTRY COUNT: 104
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002188311	A1	20021212	(200330)*		20
WO 2003094751	A1	20031120	(200403)	EN	
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT SD SE SI SK SL SZ TR TZ UG ZM ZW W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW					
US 6689141	B2	20040210	(200413)		
AU 2003233511	A1	20031111	(200442)		
EP 1513461	A1	20050316	(200519)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR					
JP 2005524479	W	20050818	(200555)		22
CN 1652726	A	20050810	(200572)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002188311	A1 CIP of	US 2000-692248	20001018
		US 2002-143724	20020510
WO 2003094751	A1	WO 2003-US14580	20030508
US 6689141	B2 CIP of	US 2000-692248	20001018
		US 2002-143724	20020510
AU 2003233511	A1	AU 2003-233511	20030508
EP 1513461	A1	EP 2003-728788	20030508
		WO 2003-US14580	20030508
JP 2005524479	W	WO 2003-US14580	20030508
		JP 2004-502847	20030508

CN 1652726

A

CN 2003-810602

20030508

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 6689141	B2 CIP of	US 6607538
AU 2003233511	A1 Based on	WO 2003094751
EP 1513461	A1 Based on	WO 2003094751
JP 2005524479	W Based on	WO 2003094751

PRIORITY APPLN. INFO: US 2002-143724 20020510; US
2000-692248 20001018

AN 2003-311315 [30] WPIX
CR 2002-394528 [42]; 2004-728044 [71]
AB US2002188311 A UPAB: 20051109

NOVELTY - A deployment device comprises flexible, hollow deployment tube, retention sleeve, and coupling element. The deployment tube has an open proximal end, and a lumen. The retention sleeve is fixed around the distal section of the deployment tube. The coupling element is formed with purge passage that is designed to provide restriction to the flow of the fluid.

DETAILED DESCRIPTION - A deployment device comprises flexible, hollow deployment tube, retention sleeve (12), and coupling element (14). The deployment tube has open proximal end, distal section, and a lumen between the proximal and distal ends. The retention sleeve is fixed around the distal section of the deployment tube. The coupling element is attached to the proximal end of the endovascular device and is releasably held within the distal extension of the retention sleeve such that it can be displaceable from the retention sleeve in response to fluid pressure applied to the coupling element through the lumen and the distal end of the deployment tube. The coupling element is formed with purge passage (72) that is dimensioned so as to provide restriction to the flow of the fluid having a viscosity that is greater than that of the saline solution.

An INDEPENDENT CLAIM is also included for a method of deploying a **filamentous** endovascular device into a target vascular site comprising purging air from the lumen by injecting saline solution through the lumen with a pressure enough to displace air from the lumen through the purge passage but not enough to separate the endovascular device from the deployment tube. The endovascular device is introduced intravascularly to the target vascular site while it is attached to the deployment tube. A liquid through the lumen is injected under pressure to separate the endovascular device from the deployment tube in response to the liquid pressure applied to the coupling element through the open distal end of the deployment tube.

USE - For deploying endovascular implant (16), such as microcoil (24), into a targeted vascular site.

ADVANTAGE - The inventive device allows for easy and reliable detachment of the embolic implant once it is properly situated with respect to the target site. It has improved control of implant during deployment. It allows the implant to be easily repositioned before detachment.

DESCRIPTION OF DRAWING(S) - The drawing shows a cross-sectional view of the inventive deployment device.

Retention sleeve 12

Coupling element 14

Endovascular implant 16

Microcoil 24

Purge passage 72

Dwg. 17/22

L18 ANSWER 9 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2003-266113 [26] WPIX
 CROSS REFERENCE: 2001-343247 [36]; 2002-691223 [74]; 2004-339065 [31];
 2006-492530 [50]
 DOC. NO. NON-CPI: N2003-211320
 TITLE: Vascular **embolization** device manufacturing
 method involves coaxially encapsulating
filamentous carrier in **expansile**,
 hydrophilic polymer.
 DERWENT CLASS: P31 P32
 INVENTOR(S): **CONSTANT, M; COX, B J; CRUISE, G**
M; GREENE, G R; TRAN, T
 PATENT ASSIGNEE(S): (MICR-N) MICROVENTION INC; (CONS-I) CONSTANT M; (COXB-I)
 COX B J; (CRUI-I) CRUISE G M; (GREE-I) GREENE G R;
 (TRAN-I) TRAN T
 COUNTRY COUNT: 101
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002177855	A1	20021128	(200326)*		29
WO 2002096302	A1	20021205	(200326)	EN	
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW					
EP 1401338	A1	20040331	(200424)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
AU 2002344223	A1	20021209	(200452)		
JP 2004527342	W	20040909	(200459)		93
US 7014645	B2	20060321	(200621)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002177855	A1 CIP of	US 1999-410970	19991004
	CIP of	US 2000-542145	20000404
	CIP of	US 2001-867340	20010529
		US 2002-157621	20020529
WO 2002096302	A1	WO 2002-US16873	20020529
EP 1401338	A1	EP 2002-752008	20020529
		WO 2002-US16873	20020529
AU 2002344223	A1	AU 2002-344223	20020529
JP 2004527342	W	JP 2002-592820	20020529
		WO 2002-US16873	20020529
US 7014645	B2 CIP of	US 1999-410970	19991004
	CIP of	US 2000-542145	20000404
	CIP of	US 2001-867340	20010529
		US 2002-157621	20020529

FILING DETAILS:

PATENT NO	KIND	PATENT NO

US 2002177855	A1 CIP of	US 6238403
	CIP of	US 6299619
EP 1401338	A1 Based on	WO 2002096302
AU 2002344223	A1 Based on	WO 2002096302
JP 2004527342	W Based on	WO 2002096302
US 7014645	B2 CIP of	US 6238403
	CIP of	US 6299619
	CIP of	US 6602261

PRIORITY APPLN. INFO: US 2002-157621 20020529; US
 1999-410970 19991004; US
 2000-542145 20000404; US
 2001-867340 20010529

AN 2003-266113 [26] WPIX
 CR 2001-343247 [36]; 2002-691223 [74]; 2004-339065 [31]; 2006-492530 [50]
 AB US2002177855 A UPAB: 20060804

NOVELTY - The carrier made of thin **filament** of a suitable polymer is coaxially encapsulated in **expansile**, hydrophilic polymer such as polyvinyl alcohol (PVA).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

- (1) method for delivering therapeutic agent to patient; and
- (2) **embolization** device.

USE - For manufacturing vascular **embolization** device (claimed) used in **embolization** of vascular aneurysms, during treatment of vascular anomalies, such as arteriovenous malformations and arteriovenous fistulas. Also, used for occlusion of fallopian tubes for sterilization, treating cardiac defects like foramen ovale, ductus arteriosus, left-atrial-appendage and atrial-septal defects.

ADVANTAGE - The **embolization** device can be placed within the cavity with excellent locational control, lower risk of vascular rupture, tissue damage. Embolizes body cavities having a wide variety of sizes, configurations and neck widths.

Dwg.0/44

L18 ANSWER 10 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2003-229183 [22] WPIX
 CROSS REFERENCE: 2002-643005 [69]; 2003-625320 [59]; 2004-225901 [21]
 DOC. NO. NON-CPI: N2003-182422
 TITLE: Microcoil vaso-occlusive device for embolizing vascular site, has microcoil formed into minimum energy state secondary configuration, forming curved segments and having predetermined overall length.
 DERWENT CLASS: P31 P34
 INVENTOR(S): COX, B J; FERRERA, D A; FITZ, M; GREENE, G R; ROSENBLUTH, R F; SCHAEFER, D
 PATENT ASSIGNEE(S): (COXB-I) COX B J; (FERR-I) FERRERA D A; (FITZ-I) FITZ M; (GREE-I) GREENE G R; (ROSE-I) ROSENBLUTH R F; (SCHA-I) SCHAEFER D; (MICR-N) MICROVENTION INC
 COUNTRY COUNT: 106
 PATENT INFORMATION:

PATENT NO	KIND DATE	WEEK	LA	PG
US 2003018356	A1 20030123	(200322)*	14	
WO 2004026149	A1 20040401	(200431)	EN	
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS				
LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW				
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK				

DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH
 PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN
 YU ZA ZM ZW

AU 2003267287 A1 20040408 (200462)
 EP 1542599 A1 20050622 (200541) EN
 R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV
 MC MK NL PT RO SE SI SK TR

JP 2006500108 W 20060105 (200603) 19
 CN 1681440 A 20051012 (200612)
 US 7029486 B2 20060418 (200627)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2003018356	A1 CIP of	US 2000-671021	20000926
	CIP of	US 2002-43947	20020111
		US 2002-247231	20020919
WO 2004026149	A1	WO 2003-US29394	20030917
AU 2003267287	A1	AU 2003-267287	20030917
EP 1542599	A1	EP 2003-749761	20030917
		WO 2003-US29394	20030917
JP 2006500108	W	WO 2003-US29394	20030917
		JP 2004-537987	20030917
CN 1681440	A	CN 2003-822390	20030917
US 7029486	B2 CIP of	US 2000-671021	20000926
	CIP of	US 2002-43947	20020111
		US 2002-247231	20020919

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003267287	A1 Based on	WO 2004026149
EP 1542599	A1 Based on	WO 2004026149
JP 2006500108	W Based on	WO 2004026149
US 7029486	B2 CIP of	US 6605101

PRIORITY APPLN. INFO: US 2002-247231 20020919; US
 2000-671021 20000926; US
 2002-43947 20020111

AN 2003-229183 [22] WPIX
 CR 2002-643005 [69]; 2003-625320 [59]; 2004-225901 [21]
 AB US2003018356 A UPAB: 20060426

NOVELTY - The device (10) has a **filamentous** microcoil formed into a minimum energy state secondary configuration having curved segments. Each of the curved segment has a diameter equal to the know maximum diameter of the vascular site. At its minimum energy state secondary configuration, the microcoil has an overall length at least twice the know maximum length of the vascular site.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for the vascular site embolizing method.

USE - For embolizing vascular site having know maximum dimension.

ADVANTAGE - Ensures reliable treatment of aneurysms of varying sizes. Ensures compatible use of device with existing guidewire and microcatheter microcoil delivery mechanism. Suppresses increase in manufacturing cost of device. Minimizes shifting or tumbling of device when engaged with aneurysm.

DESCRIPTION OF DRAWING(S) - The figure shows the isometric view of the vaso-occlusive device.

Microcoil vaso-occlusive device 10

Dwg.1/17

L18 ANSWER 11 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2003-138431 [13] WPIX
 DOC. NO. CPI: C2003-035151
 TITLE: Treatment of disease, deformation or disorder of human or veterinary patient, involves irradiating polymer to cause crosslinking of polymer, and introducing crosslinked polymer into or onto patient's body.
 DERWENT CLASS: A96 D22 P34
 INVENTOR(S): CRUISE, G M
 PATENT ASSIGNEE(S): (MICR-N) MICROVENTION INC
 COUNTRY COUNT: 101
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002111392	A1	20020815	(200313)*		6
WO 2002064189	A2	20020822	(200313)	EN	
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW					
US 6537569	B2	20030325	(200325)		
EP 1365704	A2	20031203	(200380)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
BR 2002007249	A	20040309	(200420)		
AU 2002253939	A1	20020828	(200427)		
JP 2004520134	W	20040708	(200445)		30
CN 1496241	A	20040512	(200452)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002111392	A1	US 2001-783762	20010214
WO 2002064189	A2	WO 2002-US4166	20020213
US 6537569	B2	US 2001-783762	20010214
EP 1365704	A2	EP 2002-723139	20020213
		WO 2002-US4166	20020213
BR 2002007249	A	BR 2002-7249	20020213
		WO 2002-US4166	20020213
AU 2002253939	A1	AU 2002-253939	20020213
JP 2004520134	W	JP 2002-563981	20020213
		WO 2002-US4166	20020213
CN 1496241	A	CN 2002-804996	20020213

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1365704	A2 Based on	WO 2002064189
BR 2002007249	A Based on	WO 2002064189

AU 2002253939 A1 Based on WO 2002064189
 JP 2004520134 W Based on WO 2002064189

PRIORITY APPLN. INFO: US 2001-783762 20010214

AN 2003-138431 [13] WPIX

AB US2002111392 A UPAB: 20030224

NOVELTY - A disease, deformation or disorder of a human or veterinary patient is treated by providing a biocompatible, hydrophilic polymer; irradiating the polymer to cause crosslinking of the polymer; and introducing the crosslinked polymer into or onto the patient's body.

USE - For the treatment of disease, deformation or disorder of human or veterinary patient, (particularly for hemostasis, tissue augmentation, tissue engineering, **embolization** of blood vessel or other anatomical conduit having a lumen, absorbing body fluid, or closure of vascular punctures or wounds (all claimed)).

ADVANTAGE - The inventive method can treat disease, deformation or disorder of human or veterinary patient. The polymers used are able to absorb and hold water. The materials used are biodegradable under physiological conditions.

Dwg.0/0

L18 ANSWER 12 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 2002-691223 [74] WPIX

CROSS REFERENCE: 2001-343247 [36]; 2003-266113 [26]; 2004-339065 [31];
 2006-492530 [50]

DOC. NO. NON-CPI: N2002-545343

TITLE: Vascular **embolization** device has micropellets
 fixed at spaced intervals to exterior surface of carrier
 along substantial portion of length of carrier proximally
 from distal tip.

DERWENT CLASS: P31 P32

INVENTOR(S): **CONSTANT, M; COX, B J; CRUISE, G**
M; GREENE, G R; TRAN, T

PATENT ASSIGNEE(S): (MICR-N) MICROVENTION INC; (CONS-I) CONSTANT M; (COXB-I)
 COX B J; (CRUI-I) CRUISE G M; (GREE-I) GREENE G R;
 (TRAN-I) TRAN T

COUNTRY COUNT: 3

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002120276	A1	20020829	(200274)*		19
US 6602261	B2	20030805	(200353)		
AU 2002344223	A1	20021209	(200452)		
JP 2004527342	W	20040909	(200459)		93

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002120276	A1 CIP of	US 1999-410970	19991004
	CIP of	US 2000-542145	20000404
		US 2001-867340	20010529
US 6602261	B2 CIP of	US 1999-410970	19991004
	CIP of	US 2000-542145	20000404
		US 2001-867340	20010529
AU 2002344223	A1	AU 2002-344223	20020529
JP 2004527342	W	JP 2002-592820	20020529
		WO 2002-US16873	20020529

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 2002120276	A1 CIP of	US 6238403
US 6602261	B2 CIP of	US 6238403
	CIP of	US 6299619
AU 2002344223	A1 Based on	WO 2002096302
JP 2004527342	W Based on	WO 2002096302

PRIORITY APPLN. INFO: US 2001-867340 20010529; US
 1999-410970 19991004; US
 2000-542145 20000404; US
 2002-157621 20020529

AN 2002-691223 [74] WPIX
 CR 2001-343247 [36]; 2003-266113 [26]; 2004-339065 [31]; 2006-492530 [50]
 AB US2002120276 A UPAB: 20060804

NOVELTY - The device (10) includes a flexible, **filamentous** carrier having a distal tip and an exterior surface. Elongated continuous, coaxial micropellets (12) are fixed at spaced intervals to the exterior surface of the carrier along a substantial portion of the length of the carrier proximally from the distal tip.

USE - For embolizing vascular aneurysms and similar vascular abnormalities. Used for controlling vascular bleeding to occlude blood supply to tumors.

ADVANTAGE - Provides a vascular **embolization** device which effects a conformal fit within the site that promotes effective **embolization**. Facilitates precise and highly controllable deployment of the vascular **embolization** device. Effectively embolizes vascular sites having a wide variety of sizes, configurations and neck widths.

DESCRIPTION OF DRAWING(S) - The figure shows the elevational view of the vascular **embolization** device.

Vascular **embolization** device 10
 Micropellets 12
 Dwg.1/23

L18 ANSWER 13 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2002-643656 [69] WPIX
 DOC. NO. NON-CPI: N2002-508747
 TITLE: Preparation of environmentally-sensitive hydrogel polymer by allowing monomer and/or prepolymer to be crosslinked with crosslinker to form hydrogel, and treating hydrogel to render it environmentally sensitive.
 DERWENT CLASS: A96 B07 C07 D22 P32
 INVENTOR(S): CONSTANT, M J; **CRUISE, G M**
 PATENT ASSIGNEE(S): (MICR-N) MICRO VENTION INC; (MICR-N) MICROVENTION INC
 COUNTRY COUNT: 101
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002071994	A1	20020919	(200269)*	EN	22
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ					
NL OA PT SD SE SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK					
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR					
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT					

RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW
 US 2002176880 A1 20021128 (200281)
 EP 1372553 A1 20040102 (200409) EN
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI TR
 BR 2002008034 A 20040225 (200416)
 AU 2002306605 A1 20020924 (200433)
 JP 2004528880 W 20040924 (200463) 36
 US 6878384 B2 20050412 (200525)
 CN 1617694 A 20050518 (200558)
 US 2005196426 A1 20050908 (200559)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002071994	A1	WO 2002-US5988	20020228
US 2002176880	A1	US 2001-804935	20010313
EP 1372553	A1	EP 2002-750563	20020228
		WO 2002-US5988	20020228
BR 2002008034	A	BR 2002-8034	20020228
		WO 2002-US5988	20020228
AU 2002306605	A1	AU 2002-306605	20020228
JP 2004528880	W	JP 2002-570954	20020228
		WO 2002-US5988	20020228
US 6878384	B2	US 2001-804935	20010313
CN 1617694	A	CN 2002-806384	20020228
US 2005196426	A1 Cont of	US 2001-804935	20010313
		US 2005-90806	20050324

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1372553	A1 Based on	WO 2002071994
BR 2002008034	A Based on	WO 2002071994
AU 2002306605	A1 Based on	WO 2002071994
JP 2004528880	W Based on	WO 2002071994
US 2005196426	A1 Cont of	US 6878384

PRIORITY APPLN. INFO: US 2001-804935 20010313; US
 2005-90806 20050324

AN 2002-643656 [69] WPIX

AB WO 200271994 A UPAB: 20021209

NOVELTY - An environmentally-sensitive hydrogel polymer is prepared by forming a reaction mixture containing an environmentally sensitive monomer and/or prepolymer, a crosslinker, and an initiator; crosslinking the monomer and/or prepolymer with the crosslinker to form a hydrogel that will expand when immersed in an aqueous liquid; and treating the hydrogel to render it environmentally sensitive.

DETAILED DESCRIPTION - A method of preparing an environmentally-sensitive hydrogel polymer, comprising (a) forming a reaction mixture containing (i) an environmentally sensitive monomer and/or prepolymer, (ii) a crosslinker, and (iii) an initiator; (b) allowing the monomer and/or prepolymer to become crosslinked by the crosslinker to form a hydrogel that will expand when immersed in an aqueous liquid; and (c) treating the hydrogel to render it environmentally sensitive such that the environment in which the hydrogel resides affects the rate at which the hydrogel expands.

An INDEPENDENT CLAIM is included for a method of treating a disease, deformation or disorder of a human or veterinary patient by implantation of the hydrogel polymer at an implantation site within a patient's body, comprising (a) providing an amount of the hydrogel polymer that (i) occupies a first volume prior to implantation at the site and (ii) expands to a second volume, larger than the first volume, in response to an environmental condition that is present at the site; and (b) introducing the hydrogel polymer into the site such that it becomes exposed to the environmental condition present at the site and, in response to the environmental condition expands to the second volume.

USE - The inventive method is used in preparing an environmentally-sensitive hydrogel polymer (claimed). The hydrogel polymer is used for biomedical applications (e.g., for treating aneurysms, fistulae, arterio-venous malformations, and for the immobilization or occlusion of blood vessels or other luminal anatomical structures).

ADVANTAGE - The inventive method produces hydrogels that exhibit controlled rates of expansion in response to changes in their environment.

DESCRIPTION OF DRAWING(S) - The figure is a flow diagram of a method of preparing an environmentally-responsive hydrogels.
Dwg.1/2

L18 ANSWER 14 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2002-643005 [69] WPIX
 CROSS REFERENCE: 2003-229183 [22]; 2003-625320 [59]; 2004-225901 [21]
 DOC. NO. NON-CPI: N2002-508325
 TITLE: Microcoil vaso-occlusive device has **filamentous** structure formed into minimum energy state secondary configuration and with multiple curved segments individually provided with discrete axis.
 DERWENT CLASS: P31
 INVENTOR(S): COX, B; FERRERA, D A; FRITZ, M; GREENE, G R; ROSENBLUTH, R F; SCHAEFER, D; COX, B J; FITZ, M
 PATENT ASSIGNEE(S): (MICR-N) MICROVENTION INC; (COXB-I) COX B J; (FERR-I) FERRERA D A; (FITZ-I) FITZ M; (GREE-I) GREENE G R; (ROSE-I) ROSENBLUTH R F; (SCHA-I) SCHAEFER D
 COUNTRY COUNT: 101
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002107534	A1	20020808	(200269)*		14
WO 2003059176	A2	20030724	(200349)	EN	
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT SD SE SI SK SL SZ TR TZ UG ZM ZW W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW					
AU 2003209206	A1	20030730	(200421)		
EP 1467663	A2	20041020	(200469)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR					
JP 2005514978	W	20050526	(200535)		21
US 7033374	B2	20060425	(200628)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
-----------	------	-------------	------

US 2002107534	A1 CIP of	US 2000-671021	20000926
		US 2002-43947	20020111
WO 2003059176	A2	WO 2003-US779	20030110
AU 2003209206	A1	AU 2003-209206	20030110
EP 1467663	A2	EP 2003-707353	20030110
		WO 2003-US779	20030110
JP 2005514978	W	JP 2003-559346	20030110
		WO 2003-US779	20030110
US 7033374	B2 CIP of	US 2000-671021	20000926
		US 2002-43947	20020111

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003209206	A1 Based on	WO 2003059176
EP 1467663	A2 Based on	WO 2003059176
JP 2005514978	W Based on	WO 2003059176
US 7033374	B2 CIP of	US 6605101

PRIORITY APPLN. INFO: US 2002-43947 20020111; US
2000-671021 20000926

AN 2002-643005 [69] WPIX
CR 2003-229183 [22]; 2003-625320 [59]; 2004-225901 [21]
AB US2002107534 A UPAB: 20060502

NOVELTY - A **filamentous** structure formed into a minimum energy state secondary configuration has multiple curved segments individually provided with a discrete axis. The vaso-occlusive device (10) defines multiple axes (16) in its minimum energy state configuration.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for an embolizing method for vascular site having predetermined maximum diameter.

USE - For occluding blood vessel by embolizing targeted site e.g. aneurysm into a blood vessel.

ADVANTAGE - Effective in treatment of aneurysms of different sizes and those with large neck widths. Compatible for use with existing guidewire and microcatheter microcoil delivery mechanisms. Low cost manufacture.

DESCRIPTION OF DRAWING(S) - The figure shows a perspective view of the microcoil vaso-occlusive device.

Vaso-occlusive device 10
Multiple axes 16
Dwg.1/17

L18 ANSWER 15 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 2002-394528 [42] WPIX

CROSS REFERENCE: 2003-311315 [30]; 2004-728044 [71]

DOC. NO. NON-CPI: N2002-309320

DOC. NO. CPI: C2002-111109

TITLE: Deployment mechanism for deploying **filamentous** endovascular device into target vascular site in patient's vasculature comprises elongate flexible hollow deployment tube, retention sleeve, and coupling element.

DERWENT CLASS: A96 P31 P32

INVENTOR(S): COX, B J; FERRERA, D A; GRENN, G R;
ROSENBLUTH, R F; GREENE, G R

PATENT ASSIGNEE(S): (MICR-N) MICROVENTION INC

COUNTRY COUNT: 95

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002032326	A2	20020425	(200242)*	EN	42
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU DE DK DM DZ EC ES GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW					
AU 2002014623	A	20020429	(200255)		
US 6607538	B1	20030819	(200356)		
EP 1339328	A2	20030903	(200365)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
BR 2001014738	A	20040210	(200414)		
CN 1469724	A	20040121	(200425)		
JP 2004511294	W	20040415	(200426)		62

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002032326	A2	WO 2001-US32588	20011018
AU 2002014623	A	AU 2002-14623	20011018
US 6607538	B1	US 2000-692248	20001018
EP 1339328	A2	EP 2001-983174	20011018
		WO 2001-US32588	20011018
BR 2001014738	A	BR 2001-14738	20011018
		WO 2001-US32588	20011018
CN 1469724	A	CN 2001-817605	20011018
JP 2004511294	W	WO 2001-US32588	20011018
		JP 2002-535565	20011018

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2002014623	A Based on	WO 2002032326
EP 1339328	A2 Based on	WO 2002032326
BR 2001014738	A Based on	WO 2002032326
JP 2004511294	W Based on	WO 2002032326

PRIORITY APPLN. INFO: US 2000-692248 20001018

AN 2002-394528 [42] WPIX

CR 2003-311315 [30]; 2004-728044 [71]

AB WO 200232326 A UPAB: 20041104

NOVELTY - Deployment mechanism comprises an elongate flexible hollow deployment tube having an open proximal end, a distal section terminating in an open distal end, and a lumen defined between the proximal and distal ends; a retention sleeve having a distal extension extending a short distance past the distal end of the deployment tube; and a coupling element attached to the proximal end.

DETAILED DESCRIPTION - Deployment mechanism comprises an elongate flexible hollow deployment tube (10) having an open proximal end, a distal section terminating in an open distal end, and a lumen defined between the proximal and distal ends; a retention sleeve (12) fixed around the distal section of the deployment tube and having a distal extension extending a short distance past the distal end of the deployment tube; and a coupling

element attached to the proximal end of the endovascular device (16) and releasably held within the distal extension of the retention sleeve near the distal end of the deployment tube to be displaceable from the retention sleeve in response to fluid pressure applied to the coupling element through the lumen and the distal end of the deployment tube. An INDEPENDENT CLAIM is included for a method of deploying a **filamentous** endovascular device into a target vascular site, which comprises providing a **filamentous** endovascular device; introducing the endovascular device intravascularly to the target vascular site while it is attached to the deployment tube; and injecting a liquid under pressure through the lumen to separate the endovascular device from the deployment tube in response to the liquid pressure applied to the coupling element through the open distal end of the deployment tube.

USE - The deployment mechanism is used for deploying **filamentous** endovascular device, e.g. embolic implant, into a target vascular site in a patient's vasculature.

ADVANTAGE - The invention provides a secure attachment of the embolic implant to a deployment instrument during the deployment process, while also allowing for the easy and reliable detachment of the embolic implant once it is properly situated with respect to the target site. It also provides improved control of the implant during deployment, and allows the implant to be easily repositioned before detachment. It can readily be used for various endovascular implants without adding to their costs.

DESCRIPTION OF DRAWING(S) - The figure is an elevational view of an endovascular device deployment mechanism with an endovascular device attached to it.

Deployment tube 10

Retention sleeve 12

Endovascular device 16

Dwg.1/19

L18 ANSWER 16 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2001-343247 [36] WPIX
 CROSS REFERENCE: 2002-691223 [74]; 2003-266113 [26]; 2004-339065 [31];
 2006-492530 [50]
 DOC. NO. NON-CPI: N2001-248588
 DOC. NO. CPI: C2001-106231
 TITLE: **Embolization** device for, e.g. vascular aneurysm, comprises expandable embolizing micropellet connected to **filamentous** carrier at fixed location.
 DERWENT CLASS: A96 P31 P32 P34
 INVENTOR(S): COX, B J; GREENE, G R; ROSENBLUTH, R
 F
 PATENT ASSIGNEE(S): (MICR-N) MICROVENTION INC
 COUNTRY COUNT: 95
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001028434	A1	20010426	(200136)*	EN	38
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ					
NL OA PT SD SE SL SZ TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM					
DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC					
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE					
SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW					
US 6238403	B1	20010529	(200138)		
AU 2000077396	A	20010430	(200148)		

US 6299619 B1 20011009 (200162)
 BR 2000014482 A 20020611 (200248)
 EP 1225836 A1 20020731 (200257) EN
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI
 CN 1376041 A 20021023 (200313)
 JP 2003511188 W 20030325 (200330) 36
 AU 777822 B2 20041104 (200504)
 AU 2005200324 A1 20050224 (200521)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001028434	A1	WO 2000-US26926	20000929
US 6238403	B1	US 1999-410970	19991004
AU 2000077396	A	AU 2000-77396	20000929
US 6299619	B1 CIP of	US 1999-410970	19991004
		US 2000-542145	20000404
BR 2000014482	A	BR 2000-14482	20000929
		WO 2000-US26926	20000929
EP 1225836	A1	EP 2000-967148	20000929
		WO 2000-US26926	20000929
CN 1376041	A	CN 2000-813238	20000929
JP 2003511188	W	WO 2000-US26926	20000929
		JP 2001-531033	20000929
AU 777822	B2	AU 2000-77396	20000929
AU 2005200324	A1	AU 2005-200324	20050127

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000077396	A Based on	WO 2001028434
BR 2000014482	A Based on	WO 2001028434
EP 1225836	A1 Based on	WO 2001028434
JP 2003511188	W Based on	WO 2001028434
AU 777822	B2 Previous Publ.	AU 2000077396
	Based on	WO 2001028434
AU 2005200324	A1 Div ex	AU 777822

PRIORITY APPLN. INFO: US 2000-542145 20000404; US
 1999-410970 19991004

AN 2001-343247 [36] WPIX
 CR 2002-691223 [74]; 2003-266113 [26]; 2004-339065 [31]; 2006-492530 [50]
 AB WO 200128434 A UPAB: 20060804

NOVELTY - An **embolization** device comprises an elongate, **filamentous** carrier and an expandable embolizing micropellet non-releasably connected to the carrier at a fixed location.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of embolizing a vascular site comprising passing a microcatheter intravascularly so that its distal end is in a vascular site; providing a vascular **embolization** device comprising highly expandable embolizing micropellet(s) mechanically connected to a flexible **filamentous** carrier at a fixed location; passing the **embolization** device through the microcatheter so that it emerges from the distal end of the microcatheter into the vascular site; and expanding the embolizing micropellet in situ to fill the site with the embolizing micropellet(s) and the carrier while maintaining the connection

between the embolizing micropellet(s) and the carrier.

USE - For embolizing vascular aneurysm and vascular anomalies, e.g., arteriovenous malformations, arteriovenous fistulas.

ADVANTAGE - The invented device can be deployed within a vascular site with excellent locational control and with lower risk of vascular rupture, tissue damage, or migration. It effects a conformal fit within the site to promote effective **embolization** and facilitates precise and highly controllable deployment through its ability to be delivered to the site through a microcatheter.

DESCRIPTION OF DRAWING(S) - The figure shows a vascular **embolization** device of the invention.

Embolizing micropellet 12

Microcoil spacer 16

Dwg.1/13

L18 ANSWER 17 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2001-244347 [25] WPIX
 CROSS REFERENCE: 1999-312559 [26]
 DOC. NO. NON-CPI: N2001-173954
 DOC. NO. CPI: C2001-073290
 TITLE: Liquid embolic delivery system including a catheter with a lumen, a containment member, and a detachment mechanism.
 DERWENT CLASS: B07 P31 P34
 INVENTOR(S): CRAGG, H; GREENE, R; GREFF, J; JONES, M; PERL, ; WALKER, D; WALLACE, G; CRAGG, A H; **GREENE, G R**; GREFF, R J; PERL, J; WALKER, B D
 PATENT ASSIGNEE(S): (MICR-N) MICRO THERAPEUTICS INC; (CRAG-I) CRAGG A H; (GREE-I) GREENE G R; (GREF-I) GREFF R J; (JONE-I) JONES M; (PERL-I) PERL J; (WALK-I) WALKER B D; (WALL-I) WALLACE G
 COUNTRY COUNT: 28
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001015608	A1	20010308	(200125)*	EN	32
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: CA JP					
EP 1207791	A1	20020529	(200243)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT					
RO SE SI					
US 6511468	B1	20030128	(200311)		
US 2003040733	A1	20030227	(200318)		
JP 2003508107	W	20030304	(200319)		30
EP 1207791	B1	20041006	(200466)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
DE 60014672	E	20041111	(200474)		
DE 60014672	T2	20051117	(200576)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001015608	A1	WO 2000-US40603	20000807
EP 1207791	A1	EP 2000-965597	20000807
		WO 2000-US40603	20000807
US 6511468	B1 CIP of	US 1997-953149	19971017
		US 1999-387274	19990831

US 2003040733	A1 CIP of Cont of	US 1997-953149	19971017
		US 1999-387274	19990831
		US 2002-242469	20020913
JP 2003508107	W	WO 2000-US40603	20000807
		JP 2001-519825	20000807
EP 1207791	B1	EP 2000-965597	20000807
		WO 2000-US40603	20000807
DE 60014672	E	DE 2000-00014672	20000807
		EP 2000-965597	20000807
		WO 2000-US40603	20000807
DE 60014672	T2	DE 2000-00014672	20000807
		EP 2000-965597	20000807
		WO 2000-US40603	20000807

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1207791	A1 Based on	WO 2001015608
US 6511468	B1 CIP of	US 6146373
US 2003040733	A1 CIP of	US 6146373
JP 2003508107	W Based on	WO 2001015608
EP 1207791	B1 Based on	WO 2001015608
DE 60014672	E Based on	EP 1207791
	Based on	WO 2001015608
DE 60014672	T2 Based on	EP 1207791
	Based on	WO 2001015608

PRIORITY APPLN. INFO: US 1999-387274 19990831; US
 1997-953149 19971017; US
 2002-242469 20020913

AN 2001-244347 [25] WPIX

CR 1999-312559 [26]

AB WO 200115608 A UPAB: 20051125

NOVELTY - A liquid embolic delivery system, comprising a catheter with a lumen for delivery of a liquid embolic composition to a cavity, and a containment member, is new. A detachment mechanism is provided for completely detaching the containment member from the catheter after solidification of the composition to allow separation of the catheter from a mass of solidified embolic composition.

DETAILED DESCRIPTION - A liquid embolic delivery system (120) comprises a catheter (122) having a lumen (124, 126) for delivery of a liquid embolic composition to a cavity. A containment member is positioned at a distal end of the catheter and shaped to trap the liquid embolic composition delivered through the lumen. A detachment mechanism completely detaches the containment member from the catheter after solidification of the liquid embolic composition to allow separation of the catheter from a mass of solidified embolic composition.

An INDEPENDENT CLAIM is also included for a method of containing a liquid embolic composition at an **embolization** site within a body, comprising:

(1) delivering the composition to the site within the body with a catheter;

(2) containing the composition during solidification with a containment member; and

(3) detaching the containment member from the catheter after solidification of the liquid embolic composition to release the catheter from a mass of solidified embolic composition.

USE - For the delivery of liquid embolic compositions.

ADVANTAGE - The delivery system disturbs the blood flow into and out of the aneurysm (90) to improve control over the injection of the liquid embolic composition. The disturbance of blood flow into and out of the aneurysm through the aneurysm neck (92) creates a low turbulence or peaceful fluid environment within the aneurysm, which allows improved filling of the aneurysm with the embolic material.

DESCRIPTION OF DRAWING(S) - The figure shows a side cross sectional view of an aneurysm with an aneurysm neck flow disruption system.

Aneurysm 90

Aneurysm neck 92

Delivery system 120

Catheter 122

Lumen 124, 126

Dwg.18/20

L18 ANSWER 18 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2000-147306 [13] WPIX
 DOC. NO. NON-CPI: N2000-109010
 DOC. NO. CPI: C2000-046121
 TITLE: Vascular implant device for embolizing a vascular site, such as vascular aneurysms and similar vascular abnormalities.
 DERWENT CLASS: A96 D22 P31 S05
 INVENTOR(S): COX, B J; GREENE, G R; ROSENBLUTH, R
 F; COX, J; GREENE, R; ROSENBLUTH, F; COX, B;
 GREENE, G; ROSENBLUTH, R
 PATENT ASSIGNEE(S): (MICR-N) MICROVENTION INC; (COXB-I) COX B J; (GREE-I) GREENE G R; (ROSE-I) ROSENBLUTH R F
 COUNTRY COUNT: 87
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000001308	A1	20000113	(200013)*	EN	29
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SL SZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB					
GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU					
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR					
TT UA UG UZ VN YU ZA ZW					
AU 9947312	A	20000124	(200027)		
US 6165193	A	20001226	(200103)		
BR 9911860	A	20010320	(200123)		
EP 1093346	A1	20010425	(200124)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
US 2001001835	A1	20010524	(200130)		
CN 1308507	A	20010815	(200174)		
JP 2002519134	W	20020702	(200246)		31
AU 754493	B	20021121	(200305)		
US 6500190	B2	20021231	(200305)		
US 2003083737	A1	20030501	(200331)		
US 2003088311	A1	20030508	(200337)		
EP 1093346	B1	20060315	(200622)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
US 7029487	B2	20060418	(200627)		
DE 69930385	E	20060511	(200634)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000001308	A1	WO 1999-US15108	19990702
AU 9947312	A	AU 1999-47312	19990702
US 6165193	A	US 1998-110816	19980706
BR 9911860	A	BR 1999-11860	19990702
		WO 1999-US15108	19990702
EP 1093346	A1	EP 1999-930869	19990702
		WO 1999-US15108	19990702
US 2001001835	A1 Cont of	US 1998-110816	19980706
		US 2000-730071	20001205
CN 1308507	A	CN 1999-808315	19990702
JP 2002519134	W	WO 1999-US15108	19990702
		JP 2000-557758	19990702
AU 754493	B	AU 1999-47312	19990702
US 6500190	B2 Cont of	US 1998-110816	19980706
		US 2000-730071	20001205
US 2003083737	A1 Cont of Div ex	US 1998-110816	19980706
		US 2000-730071	20001205
		US 2002-309442	20021204
US 2003088311	A1 Cont of Cont of	US 1998-110816	19980706
		US 2000-730071	20001205
		US 2002-320033	20021216
EP 1093346	B1	EP 1999-930869	19990702
		WO 1999-US15108	19990702
US 7029487	B2 Cont of Div ex	US 1998-110816	19980706
		US 2000-730071	20001205
		US 2002-309442	20021204
DE 69930385	E	DE 1999-630385	19990702
		EP 1999-930869	19990702
		WO 1999-US15108	19990702

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9947312	A Based on	WO 2000001308
BR 9911860	A Based on	WO 2000001308
EP 1093346	A1 Based on	WO 2000001308
JP 2002519134	W Based on	WO 2000001308
AU 754493	B Previous Publ. Based on	AU 9947312 WO 2000001308
US 6500190	B2 Cont of	US 6165193
US 2003083737	A1 Cont of Div ex	US 6165193 US 6500190
US 2003088311	A1 Cont of Cont of	US 6165193 US 6500190
EP 1093346	B1 Based on	WO 2000001308
US 7029487	B2 Cont of Div ex	US 6165193 US 6500190
DE 69930385	E Based on Based on	EP 1093346 WO 2000001308

PRIORITY APPLN. INFO: US 1998-110816 19980706; US
2000-730071 20001205; US
2002-309442 20021204; US
2002-320033 20021216

AN 2000-147306 [13] WPIX
AB WO 200001308 A UPAB: 20000313

NOVELTY - A vascular device (20) for embolizing a vascular site (40), has a compressed configuration which is expandable into an expanded configuration conforming to the shape and size of the vascular site.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

- (A) manufacturing a vascular implant device comprising:
 - (i) imaging a vascular site by scanning the site to create a digitized scan data set;
 - (ii) creating a three-dimensional digitized virtual model of the vascular site using the scan data set, and
 - (iii) forming a vascular implant device in the configuration of a physical model of the vascular site, using the virtual model, the implant being formed from a compressible foam material;
- (B) embolizing a vascular site comprising:
 - (i) providing the invented vascular implant,
 - (ii) compressing the implant into a compressed configuration,
 - (iii) deploying the implant in a vascular site with a microcatheter, while the implant is in its compressed configuration, and
 - (iv) expanding the implant in situ to fill the vascular site; and
- (C) an apparatus (30) for embolizing a vascular site (40) comprising:
 - (i) a microcatheter having a distal end and a proximal end,
 - (ii) an invented vascular implant device (20),
 - (iii) a retention element contained within the microcatheter and having a distal end detachably connected to the implant device, and
 - (iv) a deployment element operably associated with the retention element and engageable against the implant device to separate the implant device from the retention element when the implant device has emerged from the distal end of the microcatheter.

USE - The vascular implant is used for embolizing a vascular site, to occlude vascular bleeding, the blood supply to tumors, and vascular aneurysms, particularly intracranial aneurysms.

ADVANTAGE - The vascular implant provides an effective vascular **embolization** implant that can be deployed within a vascular site with excellent locational control, and with a lower risk of vascular rupture, tissue damage, or migration than the prior art implant devices. The implant device, by being modeled on the actual vascular site in which it is to be implanted, effects a conformal fit within the site that promotes effective **embolization**, and yet its ability to be delivered to the site in a highly compressed configuration facilitates precise and highly controllable deployment with a microcatheter. It can effectively embolize vascular sites having a wide variety of sizes, configurations, and (in particular case of aneurysms) neck widths.

DESCRIPTION OF DRAWING(S) - The figure shows a schematic view of an implant device free of the implanting apparatus.

Implant device 20
 Implanting apparatus 30
 Vascular site 40

Dwg.10/10

L18 ANSWER 19 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2000-023238 [02] WPIX
 DOC. NO. NON-CPI: N2000-017316
 DOC. NO. CPI: C2000-005615
 TITLE: Apparatus for vascular **embolization** of a targeted site, such as an aneurysm in the blood vessel.
 DERWENT CLASS: A96 P31
 INVENTOR(S): COX, B J; GREENE, G R; ROSENBLUTH, R
 F; COX, J; GREENE, R; ROSENBLUTH, F; GREEN, G R
 PATENT ASSIGNEE(S): (MICR-N) MICROVENTION INC

COUNTRY COUNT: 87
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9955239	A1	19991104	(200002)*	EN	31
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW					
US 6015424	A	20000118	(200011)		
AU 9938609	A	19991116	(200015)		
BR 9910027	A	20001226	(200103)		
EP 1073377	A1	20010207	(200109)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
CN 1298287	A	20010606	(200157)		
US 6375669	B1	20020423	(200232)		
JP 2002512837	W	20020508	(200234)		32
AU 764797	B	20030828	(200361)		
AU 2003264582	A1	20040108	(200442)#		
EP 1073377	B1	20041117	(200476)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
DE 69921979	E	20041223	(200501)		
EP 1518502	A1	20050330	(200522)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
ES 2232136	T3	20050516	(200535)		
DE 69921979	T2	20051124	(200581)		
CN 1200648	C	20050511	(200652)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9955239	A1	WO 1999-US7399	19990423
US 6015424	A	US 1998-69008	19980428
AU 9938609	A	AU 1999-38609	19990423
BR 9910027	A	BR 1999-10027	19990423
		WO 1999-US7399	19990423
EP 1073377	A1	EP 1999-921377	19990423
		WO 1999-US7399	19990423
CN 1298287	A	CN 1999-805608	19990423
US 6375669	B1 Cont of	US 1998-69008	19980428
		US 1999-471507	19991223
JP 2002512837	W	WO 1999-US7399	19990423
		JP 2000-545447	19990423
AU 764797	B	AU 1999-38609	19990423
AU 2003264582	A1	AU 2003-264582	20031126
EP 1073377	B1	EP 1999-921377	19990423
		WO 1999-US7399	19990423
	Related to	EP 2004-19762	19990423
DE 69921979	E	DE 1999-621979	19990423
		EP 1999-921377	19990423
		WO 1999-US7399	19990423
EP 1518502	A1 Div ex	EP 1999-921377	19990423

ES 2232136	T3	EP 2004-19762	19990423
DE 69921979	T2	EP 1999-921377	19990423
		DE 1999-621979	19990423
		EP 1999-921377	19990423
		WO 1999-US7399	19990423
CN 1200648	C	CN 1999-805608	19990423

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9938609	A Based on	WO 9955239
BR 9910027	A Based on	WO 9955239
EP 1073377	A1 Based on	WO 9955239
US 6375669	B1 Cont of	US 6015424
JP 2002512837	W Based on	WO 9955239
AU 764797	B Previous Publ.	AU 9938609
	Based on	WO 9955239
AU 2003264582	A1 Div ex	AU 764797
EP 1073377	B1 Based on	WO 9955239
DE 69921979	E Based on	EP 1073377
	Based on	WO 9955239
EP 1518502	A1 Div ex	EP 1073377
ES 2232136	T3 Based on	EP 1073377
DE 69921979	T2 Based on	EP 1073377
	Based on	WO 9955239

PRIORITY APPLN. INFO: US 1998-69008 19980428; US
 1999-471507 19991223; AU
 2003-264582 20031126

AN 2000-023238 [02] WPIX

AB WO 9955239 A UPAB: 20000112

NOVELTY - The apparatus comprises of flexible elongated hollow deployment tube, (16) which can be inserted through the axial lumen of a micro catheter (14). The distal end of the deployment tube is detachably fixed to the proximal end of a **filamentous** embolic device. The embolic device can be transformed from soft flexible state to a rigid or semi-rigid state.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(i) The vascular embolic device; and
 (iii) Method of embolizing a vascular site, which involves deploying a catheter such that its distal end is adjacent to the vascular site.

The soft, flexible embolic device is then deployed through the catheter into the vascular site, where the device forms a web-like mass (40). The embolic device is then transformed from its soft state to its rigid or semi-rigid state.

USE - For occluding a blood vessel by embolizing a targeted site, such as an aneurysm in the blood vessel.

ADVANTAGE - The apparatus enables the formation of a stable thrombogenic plug inside the aneurysm. The embolic device is inserted into the aneurysm in a soft and compliant state, hence the risk of aneurysm rupture or vascular damage is minimized. The location of the embolic device can be controlled until it is detached from the deployment tube. The embolic device can be used in aneurysms of different shapes and sizes, without the risk of the device migrating out of the aneurysm.

DESCRIPTION OF DRAWING(S) - The figure shows embolic device inserted into an aneurysm.

Micro catheter; 14

Deployment tube; 16
 Web-like mass 40
 Dwg.3/16

L18 ANSWER 20 OF 20 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 1996-333091 [33] WPIX
 TITLE: Method for forming threading on suture anchor for driving
 into bone - involves providing anchor with eyelet and
 driving suture into bone and engaging with implement to
 remove suture through eyelet.
 DERWENT CLASS: P31
 INVENTOR(S): BRENNEMAN, R; GREENE, G R
 PATENT ASSIGNEE(S): (VESI-N) VESICA MEDICAL INC
 COUNTRY COUNT: 1
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 5534011	A	19960709	(199633)*		6

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 5534011	A	US 1994-330343	19941027

PRIORITY APPLN. INFO: US 1994-330343 19941027

AN 1996-333091 [33] WPIX

AB US 5534011 A UPAB: 19960823

The method comprises of providing a suture anchor having an eyelet, with at least a portion of a pre-installed suture engaging implement passed through the eyelet. Then driving the suture anchor into a bone, leaving the eyelet and the suture engaging implement exposed. Then engaging a suture with the suture engaging implement and removing the suture engaging implement from the eyelet so as to pull the suture through the eyelet. Finally disengaging the suture engaging implement from the suture.

The suture engaging implement comprises a thin, flexible tube having an open end. The tube is pre-installed in the anchor by passing it through the eyelet. One end of the suture is pushed into the open end of the tube. The tube is pulled out of the eyelet so as to pull the suture through the eyelet. The end of the suture is then removed from the open end of the tube. In an alternative method it employs a loop of flexible, **filamentous** material as the suture engaging implement. The loop is pre-installed in the anchor by passing a portion of the loop through the eyelet. One end of the suture is passed through the portion of the loop that has been passed through the eyelet. The loop is pulled out of the eyelet so as to pull the suture through the eyelet. The suture is then removed from the loop.

ADVANTAGE - greatly facilitates the threading of the suture through the eyelet of the anchor, reduces the risk of damage off suture during installation.

Dwg.4/7

=> d his

(FILE 'HOME' ENTERED AT 14:22:54 ON 15 AUG 2006)

FILE 'HCAPLUS' ENTERED AT 14:23:17 ON 15 AUG 2006

L1 0 (US2004059370 OR US6299619 OR US6238403 OR US6602261 OR US62996

FILE 'WPIX' ENTERED AT 14:26:38 ON 15 AUG 2006

L2 7 L1
SEL AN 1-4 6-7
L3 6 L2 AND E1-6

FILE 'HCAPLUS' ENTERED AT 14:27:30 ON 15 AUG 2006

E GREENE G/AU
L4 31 E3,E16
E CRUISE G/AU
L5 9 E4-6
E CONSTANT M/AU
L6 41 E3-6
E CONSTANT MICHAEL/AU
L7 4 E3-5
E COX B/AU
L8 399 E3,E12
E COX BRIAN/AU
L9 142 E3,E12-13
E TRAN T/AU
L10 358 E3-32
E TRAN TERRANCE/AU
E EMBOL/CT
E E8+ALL
L11 6015 E5+OLD,RT
E THROMBUS/CT
E E3+ALL
L12 3683 E5+OLD
E E24+ALL
L13 215 E4
E THROMBOSIS/CT
L14 13179 E3+OLD,NT
E THROMBOLYTICS/CT
E E3+ALL
L15 2788 E4
L16 4 L4-10 AND L11-15
SEL AN 1-2
L17 2 L16 AND E1-4
E HYDROGELS/CT
L18 7789 E3-7
E E3+ALL
L19 8818 E9+OLD
E POLYMERS/CT
L20 6689 (POLYMERS+OLD,NT1/CT OR POLYMER#/CW) (L) HYDROPHIL?
L21 10004 (POLYMERS+OLD,NT1/CT OR POLYMER#/CW) (L) (WATER SOL?)
L22 230 (POLYMERS+OLD,NT1/CT OR POLYMER#/CW) (L) (H2O SOL?)
L23 4 (POLYMERS+OLD,NT1/CT OR POLYMER#/CW) (L) STRETCH RESIST?
L24 16734 L20-23
E ANTI-EMBOL/CT
E ANTIEMBOL/CT
L25 81 L18-19,L24 AND L11-15
L26 1 L25 AND L4-10
L27 80 L25 NOT L26

```

L28      25 L27 AND (PY<=1999 OR AY<=1999 OR PRY<=1999)
          E MEDICAL/CT
          E E15 ALL
          E MEDICAL/CT
          E E15+ALL
          E E2+ALL
L29      40128 E4+OLD
          E MEDICAL IN/CT
          E E5+ALL
L30      8 L28 AND L29
          SEL AN 1-4 6-8
L31      7 E1-14 AND L30
L32      9 L17,L26,L31
L33      9 L32 AND L1,L4-31

FILE 'WPIX' ENTERED AT 14:58:07 ON 15 AUG 2006
L34      142031 A12-V03D/MC OR (B3521 OR B3372)/PLE
L35      29816 (B11-C04? OR C11-C04?)/MC
L36      2224 (B04-H19 OR C04-H19)/MC
L37      158 L34 AND L36
L38      67 L37 AND L35
L39      4 L38 NOT (PY>1999 OR AY>1999 OR AY>1999)
L40      301 L34 AND L35 AND (BLOOD CLOT? OR EMBOL? OR THROMB?)
L41      31 L40 NOT (PY>1999 OR AY>1999 OR AY>1999)
L42      29 L41 AND A96/DC
          SEL AN 1 3 5 7 10 11 20
L43      7 L42 AND E15-21
L44      13 L3,L43
  
```

=> b hcap

FILE 'HCAPLUS' ENTERED AT 15:34:22 ON 15 AUG 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Aug 2006 VOL 145 ISS 8
 FILE LAST UPDATED: 14 Aug 2006 (20060814/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all 133 tot

L33 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:987688 HCAPLUS
 DN 141:416082

ED Entered STN: 18 Nov 2004
 TI In situ polymerizable hydrogels
 IN Sawhney, Amarpreet S.
 PA Incept LLC, USA
 SO U.S., 18 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM A61F-0002/02
 INCL 623011110; 623023580; 623926000; 523113000
 CC 63-7 (Pharmaceuticals)
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US---6818018	B1	20041116	1998US-0133940	19980814 <--
PRAI 1998US-0133940		19980814 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6818018	ICM	A61F-0002/02
	INCL	623011110; 623023580; 623926000; 523113000
	IPCI	A61F0002-02 [ICM,7]
	IPCR	A61L0027-00 [I,C*]; A61L0027-34 [I,A]; A61L0027-52 [I,A]; A61L0031-08 [I,C*]; A61L0031-10 [I,A]; A61L0031-14 [I,A]; A61L0031-14 [I,C*]
	NCL	623/011.110; 523/113.000; 623/023.580; 623/926.000
	ECLA	A61L027/34; A61L027/52; A61L031/10; A61L031/14F

AB Compsns. and methods for forming hydrogels in situ through a combination of phys. and chemical crosslinking processes are provided in which phys. crosslinking is mediated by one or more natural or synthetic components that stabilize the hydrogel-forming precursor solns. at a deposition site for a period of time sufficient for more resilient chemical crosslinks to form. Methods of using such hydrogels as tissue coatings to prevent postsurgical adhesion formation, as tissue augmentation or luminal occlusion aids, as matrixes for carrying cells, drugs or other bioactive species, as tissue sealants or adhesives, and as medical device coatings are also provided. Tissue augmentation with in situ formed hydrogel is exemplified. A water-soluble crosslinking agent solution containing 20% of a polyethylene glycol-based bifunctional crosslinking agent (preparation given) and 18% of Pluronic F127 in phosphate buffered saline and a water-soluble crosslinkable polymer, such as poly(L-lysine), dissolved at 5% in a sodium borate buffered solution at a pH 11 which addnl. contains 18% Pluronic F127 were drawn into a multichamber syringe and injected onto or into tissues in need of augmentation. As the plunger of the syringe is depressed and the material is injected beneath the skin, the components mix in the needle of syringe and crosslink in situ. Some of the activated polymer mols. addnl. may crosslink to the patient's own proteins and other natural materials to anchor the implant in place. Preferably, contact of the solns. (which are at room temperature or cooler), with tissue at warmer

physiol. temps. will result in an immediate increase in viscosity and gelation due to phys. crosslinking. Within about 1-2 min a firm gel should result due to the subsequent chemical crosslinking.

ST polymer crosslinking gelation hydrogel implant drug carrier

IT Diagnosis

(agents, carriers for; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT Polymerization

(anionic; in situ formation of hydrogels by crosslinking of water-soluble

precursors for biomedical uses)

IT Artery
(artificial, hydrogel coating of; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT Animal tissue
(augmentation or luminal occlusion of; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT Adhesives
(biol. tissue; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT Enzymes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carriers for; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT Drug delivery systems
(carriers; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT Polymerization
(cationic; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT **Medical goods**
(coatings for; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT Polymerization
(condensation; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT Eye
(cornea, shields; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT Contact lenses
(corneal shields; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT **Medical goods**
(dressings, coatings for; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT **Embolism**
(embolization; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT Animal cell
(encapsulation of; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT Hemoglobins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(encapsulation of; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT Liver
(hepatocyte, transplantation of; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT Drug delivery systems
(hydrogels; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT Drug delivery systems
Prosthetic materials and Prosthetics
(implants; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT Coating materials
Crosslinking
Crosslinking agents
Gelation

Hydrogels

Polyelectrolytes

Stabilizing agents

(in situ formation of hydrogels by crosslinking of **water-soluble** precursors for biomedical uses)

IT **Fluoropolymers, biological studies**

RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(in situ formation of hydrogels by crosslinking of **water-soluble** precursors for biomedical uses)

IT **Macromonomers**

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(in situ formation of hydrogels by crosslinking of **water-soluble** precursors for biomedical uses)

IT **Polyoxyalkylenes, biological studies**

RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)

(in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT **Polyesters, biological studies**

RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)

(lactic acid-based; in situ formation of hydrogels by crosslinking of **water-soluble** precursors for biomedical uses)

IT **Encapsulation**

(microencapsulation, of cells and tissues; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT **Transplant and Transplantation**

(of liver cells; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT **Polymers, biological studies**

RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)

(pH responsive and thermoreversible; in situ formation of hydrogels by crosslinking of **water-soluble** precursors for biomedical uses)

IT **Polymerization**

(photopolymer.; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT **Pericardium**

(prevention of postsurgical adhesion; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT **Adhesion, biological**

(prevention of postsurgical; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT **Polymerization**

(radical; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT **Polymerization**

(step-growth; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT **Medical goods**

(sutures, coatings for; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

IT **Medical goods**

(tissue adhesives; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

- IT 51-61-6, Dopamine, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (-secreting cells, encapsulation of; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)
- IT 139639-23-9, Tissue plasminogen activator
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (carriers for; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)
- IT 67-45-8, Furoxone 76-61-9, Thymol Blue 88-89-1, Picric acid
 143-74-8, Phenol Red 1837-57-6, Rivanol
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (color indicator; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)
- IT 6066-82-6DP, reaction products with polyoxyalkylene-polyesters
 91628-97-6DP, N-hydroxysuccinimide terminated
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)
 (in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)
- IT 9003-01-4, Poly(acrylic acid) 25104-18-1, Poly(L-lysine) 25322-68-3D,
 Polyethylene glycol, acrylate-terminated 26023-30-3,
 Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26100-51-6, Poly(DL-lactic
 acid) 26570-48-9, Polyethylene glycol diacrylate 38000-06-5,
 Poly(L-lysine)
 RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT
 (Reactant or reagent); USES (Uses)
 (in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)
- IT 299-29-6, Ferrous gluconate 7722-84-1, Hydrogen peroxide, biological
 studies 691397-13-4, Pluronic F 127
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)
- IT 9002-84-0, Gore-Tex
 RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological
 study); USES (Uses)
 (vascular graft, coatings for; in situ formation of hydrogels by crosslinking of water-soluble precursors for biomedical uses)

RE.CNT 89 THERE ARE 89 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Abuchowski, A; Cancer Biochem Biophys 1984, V7, P175 HCAPLUS
- (2) Anon; WO---9013540 1990 HCAPLUS
- (3) Anon; WO---9425080 1994 HCAPLUS
- (4) Anon; WO---9719973 1997 HCAPLUS
- (5) Anon; WO---9722371 1997 HCAPLUS
- (6) Anon; WO---9908718 1999 HCAPLUS
- (7) Anon; The Drug, The Nurse, The Patient (Including Current Drug Handbook),
 Falconer's 7th Ed 1974
- (8) Balazs; US---4141973 A 1979 HCAPLUS
- (9) Barrows; US---5583114 A 1996 HCAPLUS
- (10) Barry; US---5266326 A 1993 HCAPLUS
- (11) Bhatia, S; J Biomater Sci Polymer Edn 1994, V6(5), P435 HCAPLUS
- (12) Boyers, S; Fertility and Sterility 1988, V49(6), P1066 MEDLINE
- (13) Brannan; US---5366498 A 1994
- (14) Burger, A; Medicinal Chemistry, 3rd Ed, Parts 1 and 2
- (15) Cerny; US---5385561 A 1995
- (16) Chung, R; Progress in Organic Coatings 1992, V21(4), P227
- (17) Coury; US---6162241 A 2000

- (18) Damani; US---5198220 A 1993 HCAPLUS
- (19) Daniels; US---3949073 A 1976 HCAPLUS
- (20) Debelder; US---4886787 A 1989 HCAPLUS
- (21) Doi; US---4839345 A 1989 HCAPLUS
- (22) Dunn; US---5599552 A 1997
- (23) Dunn; US---5990194 A 1999 HCAPLUS
- (24) Edwards; US---5588960 A 1996
- (25) English; US---4804691 A 1989 HCAPLUS
- (26) Fan; US---5509899 A 1996
- (27) Fukui; US---4195129 A 1980 HCAPLUS
- (28) Goldberg; US---5140016 A 1992 HCAPLUS
- (29) Guire; US---4979959 A 1990
- (30) Henry; US---4911926 A 1990 HCAPLUS
- (31) Henry; US---5126141 A 1992 HCAPLUS
- (32) Higham; US---4994277 A 1991 HCAPLUS
- (33) Higham; US---5093319 A 1992 HCAPLUS
- (34) Holtz, G; Fertility and Sterility 1984, V41(4), P497 MEDLINE
- (35) Hoover, J; Remington's Pharamceutical Sciences, 14th Ed 1970
- (36) Hubbell; US---5410016 A 1995 HCAPLUS
- (37) Hubbell; US---5462990 A 1995 HCAPLUS
- (38) Hubbell; US---5529914 A 1996 HCAPLUS
- (39) Hubbell; US---5573934 A 1996 HCAPLUS
- (40) Hubbell; US---5626863 A 1997 HCAPLUS
- (41) Jarrett, P; Trans Soc Biomater 1995, VXVIII, P182
- (42) Johnson; US---5304147 A 1994
- (43) Ken; US---6113629 A 2000
- (44) Kowligi; US---5152782 A 1992
- (45) Leshchiner; US---5246698 A 1993 HCAPLUS
- (46) Lindblad; US---5190759 A 1993 HCAPLUS
- (47) Loomis; US---6005020 A 1999 HCAPLUS
- (48) Malette; US---4532134 A 1985 HCAPLUS
- (49) Matsuda; US---4740534 A 1988 HCAPLUS
- (50) Matsuda; US---5462976 A 1995 HCAPLUS
- (51) Meathrel; US---5665477 A 1997 HCAPLUS
- (52) Morrison; Organic Chemistry, Third Edition 1973, P27
- (53) Nagaoka, S; Polymers As Biomaterials 1984, P361
- (54) Naughton; US---5624840 A 1997 HCAPLUS
- (55) Nowinski; US---4511478 A 1985 HCAPLUS
- (56) Park, K; Biodegradable Hydrogels for Drug Delivery 1993
- (57) Park, K; Biomaterials 1988, V9, P435 HCAPLUS
- (58) Pathak; US---6201065 B1 2001 HCAPLUS
- (59) Perrault; US---4717378 A 1988
- (60) Polson; US---5660849 A 1997
- (61) Rhee; US---5744545 A 1998
- (62) Rhee; US---5752974 A 1998
- (63) Rhee; US---5874500 A 1999 HCAPLUS
- (64) Rhee; US---6051648 A 2000 HCAPLUS
- (65) Ronan; US---5820918 A 1998 HCAPLUS
- (66) Ronan; US---6060534 A 2000 HCAPLUS
- (67) Roth; US---5665063 A 1997
- (68) Roufa; US---5605938 A 1997 HCAPLUS
- (69) Rowe; US---5612050 A 1997 HCAPLUS
- (70) Rubinstein; US---4101380 A 1978
- (71) Sawhney, A; Macromolecules 1993, V26, P581 HCAPLUS
- (72) Schmitt; US---3991766 A 1976 HCAPLUS
- (73) Shalaby, S; Encyclopedia of Pharmaceutical Technology 1988, V1, P465
- (74) Shalaby, S; J Controlled Release 1992, V19, P131
- (75) Silberberg, A; Molecular Basis of Polymer Networks 1989, V42, P147
- (76) Slepian; US---5213580 A 1993

(77) Smith; US---5328939 A 1994 HCAPLUS
 (78) Smith, K; Ind Eng Chem 1959, V51(11), P1361
 (79) Stoy; US---4107121 A 1978 HCAPLUS
 (80) Stoy; US---5688855 A 1997 HCAPLUS
 (81) Taricco; US---3833003 A 1974
 (82) Tomalia; US---4507466 A 1985 HCAPLUS
 (83) Tomalia; US---4568737 A 1986 HCAPLUS
 (84) Wasserman; US---5171148 A 1992
 (85) Weissleder; US---5514379 A 1996 HCAPLUS
 (86) Woerly; US---5863551 A 1999 HCAPLUS
 (87) Yeung; US---5580923 A 1996 HCAPLUS
 (88) Zalipsky; US---5122614 A 1992 HCAPLUS
 (89) Zalipsky, S; J Macromol Sci-Chem 1984, VA21(6&7), P839

L33 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:716008 HCAPLUS
 DN 137:237799
 ED Entered STN: 20 Sep 2002
 TI Hydrogels that undergo volumetric expansion in response to changes in their environment and their methods of manufacture and use
 IN Cruise, Gregory M.; Constant, Michael J.
 PA Microvention, Inc., USA
 SO PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61F-0013/00
 ICS A61F-0002/00; A61K-0009/70; A61K-0009/14; A61K-0031/74; A61K-0047/48
 CC 63-7 (Pharmaceuticals)
 Section cross-reference(s): 38
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2002071994	A1	20020919	2002WO-US05988	20020228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US2002176880	A1	20021128	2001US-0804935	20010313
US---6878384	B2	20050412		
CA---2439925	AA	20020919	2002CA-2439925	20020228
EP---1372553	A1	20040102	2002EP-0750563	20020228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR2002008034	A	20040225	2002BR-0008034	20020228
JP2004528880	T2	20040924	2002JP-0570954	20020228
CN---1617694	A	20050518	2002CN-0806384	20020228
US2005196426	A1	20050908	2005US-0090806	20050324
PRAI 2001US-0804935	A	20010313		
2002WO-US05988	W	20020228		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002071994	ICM	A61F-0013/00

ICS A61F-0002/00; A61K-0009/70; A61K-0009/14; A61K-0031/74;
 A61K-0047/48
 IPCI A61F0013-00 [ICM,7]; A61F0002-00 [ICS,7]; A61K0009-70
 [ICS,7]; A61K0009-14 [ICS,7]; A61K0031-74 [ICS,7];
 A61K0047-48 [ICS,7]
 IPCR A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0049-04
 [I,A]; A61K0049-04 [I,C*]
 ECLA A61K009/00M5D; A61K049/04H8D
 US2002176880 IPCI A61F0013-00 [ICM,7]
 IPCR A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0049-04
 [I,A]; A61K0049-04 [I,C*]
 NCL 424/423.000
 ECLA A61K009/00M4; A61K049/04H8D; A61K009/00M5D
 CA---2439925 IPCI A61F0013-00 [ICM,7]; A61F0002-00 [ICS,7]; A61K0009-14
 [ICS,7]; A61K0047-48 [ICS,7]; A61K0009-70 [ICS,7];
 A61K0031-74 [ICS,7]
 IPCR A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0049-04
 [I,A]; A61K0049-04 [I,C*]
 ECLA A61K009/00M5D; A61K049/04H8D
 EP---1372553 IPCI A61F0013-00 [ICM,7]; A61F0002-00 [ICS,7]; A61K0009-70
 [ICS,7]; A61K0009-14 [ICS,7]; A61K0031-74 [ICS,7];
 A61K0047-48 [ICS,7]
 IPCR A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0049-04
 [I,A]; A61K0049-04 [I,C*]
 BR2002008034 IPCI A61F0013-00 [ICM,7]; A61F0002-00 [ICS,7]; A61K0009-70
 [ICS,7]; A61K0009-14 [ICS,7]; A61K0031-74 [ICS,7];
 A61K0047-48 [ICS,7]
 IPCR A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0049-04
 [I,A]; A61K0049-04 [I,C*]
 ECLA A61K009/00M5D; A61K049/04H8D
 JP2004528880 IPCI A61L0031-00 [ICM,7]; A61L0026-00 [ICS,7]; A61L0027-00
 [ICS,7]
 IPCR A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0049-04
 [I,A]; A61K0049-04 [I,C*]
 FTERM 4C081/AA02; 4C081/AA12; 4C081/AB13; 4C081/AC03;
 4C081/BA11; 4C081/BB02; 4C081/CA081; 4C081/CA101;
 4C081/CB041; 4C081/CC01; 4C081/CC05; 4C081/CF21;
 4C081/DA01; 4C081/DA12; 4C081/DB03; 4C081/DC12;
 4C081/EA02; 4C081/EA11; 4C081/EA13
 CN---1617694 IPCI A61F0013-00 [ICM,7]; A61F0002-00 [ICS,7]; A61K0009-70
 [ICS,7]; A61K0009-14 [ICS,7]; A61K0031-74 [ICS,7];
 A61K0047-48 [ICS,7]
 IPCR A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0049-04
 [I,A]; A61K0049-04 [I,C*]
 ECLA A61K009/00M5D; A61K049/04H8D
 US2005196426 IPCI A61F0002-00 [ICM,7]; A61K0009-14 [ICS,7]
 IPCR A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0049-04
 [I,A]; A61K0049-04 [I,C*]
 NCL 424/426.000
 ECLA A61K009/00M5D; A61K049/04H8D

AB Hydrogels that expand volumetrically in response to a change in their
 environment (e.g., a change in pH or temperature) and their methods of
 manufacture
 and use. Generally, the hydrogels are prepared by forming a liquid reaction
 mixture that contains (a) monomer(s) and/or polymer(s) at least portion(s)
 of which are sensitive to environmental changes (e.g., changes in pH or
 temperature), (b) a crosslinker and (c) a polymerization initiator. If
 desired, a
 porosigen may be incorporated into the liquid reaction mixture to create

pores. After the hydrogel is formed, the porosigen is removed to create pores in the hydrogel. The hydrogel may also be treated to cause it to assume a non-expanded volume in which it remains until a change in its environment causes it to expand. These hydrogels may be prepared in many forms including pellets, filaments, and particles. Biomedical uses of these hydrogels include applications wherein the hydrogel is implanted in the body of a patient and an environmental condition at the implantation site causes the hydrogel to expand it situ. A hydrogel was prepared by the polymerization of acrylamide, sodium acrylate, and

N,N-methylene-bis-acrylamide.

The hydrogel can be used for embolization of aneurysm.

ST hydrogel expansion environment temp pH; acrylic polymer hydrogel embolization aneurysm

IT Blood vessel, disease
(arteriovenous malformation; hydrogels that undergo volumetric expansion in response to changes in their environment)

IT **Medical goods**
(catheters; hydrogels that undergo volumetric expansion in response to changes in their environment)

IT Imaging agents
(contrast, radiog.; hydrogels that undergo volumetric expansion in response to changes in their environment)

IT **Embolism**
(embolization; hydrogels that undergo volumetric expansion in response to changes in their environment)

IT Aneurysm

Catalysts

Crosslinking agents

Expansion

Ice

Polymerization catalysts

Porosity

Temperature

pH

(hydrogels that undergo volumetric expansion in response to changes in their environment)

IT Acrylic polymers, biological studies

RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(hydrogels that undergo volumetric expansion in response to changes in their environment)

IT Polymers, biological studies

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(hydrogels that undergo volumetric expansion in response to changes in their environment)

IT Drug delivery systems

(hydrogels; hydrogels that undergo volumetric expansion in response to changes in their environment)

IT Drug delivery systems

(implants; hydrogels that undergo volumetric expansion in response to changes in their environment)

IT Blood vessel, disease

(occlusion; hydrogels that undergo volumetric expansion in response to changes in their environment)

IT 110-26-9

RL: POF (Polymer in formulation); RCT (Reactant); RACT (Reactant or reagent); USES (Uses)

(crosslinker; hydrogels that undergo volumetric expansion in response to changes in their environment)

IT 51-80-9, N,N,N',N'-Tetramethylmethylenediamine 7727-54-0, Ammonium persulfate
 RL: CAT (Catalyst use); USES (Uses)
 (hydrogels that undergo volumetric expansion in response to changes in their environment)

IT 33882-67-6P
 RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (hydrogels that undergo volumetric expansion in response to changes in their environment)

IT 57-50-1, Sucrose, uses 144-55-8, Sodium bicarbonate, uses 7447-40-7, Potassium chloride, uses 7647-14-5, Sodium chloride, uses
 RL: NUU (Other use, unclassified); USES (Uses)
 (hydrogels that undergo volumetric expansion in response to changes in their environment)

IT 7440-06-4, Platinum, biological studies 7440-25-7, Tantalum, biological studies 7440-57-5, Gold, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (hydrogels that undergo volumetric expansion in response to changes in their environment)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
 (1) Graham; US---5447727 A 1995 HCAPLUS
 (2) Harada; US---6333109 B1 2001 HCAPLUS
 (3) Vogel; US---6335028 B1 2002 HCAPLUS

L33 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:616378 HCAPLUS

DN 137:175033

ED Entered STN: 16 Aug 2002

TI Radiation cross-linked polymer hydrogels

IN **Cruise, Gregory M.**

PA Microvention, Inc., USA

SO U.S. Pat. Appl. Publ., 6 pp.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K-0031/74

ICS C08K-0003/00

INCL 523105000

CC 63-8 (Pharmaceuticals)

Section cross-reference(s): 38

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2002111392	A1	20020815	2001US-0783762	20010214
	US---6537569	B2	20030325		
	CA---2437870	AA	20020822	2002CA-2437870	20020213
	WO2002064189	A2	20020822	2002WO-US04166	20020213
	WO2002064189	A3	20021205		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP---1365704 A2 20031203 2002EP-0723139 20020213

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR2002007249 A 20040309 2002BR-0007249 20020213

CN---1496241 A 20040512 2002CN-0804996 20020213

JP2004520134 T2 20040708 2002JP-0563981 20020213

PRAI 2001US-0783762 A 20010214

2002WO-US04166 W 20020213

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2002111392	ICM	A61K-0031/74
	ICS	C08K-0003/00
	INCL	523105000
	IPCI	A61K0031-74 [ICM,7]; C08K0003-00 [ICS,7]
	IPCR	A61K0009-20 [I,A]; A61K0009-20 [I,C*]; A61K0031-74 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A]; A61L0024-00 [I,A]; A61L0024-00 [I,C*]; A61L0024-04 [I,A]; A61L0026-00 [I,A]; A61L0026-00 [I,C*]; A61L0027-00 [I,C*]; A61L0027-18 [I,A]; A61L0027-52 [I,A]; A61L0027-58 [I,A]; A61L0031-04 [I,C*]; A61L0031-06 [I,A]; A61L0031-14 [I,A]; A61L0031-14 [I,C*]; C08L0071-00 [I,C*]; C08L0071-02 [I,A]
	NCL	523/105.000
	ECLA	A61K009/20H6D; A61K031/765; A61L024/00H7; A61L026/00H7; A61L027/52; A61L031/14F
CA---2437870	IPCI	A61K0031-74 [ICM,7]; A61K0009-00 [ICS,7]; A61L0024-04 [ICS,7]; A61L0024-00 [ICS,7,C*]; A61L0027-14 [ICS,7]; A61L0027-00 [ICS,7,C*]; C08J0003-28 [ICS,7]; A61K0047-30 [ICS,7]; A61K0031-765 [ICS,7]
	IPCR	A61K0009-20 [I,A]; A61K0009-20 [I,C*]; A61K0031-74 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A]; A61L0024-00 [I,A]; A61L0024-00 [I,C*]; A61L0024-04 [I,A]; A61L0026-00 [I,A]; A61L0026-00 [I,C*]; A61L0027-00 [I,C*]; A61L0027-18 [I,A]; A61L0027-52 [I,A]; A61L0027-58 [I,A]; A61L0031-04 [I,C*]; A61L0031-06 [I,A]; A61L0031-14 [I,A]; A61L0031-14 [I,C*]; C08L0071-00 [I,C*]; C08L0071-02 [I,A]
WO2002064189	IPCI	A61F0002-02 [ICM,7]; A61K0047-30 [ICS,7]
	IPCR	A61K0009-20 [I,A]; A61K0009-20 [I,C*]; A61K0031-74 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A]; A61L0024-00 [I,A]; A61L0024-00 [I,C*]; A61L0024-04 [I,A]; A61L0026-00 [I,A]; A61L0026-00 [I,C*]; A61L0027-00 [I,C*]; A61L0027-18 [I,A]; A61L0027-52 [I,A]; A61L0027-58 [I,A]; A61L0031-04 [I,C*]; A61L0031-06 [I,A]; A61L0031-14 [I,A]; A61L0031-14 [I,C*]; C08L0071-00 [I,C*]; C08L0071-02 [I,A]
	ECLA	A61K009/20H6D; A61K031/765; A61L024/00H7; A61L026/00H7; A61L027/52; A61L031/14F
EP---1365704	IPCI	A61F0002-02 [ICM,7]; A61K0047-30 [ICS,7]
	IPCR	A61K0009-20 [I,A]; A61K0009-20 [I,C*]; A61K0031-74 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A]; A61L0024-00 [I,A]; A61L0024-00 [I,C*]; A61L0024-04 [I,A]; A61L0026-00 [I,A]; A61L0026-00 [I,C*]; A61L0027-00 [I,C*]; A61L0027-18 [I,A]; A61L0027-52

BR2002007249 IPCI [I,A]; A61L0027-58 [I,A]; A61L0031-04 [I,C*];
 IPCR A61L0031-06 [I,A]; A61L0031-14 [I,A]; A61L0031-14
 [I,C*]; C08L0071-00 [I,C*]; C08L0071-02 [I,A]
 A61F0002-02 [ICM,7]; A61K0047-30 [ICS,7]
 A61K0009-20 [I,A]; A61K0009-20 [I,C*]; A61K0031-74
 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
 A61L0024-00 [I,A]; A61L0024-00 [I,C*]; A61L0024-04
 [I,A]; A61L0026-00 [I,A]; A61L0026-00 [I,C*];
 A61L0027-00 [I,C*]; A61L0027-18 [I,A]; A61L0027-52
 [I,A]; A61L0027-58 [I,A]; A61L0031-04 [I,C*];
 A61L0031-06 [I,A]; A61L0031-14 [I,A]; A61L0031-14
 [I,C*]; C08L0071-00 [I,C*]; C08L0071-02 [I,A]
 CN---1496241 IPCI A61F0002-02 [ICM,7]; A61K0047-30 [ICS,7]
 IPCR A61K0009-20 [I,A]; A61K0009-20 [I,C*]; A61K0031-74
 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
 A61L0024-00 [I,A]; A61L0024-00 [I,C*]; A61L0024-04
 [I,A]; A61L0026-00 [I,A]; A61L0026-00 [I,C*];
 A61L0027-00 [I,C*]; A61L0027-18 [I,A]; A61L0027-52
 [I,A]; A61L0027-58 [I,A]; A61L0031-04 [I,C*];
 A61L0031-06 [I,A]; A61L0031-14 [I,A]; A61L0031-14
 [I,C*]; C08L0071-00 [I,C*]; C08L0071-02 [I,A]
 ECLA A61K009/20H6D; A61K031/765; A61L024/00H7; A61L026/00H7;
 A61L027/52; A61L031/14F
 JP2004520134 IPCI A61L0031-00 [ICM,7]
 IPCR A61K0009-20 [I,A]; A61K0009-20 [I,C*]; A61K0031-74
 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
 A61L0024-00 [I,A]; A61L0024-00 [I,C*]; A61L0024-04
 [I,A]; A61L0026-00 [I,A]; A61L0026-00 [I,C*];
 A61L0027-00 [I,C*]; A61L0027-18 [I,A]; A61L0027-52
 [I,A]; A61L0027-58 [I,A]; A61L0031-04 [I,C*];
 A61L0031-06 [I,A]; A61L0031-14 [I,A]; A61L0031-14
 [I,C*]; C08L0071-00 [I,C*]; C08L0071-02 [I,A]
 FTERM 4C081/AB11; 4C081/AB36; 4C081/AC06; 4C081/BA16;
 4C081/CA05; 4C081/CA08; 4C081/CA18; 4C081/CC06
 AB Radiation-crosslinked, biodegradable, synthetic hydrogels and their use in
 various applications, including certain medical applications wherein the
 hydrogel(s) are implanted on or in the body of a human or animal patient
 are described. Radiation-crosslinked, biodegradable, synthetic hydrogels
 of this invention may be prepared by irradiating monomers (e.g.,
 ethylenically unsatd. hydrocarbons such as acrylic monomers and
 methacrylic monomers) or polymers, some or which are biodegradable or
 which contain biodegradable units or subunits. Specific medical
 applications of these radiation-crosslinked, biodegradable, synthetic
 hydrogels include applications wherein the hydrogel is used for
 hemostasis, tissue augmentation, tissue engineering, embolization, closure
 of vascular punctures or wounds and other medical applications. For
 example, a biodegradable PEG hydrogel was prepared from
 monomethoxypoly(ethylene glycol) (mPEG)-succinic acid-mPEG macromer. The
 mPEG dimer (17.05 g) was dissolved in 82.5 g of 50 mM sodium phosphate pH
 5, the macromer solution was placed into syringes and the syringes were
 irradiated with 30 kGy of electron beam radiation.
 ST polymer hydrogel radiation crosslinking biomedical
 IT Body fluid
 (absorption; radiation cross-linked polymer hydrogels for biomedical
 applications)
 IT Animal tissue
 (augmentation; radiation cross-linked polymer hydrogels for biomedical
 applications)
 IT Adhesives

(biol. tissue; radiation cross-linked polymer hydrogels for biomedical applications)

IT Polymer degradation
(biol.; radiation cross-linked polymer hydrogels for biomedical applications)

IT Absorption
(body fluid; radiation cross-linked polymer hydrogels for biomedical applications)

IT Blood vessel
(closure of punctures of; radiation cross-linked polymer hydrogels for biomedical applications)

IT Wound
(closure; radiation cross-linked polymer hydrogels for biomedical applications)

IT Polymers, biological studies
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crosslinked; radiation cross-linked polymer hydrogels for biomedical applications)

IT Carboxylic acids, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(dicarboxylic, chlorides; radiation cross-linked polymer hydrogels for biomedical applications)

IT Polyoxyalkylenes, biological studies
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(dimers; radiation cross-linked polymer hydrogels for biomedical applications)

IT **Embolism**
(embolization; radiation cross-linked polymer hydrogels for biomedical applications)

IT Animal tissue
(engineering; radiation cross-linked polymer hydrogels for biomedical applications)

IT Syringes
(glass; radiation cross-linked polymer hydrogels for biomedical applications)

IT Drug delivery systems
(hydrogels; radiation cross-linked polymer hydrogels for biomedical applications)

IT Buffers
(phosphate; radiation cross-linked polymer hydrogels for biomedical applications)

IT Alcohols, biological studies
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polyhydric, polymerized; radiation cross-linked polymer hydrogels for biomedical applications)

IT Dimerization
Electron beams
Hemostatics
Human
Hydrogels
(radiation cross-linked polymer hydrogels for biomedical applications)

IT Dimers
RL: RCT (Reactant); RACT (Reactant or reagent)
(radiation cross-linked polymer hydrogels for biomedical applications)

IT Containers

(radiation-permeable; radiation cross-linked polymer hydrogels for biomedical applications)

IT Crosslinking
Polymerization
(radiochem.; radiation cross-linked polymer hydrogels for biomedical applications)

IT **Medical goods**
(tissue adhesives; radiation cross-linked polymer hydrogels for biomedical applications)

IT Engineering
(tissue; radiation cross-linked polymer hydrogels for biomedical applications)

IT 7632-05-5, Sodium phosphate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(buffer; radiation cross-linked polymer hydrogels for biomedical applications)

IT 121-44-8, Triethylamine, uses
RL: NUU (Other use, unclassified); USES (Uses)
(chloride scavenger; radiation cross-linked polymer hydrogels for biomedical applications)

IT 415901-92-7P
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(macromer; radiation cross-linked polymer hydrogels for biomedical applications)

IT 9004-74-4DP, Monomethoxypoly(ethylene glycol), dimers 25322-68-3DP, Poly(ethylene glycol), dimers 25322-69-4DP, Poly(propylene glycol), dimers
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(radiation cross-linked polymer hydrogels for biomedical applications)

IT 108-88-3, Toluene, uses
RL: NUU (Other use, unclassified); USES (Uses)
(radiation cross-linked polymer hydrogels for biomedical applications)

IT 543-20-4, Succinic chloride 2873-74-7, Pentanedioyl dichloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(radiation cross-linked polymer hydrogels for biomedical applications)

IT 7782-44-7, Oxygen, processes
RL: REM (Removal or disposal); PROC (Process)
(radiation cross-linked polymer hydrogels for biomedical applications)

L33 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:171652 HCAPLUS

DN 136:236888

ED Entered STN: 08 Mar 2002

TI Nitric oxide-producing hydrogel materials

IN Hill-West, Jennifer L.; Masters, Kristyn Simcha

PA Rice University, USA

SO PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K-0009/00

CC 63-7 (Pharmaceuticals)

Section cross-reference(s): 38

FAN.CNT 2

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

```

-----
PI WO2002017880      A2      20020307      2001WO-US27414      20010904
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
    CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
    GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
    LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
    PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
    US, UZ, VN, YU, ZA, ZW
RW:  GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
    KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
    IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
    GQ, GW, ML, MR, NE, SN, TD, TG
JP2002155137      A2      20020528      2001JP-0188905      20010521
AU2001088694      A5      20020313      2001AU-0088694      20010904
EP---1315476      A2      20030604      2001EP-0968448      20010904
R:   AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
    IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US2003012816      A1      20030116      2002US-0129418      20020517 <--
US---7052711      B2      20060530
US2006153795      A1      20060713      2005US-0281242      20051117 <--
PRAI 2000US-0653406      A      20000901
    1999US-152054P      P      19990902 <--
    2001WO-US27414      W      20010904
    2002US-0129418      A3      20020517

```

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002017880	ICM	A61K-0009/00
	IPCI	A61K0009-00 [ICM,7]
	IPCR	A61K0047-48 [I,A]; A61K0047-48 [I,C*]
	ECLA	A61K047/48H4P; A61K047/48K4; A61K047/48W4
JP2002155137	IPCI	C08G0065-334 [ICM,7]; A61K0045-00 [ICS,7]; A61K0045-06 [ICS,7]; A61P0009-08 [ICS,7]; A61P0009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]; A61P0011-06 [ICS,7]; A61P0011-00 [ICS,7,C*]; A61P0015-10 [ICS,7]; A61P0015-00 [ICS,7,C*]; A61P0017-02 [ICS,7]; A61P0017-00 [ICS,7,C*]; A61P0019-02 [ICS,7]; A61P0019-00 [ICS,7,C*]; C08F0299-02 [ICS,7]; C08F0299-00 [ICS,7,C*]; C08G0065-333 [ICS,7]; C08G0065-00 [ICS,7,C*]
	IPCR	A61K0047-48 [I,A]; A61K0047-48 [I,C*]
AU2001088694	IPCI	A61K0009-00 [ICM,7]
	IPCR	A61K0047-48 [I,A]; A61K0047-48 [I,C*]
EP---1315476	IPCI	A61K0009-00 [ICM,7]
	IPCR	A61K0047-48 [I,A]; A61K0047-48 [I,C*]
US2003012816	IPCI	A61F0002-02 [I,A]; A61K0009-14 [I,A]
	IPCR	A61K0047-48 [I,A]; A61K0047-48 [I,C*]
	NCL	424/484.000
	ECLA	A61K047/48H4P; A61K047/48K4; A61K047/48W4
US2006153795	IPCI	A61K0031-765 [I,A]; A61K0031-74 [I,C*]; C08G0063-91 [I,A]; C08G0063-00 [I,C*]
	NCL	424/078.300; 525/054.100
	ECLA	A61K047/48H4P; A61K047/48K4; A61K047/48W4

AB Hydrogels releasing or producing NO, most preferably polymerizable biodegradable hydrogels capable of releasing physiolo. amts. of NO for prolonged periods of time, are applied to sites on or in a patient in need of treatment thereof for disorders such as restenosis, thrombosis, asthma, wound healing, arthritis, penile erectile dysfunction or other conditions where NO plays a significant role. The polymeric materials can be formed

into films, coatings, or microparticles for application to medical devices, such as stents, vascular grafts and catheters. The polymeric materials can also be applied directly to biol. tissues and can be polymerized in situ. The hydrogels are formed of macromers, which preferably include biodegradable regions, and have bound thereto groups that are released in situ to elevate or otherwise modulate NO levels at the site where treatment is needed. The macromers can form a homo or hetero-dispersion or solution, which is polymerized to form a hydrogel material, that in the

latter

case can be a semi-interpenetrating network or interpenetrating network. Compsds. to be released can be phys. entrapped, covalently or ionically bound to macromer, or actually form a part of the polymeric material. The hydrogel can be formed by ionic and/or covalent crosslinking. Other active agents, including therapeutic, prophylactic, or diagnostic agents, can also be included within the polymeric material. Acryloyl-PEG-Cys (preparation given) was reacted with sodium nitrite to form S-nitrosocysteine. The acryloyl-PEG-Cys-NO was incorporated into photopolymerizable hydrogel by mixing with PEG-diacrylate and an initiator and exposed to UV light. Adhesion of blood platelets which were incubated with the above hydrogel was decreased when exposed to thrombogenic surfaces (glass slides coated with collagen).

ST nitric oxide hydrogel polymer platelet adhesion inhibitor
 IT Platelet (blood)
 (adhesion, inhibitors; nitric oxide-producing hydrogel materials)
 IT Diagnosis
 (agents; nitric oxide-producing hydrogel materials)
 IT Blood vessel
 (artificial; nitric oxide-producing hydrogel materials)
 IT **Medical goods**
 (catheters; nitric oxide-producing hydrogel materials)
 IT Blood vessel
 (endothelium; nitric oxide-producing hydrogel materials)
 IT Cell proliferation
 (enhancers; nitric oxide-producing hydrogel materials)
 IT Prosthetic materials and Prosthetics
 (implants; nitric oxide-producing hydrogel materials)
 IT Sexual disorders
 (impotence; nitric oxide-producing hydrogel materials)
 IT Adhesion, biological
 Animal tissue
 Arthritis
 Asthma
 Fibroblast
 Hydrogels
 Medical goods
 Thrombosis
 Wound healing
 (nitric oxide-producing hydrogel materials)
 IT Carbohydrates, biological studies
 Nucleic acids
 Proteins
 RGD peptides
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nitric oxide-producing hydrogel materials)
 IT Artery, disease
 (restenosis; nitric oxide-producing hydrogel materials)
 IT **Medical goods**
 (stents; nitric oxide-producing hydrogel materials)
 IT Endothelium

(vascular; nitric oxide-producing hydrogel materials)
 IT 52-90-4, Cysteine, reactions 111-40-0 7632-00-0, Sodium nitrite
 19431-21-1 26570-48-9 262356-92-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (nitric oxide-producing hydrogel materials)
 IT 616-91-1DP, reaction product with vinyl alc. copolymers 181798-26-5P
 310460-40-3DP, S-nitrosylated 310460-40-3P 329191-28-8DP, nitrosylated
 329191-28-8P 329191-29-9DP, nitrosylated 329191-29-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (nitric oxide-producing hydrogel materials)
 IT 51209-75-7P 181798-26-5DP, nitrosylated, reaction product with
 N-acetyl-L-cysteine
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)
 (nitric oxide-producing hydrogel materials)
 IT 9002-89-5, Polyvinyl alcohol 91037-65-9
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nitric oxide-producing hydrogel materials)

L33 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:100989 HCAPLUS

DN 134:144224

ED Entered STN: 09 Feb 2001

TI Direct arterial infiltration for production of vascular pathology

IN Edelman, Elazer R.; Rogers, Campbell; Welt, Frederick G.

PA Massachusetts Institute of Technology, USA

SO PCT Int. Appl., 10 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K-0035/00

CC 9-16 (Biochemical Methods)

Section cross-reference(s): 1, 14

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2001008694	A2	20010208	2000WO-US20860	20000731 <--
	WO2001008694	A3	20010809		
	W: CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	1999US-146622P	P	19990730 <--		
	2000US-0627752	A	20000728		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001008694	ICM	A61K-0035/00
	IPCI	A61K0035-00 [I,C,7]
	IPCR	A61K0035-14 [I,A]; A61K0035-14 [I,C*]; A61K0035-34 [I,A]; A61K0035-34 [I,C*]; A61K0038-17 [I,A]; A61K0038-17 [I,C*]; A61K0048-00 [N,A]; A61K0048-00 [N,C*]
	ECLA	A61K035/14; A61K035/34; A61K038/17A2
AB		A method of producing a vascular lesion in an animal that resembles atherosclerotic lesions in humans. The method includes introducing cholesterol enriched with LDL or cholesterol enriched with LDL and monocytes, macrophages, leukocytes, smooth muscle cells or platelets into

a proliferative lesion created by standard methods, to promote atherosclerosis.

ST artery infiltration prodn vessel pathol

IT Surgery
(Balloon catheter inflation; direct arterial infiltration for production of vascular pathol.)

IT Diet
(Hyperlipidemic; direct arterial infiltration for production of vascular pathol.)

IT Air
(Insufflated; direct arterial infiltration for production of vascular pathol.)

IT Leukocyte
(Polymorphonuclear; direct arterial infiltration for production of vascular pathol.)

IT Polymers, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(co-; direct arterial infiltration for production of vascular pathol.)

IT Animal
Animal tissue
Artery
Artery, disease
Atherosclerosis
Basophil
Blood vessel, disease
Bone
Cardiovascular system
Cartilage
Cell
Cell adhesion
Cell migration
Cell proliferation
Chemicals
Coils
Diffusion
Digestive tract
Disease, animal
Drugs
Encapsulation
Eosinophil
Feeding
Filaments
Foams
Gels
Genetic engineering
Hydrogels
Inflammation
Leukocyte
Macrophage
Mitochondria
Monocyte
Nervous system
Osteoblast
Osteoclast
Platelet (blood)
Reproductive tract
Respiratory tract
Solutions

Susceptibility (genetic)
Temperature effects, biological

Thrombosis

Transformation, genetic
(direct arterial infiltration for production of vascular pathol.)

- IT DNA
 - Oligonucleotides
 - Polysaccharides, biological studies
 - Prostaglandins
 - Proteins, general, biological studies
 - RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
 - BIOL (Biological study); OCCU (Occurrence)
 - (direct arterial infiltration for production of vascular pathol.)
- IT Fats and Glyceridic oils, biological studies
 - Glycerides, biological studies
 - Lipids, biological studies
 - Lipopolysaccharides
 - Polymers, biological studies
 - RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
 - (Uses)
 - (direct arterial infiltration for production of vascular pathol.)
- IT Blood vessel
 - (endothelium; direct arterial infiltration for production of vascular pathol.)
- IT Compression
 - (external; direct arterial infiltration for production of vascular pathol.)
- IT Lipids, biological studies
 - RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 - (hyperlipidemia; direct arterial infiltration for production of vascular pathol.)
- IT Animal tissue
 - (hyperplasia; direct arterial infiltration for production of vascular pathol.)
- IT Prosthetic materials and Prosthetics
 - (implants; direct arterial infiltration for production of vascular pathol.)
- IT Energy
 - (injury; direct arterial infiltration for production of vascular pathol.)
- IT Blood vessel, disease
 - (lesion; direct arterial infiltration for production of vascular pathol.)
- IT Wires
 - (loops; direct arterial infiltration for production of vascular pathol.)
- IT Lipoproteins
 - RL: ANT (Analyte); ANST (Analytical study)
 - (low-d.; direct arterial infiltration for production of vascular pathol.)
- IT Muscle
 - (smooth; direct arterial infiltration for production of vascular pathol.)
- IT **Medical goods**
 - (stents, Endovascular; direct arterial infiltration for production of vascular pathol.)
- IT Electric current
 - (stimulation; direct arterial infiltration for production of vascular pathol.)
- IT Diet
 - (supplements; direct arterial infiltration for production of vascular pathol.)
- IT 57-88-5, Cholesterol, biological studies 60-00-4, EDTA, biological studies 9005-32-7, Alginic acid 24937-78-8 26009-03-0, Poly(glycolic acid) 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26100-51-6, Poly(lactic acid) 26124-68-5, Poly(glycolic acid) 106392-12-5,

Pluronic

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(direct arterial infiltration for production of vascular pathol.)

L33 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:841940 HCAPLUS
 DN 134:21447
 ED Entered STN: 01 Dec 2000
 TI Methods for delivering in vivo uniform dispersed embolic compositions of high viscosity
 IN Tran, Chinh Ngoc; Hayman, Douglas Ray; Whalen, Tom, II
 PA Micro Therapeutics, Inc., USA
 SO PCT Int. Appl., 28 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61F-0013/00
 ICS C08J-0003/00; A61K-0009/10; A61M-0031/00
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2000071064	A1	20001130	2000WO-US13719	20000519 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA---2371915	AA	20001130	2000CA-2371915	20000519 <--
	EP---1185223	A1	20020313	2000EP-0936066	20000519 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US---6454738	B1	20020924	2000US-0574963	20000519 <--
	JP2003500106	T2	20030107	2000JP-0619376	20000519 <--
	US---6645167	B1	20031111	2000US-0574500	20000519 <--
	US2004097901	A1	20040520	2003US-0705108	20031110 <--
PRAI	1999US-135222P	P	19990521	<--	
	1999US-135289P	P	19990521	<--	
	2000US-0574500	A1	20000519		
	2000WO-US13719	W	20000519		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000071064	ICM	A61F-0013/00
	ICS	C08J-0003/00; A61K-0009/10; A61M-0031/00
	IPCI	A61F0013-00 [ICM,7]; C08J0003-00 [ICS,7]; A61K0009-10 [ICS,7]; A61M0031-00 [ICS,7]
	IPCR	A61K0049-04 [I,A]; A61K0049-04 [I,C*]; A61L0024-00 [I,A]; A61L0024-00 [I,C*]; A61L0024-04 [I,A]; A61L0024-06 [I,A]; A61L0024-08 [I,A]; C08J0003-02 [I,C*]; C08J0003-09 [I,A]
	ECLA	A61K049/04F8M; A61L024/00H; A61L024/04R; A61L024/06; A61L024/06+C08L29/04; A61L024/08; C08J003/09B

CA---2371915 IPCI A61F0013-00 [ICM,7]; C08J0003-00 [ICS,7]; A61M0031-00 [ICS,7]; A61K0009-10 [ICS,7]
 IPCR A61K0049-04 [I,A]; A61K0049-04 [I,C*]; A61L0024-00 [I,A]; A61L0024-00 [I,C*]; A61L0024-04 [I,A]; A61L0024-06 [I,A]; A61L0024-08 [I,A]; C08J0003-02 [I,C*]; C08J0003-09 [I,A]

EP---1185223 IPCI A61F0013-00 [ICM,6]; C08J0003-00 [ICS,6]; A61K0009-10 [ICS,6]; A61M0031-00 [ICS,6]
 IPCR A61K0049-04 [I,A]; A61K0049-04 [I,C*]; A61L0024-00 [I,A]; A61L0024-00 [I,C*]; A61L0024-04 [I,A]; A61L0024-06 [I,A]; A61L0024-08 [I,A]; C08J0003-02 [I,C*]; C08J0003-09 [I,A]

US---6454738 IPCI A61M0031-00 [ICM,7]
 IPCR A61L0024-00 [I,A]; A61L0024-00 [I,C*]; A61L0024-04 [I,A]; A61L0024-06 [I,A]; A61L0024-08 [I,A]
 NCL 604/500.000; 424/009.411; 424/078.370; 424/423.000; 424/484.000; 514/002.000; 514/021.000; 604/030.000
 ECLA A61L024/00H; A61L024/04R; A61L024/06; A61L024/06+C08L29/04; A61L024/08

JP2003500106 IPCI A61B0017-12 [ICM,7]; A61B0017-00 [ICS,7]; A61K0049-04 [ICS,7]; A61L0031-00 [ICS,7]; A61M0005-44 [ICS,7]; A61M0025-00 [ICS,7]
 IPCR A61K0049-04 [I,A]; A61K0049-04 [I,C*]; A61L0024-00 [I,A]; A61L0024-00 [I,C*]; A61L0024-04 [I,A]; A61L0024-06 [I,A]; A61L0024-08 [I,A]; C08J0003-02 [I,C*]; C08J0003-09 [I,A]

US---6645167 IPCI A61F0002-00 [ICM,7]; A61M0001-00 [ICS,7]; A61M0029-00 [ICS,7]
 IPCR A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0049-04 [I,A]; A61K0049-04 [I,C*]; A61L0024-00 [I,A]; A61L0024-00 [I,C*]; A61L0024-04 [I,A]; A61L0024-06 [I,A]; A61L0024-08 [I,A]; A61M0005-315 [I,A]; A61M0005-315 [I,C*]; C08J0003-02 [I,C*]; C08J0003-09 [I,A]
 NCL 604/028.000; 424/423.000; 523/113.000; 604/096.010
 ECLA A61K009/00M5D; A61K049/04F8M; A61L024/00H; A61L024/04R; A61L024/06; A61L024/06+C08L29/04; A61L024/08; A61M005/315D1; C08J003/09B

US2004097901 IPCI A61M0031-00 [ICM,7]
 IPCR A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0049-04 [I,A]; A61K0049-04 [I,C*]; A61L0024-00 [I,A]; A61L0024-00 [I,C*]; A61L0024-04 [I,A]; A61L0024-06 [I,A]; A61L0024-08 [I,A]; A61M0005-315 [I,A]; A61M0005-315 [I,C*]; C08J0003-02 [I,C*]; C08J0003-09 [I,A]
 NCL 604/509.000
 ECLA A61K009/00M5D; A61K049/04F8M; A61L024/00H; A61L024/04R; A61L024/06; A61L024/06+C08L29/04; A61L024/08; A61M005/315D1; C08J003/09B

AB Disclosed are novel techniques for embolizing blood vessels which are particularly suited for treating vascular lesions via catheter delivery of an embolic composition. An embolic composition contained Et vinyl alc. copolymer (mol. weight approx. 136,000) 17.5, micronized tantalum 30, and DMSO 52.5%. The composition was used for treatment of venous pouch aneurysm in swine.

ST embolism viscosity blood vessel catheter

IT Polymers, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (biocompatible; methods for delivering in vivo uniform dispersed

embolic compns. of high viscosity)

IT **Medical goods**
(catheters; methods for delivering in vivo uniform dispersed embolic compns. of high viscosity)

IT Imaging agents
(contrast; methods for delivering in vivo uniform dispersed embolic compns. of high viscosity)

IT **Embolism**
(embolization; methods for delivering in vivo uniform dispersed embolic compns. of high viscosity)

IT Blood vessel, disease
(lesion; methods for delivering in vivo uniform dispersed embolic compns. of high viscosity)

IT Aneurysm
Blood vessel
Hydrogels
Viscosity
(methods for delivering in vivo uniform dispersed embolic compns. of high viscosity)

IT Urethane rubber, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polycarbonate-; methods for delivering in vivo uniform dispersed embolic compns. of high viscosity)

IT Synthetic rubber, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polycarbonate-polyurethane; methods for delivering in vivo uniform dispersed embolic compns. of high viscosity)

IT 64-17-5, Ethanol, uses 67-64-1, Acetone, uses 67-68-5,
Dimethylsulfoxide, uses 97-64-3, Ethyl lactate
RL: NUU (Other use, unclassified); USES (Uses)
(methods for delivering in vivo uniform dispersed embolic compns. of high viscosity)

IT 1314-61-0, Tantalum oxide 7440-25-7, Tantalum, biological studies
7440-33-7, Tungsten, biological studies 7727-43-7, Barium sulfate
9004-35-7, Cellulose acetate 9004-36-8, Cellulose acetate butyrate
9004-70-0, Nitrocellulose 25014-41-9, Polyacrylonitrile 25067-34-9,
Ethylene vinyl alcohol copolymer 25300-64-5, Maleic acid styrene
copolymer
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for delivering in vivo uniform dispersed embolic compns. of high viscosity)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Greff; US---5667767 A 1997 HCAPLUS
- (2) Ji; US---5888546 A 1999 HCAPLUS
- (3) Ji; US---5894022 A 1999 HCAPLUS
- (4) Jones; US---5830178 A 1998
- (5) Micro Therapeutics Inc; WO---9804312 1998 HCAPLUS
- (6) Micro Therapeutics Inc; WO---9920326 1999

L33 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:692845 HCAPLUS

DN 123:123043

ED Entered STN: 21 Jul 1995

TI Resorbable hydrogel barriers for controlling intravascular thrombosis and healing

AU Hill-West, Jennifer L.; Chowdhury, Sanghamitra M.; Slepain, Marvin J.; Hubbell, Jeffrey A.

CS Univ. Texas, Austin, Austin, TX, 78712, USA

SO Polymer Preprints (American Chemical Society, Division of Polymer Chemistry) (1994), 35(2), 397-8
 CODEN: ACPPAY; ISSN: 0032-3934

PB American Chemical Society, Division of Polymer Chemistry

DT Journal

LA English

CC 63-7 (Pharmaceuticals)

AB A non-pharmacol. approach for the prevention of restenosis by using a resorbable PEG-based polymer hydrogel is presented.

ST polymer hydrogel intravascular thrombosis healing

IT **Medical goods**
 (barriers; resorbable hydrogel barriers for controlling intravascular thrombosis and healing)

IT **Thrombosis**
 (intravascular; resorbable hydrogel barriers for controlling intravascular thrombosis and healing)

IT Wound healing
 (resorbable hydrogel barriers for controlling intravascular thrombosis and healing)

IT Polymers, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (resorbable hydrogel barriers for controlling intravascular thrombosis and healing)

IT **Gels**
 (hydro-, resorbable hydrogel barriers for controlling intravascular thrombosis and healing)

IT Artery, disease
 (restenosis, prevention; resorbable hydrogel barriers for controlling intravascular thrombosis and healing)

L33 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1994:264829 HCAPLUS

DN 120:264829

ED Entered STN: 28 May 1994

TI Crosslinked protein or polysaccharide hydrogels, their preparation, and their use in imaging and therapy

IN Weissleder, Ralph; Bogdanov, Alexei

PA General Hospital Corp., USA

SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K-0009/10

CC 8-9 (Radiation Biochemistry)

Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---9403155	A1	19940217	1993WO-US07314	19930804 <--
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US---5514379	A	19960507	1992US-0927068	19920807 <--
PRAI	1992US-0927068	A	19920807	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9403155	ICM	A61K-0009/10
	IPCI	A61K0009-10 [ICM,5]
	IPCR	A61K0009-16 [I,A]; A61K0009-16 [I,C*]; A61K0047-42

[I,A]; A61K0047-42 [I,C*]; A61K0049-06 [I,C*];
A61K0049-18 [I,A]
US---5514379 IPCI A61K0009-10 [ICM,6]; A61K0049-00 [ICS,6]; A61K0049-04
[ICS,6]
IPCR A61K0009-16 [I,A]; A61K0009-16 [I,C*]; A61K0047-42
[I,A]; A61K0047-42 [I,C*]; A61K0049-06 [I,C*];
A61K0049-18 [I,A]
NCL 424/426.000; 424/009.364; 424/484.000; 424/486.000;
424/488.000; 514/944.000; 516/102.000; 516/103.000;
516/105.000; 516/106.000
ECLA A61K009/16H6H; A61K047/42; A61K049/18F
AB Biocompatible, biodegradable hydrogels are prepared from a backbone compound
(proteins and polysaccharides, e.g., albumin, polymannuronic acid, or
polygalacturonic acid.) bonded to a crosslinking agent. Suitable
crosslinking agents include polyvalent derivs. of polyethylene or
polyalkylene glycol. These hydrogel compns. may be loaded with diagnostic
labels, e.g., radiopaque, paramagnetic, or superparamagnetic materials, or
therapeutic drugs, e.g., chemotherapeutic drugs, antibiotics, or cells
that produce therapeutic agents. Such hydrogels are used for imaging,
treatment, and embolization. Bis(N-hydroxysuccinimidyl)polyethylene
glycol disuccinate was prepared and reacted with bovine serum albumin (BSA)
and Gd-DTPA-BSA to form a paramagnetic hydrogel. The hydrogel was
implanted in rats and the dissoln. was observed by repeated magnetic
resonance imaging. Peritoneally implanted samples degraded faster than
i.m. implanted samples.
ST hydrogel protein polysaccharide crosslinking agent imaging; albumin PEG
gadolinium hydrogel MRI; therapy hydrogel protein polysaccharide
IT Crosslinking agents
(biocompatible and biodegradable hydrogel containing protein or
polysaccharide backbone bonded to, for imaging and therapy)
IT Cell
(crosslinked protein or polysaccharide hydrogel loaded with)
IT Therapeutics
(crosslinked protein or polysaccharide hydrogel loaded with cells
producing agents for)
IT Analgesics
Antibiotics
Cardiovascular agents
Hemostatics
Neoplasm inhibitors
Nervous system agents
Enzymes
Hormones
RL: BIOL (Biological study)
(crosslinked protein or polysaccharide hydrogel with)
IT Hematopoiesis
(crosslinked protein or polysaccharide hydrogel with agents for)
IT Pharmaceuticals
(crosslinked protein or polysaccharide hydrogel with reporter group of)
IT Diagnosis
(crosslinked protein or polysaccharide hydrogels for use in)
IT Neoplasm, toxic chemical and physical damage
(embolization of, with hydrogel of PEG derivative-crosslinked albumin)
IT Imaging
(NMR, crosslinked protein or polysaccharide hydrogel with detectable
label for)
IT **Medical goods**
(catheters, angiog., coated with paramagnetic hydrogel for magnetic
resonance imaging)

- IT **Embolism**
(embolization, crosslinked protein or polysaccharide hydrogels for use in)
- IT **Gels**
(hydro-, biocompatible and biodegradable, of protein or polysaccharide backbone bonded to crosslinking agent, for imaging and therapy)
- IT Pharmaceutical dosage forms
(hydrogels, crosslinked protein or polysaccharide for)
- IT Polyamides, compounds
RL: BIOL (Biological study)
(poly(amino acids), reaction products, with crosslinking agent, biocompatible and biodegradable hydrogel containing, for imaging and therapy)
- IT Hormones
RL: BIOL (Biological study)
(pro-, crosslinked protein or polysaccharide hydrogel with)
- IT Albumins, compounds
Glycoproteins, specific or class
Glycosaminoglycans, compounds
Polymers, compounds
Polysaccharides, compounds
Proteins, specific or class
RL: BIOL (Biological study)
(reaction products, with crosslinking agent, biocompatible and biodegradable hydrogel containing, for imaging and therapy)
- IT Polyoxyalkylenes, compounds
RL: BIOL (Biological study)
(reaction products, with protein or polysaccharide backbone, biocompatible and biodegradable hydrogel containing, for imaging and therapy)
- IT Imaging
(x-ray, crosslinked protein or polysaccharide hydrogel with detectable label for)
- IT 9002-98-6D, Polyethyleneimine, reaction products with crosslinking agent
9004-54-0D, Dextran, derivs., reaction products with crosslinking agent
9005-25-8D, Starch, derivs., reaction products with crosslinking agent
9046-38-2D, Polygalacturonic acid, reaction products with crosslinking agent
25322-68-3D, Polyoxyethylene glycol, derivs., reaction products with protein or polysaccharide backbone
25322-68-3D, Polyethylene glycol, halide- and benzoxazole-terminated derivs., reaction products with crosslinking agent
25322-69-4D, Polypropylene glycol, derivs., reaction products with protein or polysaccharide backbone
29894-36-8D, Polymannuronic acid, reaction products with crosslinking agent
35625-91-3D, reaction products with protein or polysaccharide backbone
154623-96-8D, reaction products with protein or polysaccharide backbone
154623-97-9D, reaction products with protein or polysaccharide backbone
154623-98-0D, reaction products with protein or polysaccharide backbone
154623-99-1D, reaction products with protein or polysaccharide backbone
154624-00-7D, reaction products with protein or polysaccharide backbone
RL: BIOL (Biological study)
(biocompatible and biodegradable hydrogel containing, for imaging and therapy)
- IT 9004-10-8, Insulin, uses
RL: USES (Uses)
(crosslinked protein or polysaccharide hydrogel loaded with cells producing)
- IT 20694-16-0, Gadolinium-DTPA 7440-54-2, Gadolinium, uses
RL: BIOL (Biological study)

(crosslinked protein or polysaccharide hydrogel with detectable label of, for magnetic resonance imaging)

IT 7553-56-2, Iodine, uses
RL: USES (Uses)
(crosslinked protein or polysaccharide hydrogel with detectable label of, for x-ray imaging)

IT 9005-38-3, Sodium alginate
RL: BIOL (Biological study)
(paramagnetic hydrogel containing bivalent PEG derivative-crosslinked)

IT 23214-92-8P, Doxorubicin
RL: SPN (Synthetic preparation); PREP (Preparation)
(paramagnetic hydrogel of albumin-gadolinium-DTPA-albumin with, preparation of)

IT 37684-51-8P, Polyethylene glycol disuccinate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of paramagnetic hydrogel)

IT 85419-94-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with albumin and albumin-gadolinium DTPA conjugate, in preparation of paramagnetic hydrogel)

IT 20694-16-0DP, Gadolinium-DTPA, reaction products with albumin and PEG derivative
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as paramagnetic hydrogel)

IT 737-31-5P, Sodium diatrizoate
RL: SPN (Synthetic preparation); PREP (Preparation)
(radiopaque crosslinked hydrogel of albumin-gadolinium-DTPA-albumin and, preparation of)

IT 108-30-5, Succinic anhydride, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with PEG)

IT 23911-26-4, Cyclic DTPA anhydride
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with bovine serum albumin)

IT 25322-68-3, Polyethylene glycol
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with succinic anhydride)

IT 123119-57-3
RL: BIOL (Biological study)
(sodium alginate crosslinked with, paramagnetic hydrogel containing)

L33 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1992:537624 HCAPLUS

DN 117:137624

ED Entered STN: 04 Oct 1992

TI Hemostatic activity of ethamsylate and aminocaproic acid adsorbed poly(2-hydroxyethyl methacrylate) particles

AU Horak, Daniel; Svec, Frantisek; Adamyan, A.; Titova, M.; Skuba, N.; Voronkova, O.; Trostenyuk, N.; Vishnevskii, V.; Gumargalieva, K.

CS Inst. Macromol. Chem., Czech. Acad. Sci., Prague, 162 06, Czech.

SO Biomaterials (1992), 13(8), 521-6

CODEN: BIMADU; ISSN: 0142-9612

DT Journal

LA English

CC 63-7 (Pharmaceuticals)

Section cross-reference(s): 1

AB A hemostatic material suitable for embolization was prepared by the

adsorption of hemostatics, ethamsylate and aminocaproic acid, in the spherical particles of porous poly(2-hydroxyethyl methacrylate) [p(HEMA)]. The degree of purification of ethamsylate-treated particles was tested by an anal. of donor blood in contact with the material. An evaluation of the hemostatic properties of these materials was obtained by the determination of the indicators of blood clotting: activated partial thromboplastin time, thrombin time, and prothrombin time. Ethamsylate or aminocaproic acid-containing p(HEMA) has a distinct hemostatic effect on pathol. blood of patients suffering from focal alterations of the liver. These hemostatic emboli materials show promise for the immediate control of various hemorrhages; when introduced into a zone with increased hemorrhage, they may help to correct disturbed hemostasis.

ST ethamsylate aminocaproate polymethacrylate hydrogel hemostatic embolization

IT Artery
(embolization of, poly(hydroxyethyl methacrylate) hydrogel containing ethamsylate or aminocaproate for)

IT Hemostatics
(ethamsylate and aminocaproate in poly(hydroxyethyl methacrylate) hydrogels, for embolization)

IT Blood coagulation
(poly(hydroxyethyl methacrylate) hydrogels containing ethamsylate or aminocaproate for, by embolization)

IT **Medical goods**
(dressings, hemostatic, poly(hydroxyethyl methacrylate) hydrogels containing ethamsylate or aminocaproate for, for embolization)

IT **Embolism**
(embolization, poly(hydroxyethyl methacrylate) hydrogels containing ethamsylate or aminocaproate for)

IT **Gels**
(hydro-, poly(hydroxyethyl methacrylate), ethamsylate- or aminocaproate-containing, hemostatic activity of, for embolization)

IT 25249-16-5, Poly(2-hydroxyethyl methacrylate)
RL: BIOL (Biological study)
(hydrogels, ethamsylate- or aminocaproate-containing, hemostatic activity of, for embolization)

IT 1319-82-0, Aminocaproic acid 2624-44-4, Ethamsylate
RL: BIOL (Biological study)
(poly(hydroxyethyl methacrylate) hydrogel containing, hemostatic activity of, for embolization)

=> b wpix

FILE 'WPIX' ENTERED AT 15:34:53 ON 15 AUG 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE LAST UPDATED: 14 AUG 2006 <20060814/UP>
MOST RECENT DERWENT UPDATE: 200652 <200652/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE

http://www.stn-international.de/stndatabases/details/ipc_reform.html and
<http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf> <<<

>>> FOR FURTHER DETAILS ON THE FORTHCOMING DERWENT WORLD PATENTS
INDEX ENHANCEMENTS PLEASE VISIT:

http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<
'BIX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> d all abex tech l44 tot

L44 ANSWER 1 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2006-492530 [50] WPIX
CR 2001-343247 [36]; 2002-691223 [74]; 2003-266113 [26]; 2004-339065 [31]
DNN N2006-397580 DNC C2006-154124
TI Embolization device manufacturing method for treatment of vascular
aneurysms, involves coaxially encapsulating portion of length of
filamentous carrier in expansile hydrophilic polymer.
DC A32 A96 D22 P31
IN CONSTANT, M; COX, B J; CRUISE, G M; GREENE, G R; TRAN, T
PA (MICR-N) MICROVENTION INC
CYC 1
PI US--2006149299 A1 20060706 (200650)* 29 A61B-017-03
ADT US--2006149299 A1 CIP of 1999US-0410970 19991004, CIP of
2000US-0542145 20000404, CIP of 2001US-0867340 20010529, Div ex
2002US-0157621 20020529, 2006US-0350357 20060208
FDT US--2006149299 A1 CIP of US-----6238403, CIP of US-----6299619, CIP of
US-----6602261, Div ex US-----7014645
PRAI 2002US-0157621 20020529; 1999US-0410970
19991004; 2000US-0542145 20000404; 2001US-0867340
20010529; 2006US-0350357 20060208
IC ICM A61B-017-03; A61B-017-08
AB US2006149299 A UPAB: 20060804
NOVELTY - The method involves providing elongated flexible filamentous
carrier, and coaxially encapsulating portion of the length of the carrier
in an expansile hydrophilic polymer set in softened state.
DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for
method for delivering therapeutic agent to patient.
USE - For manufacturing embolization device used for treatment of
vascular aneurysms, arteriovenous malformation and arteriovenous fistulas,
tumor and other soft tissue voids. The device is also used for occluding
body cavity and blood vessel for therapeutic benefit of patient, and
fallopian tubes for the purpose of sterilization, and also for occlusive
repair of cardiac defects such as patent foramen ovale, patent ductus
arteriosus and left-atrial-appendage and atrial-septal defects.
ADVANTAGE - Vascular embolization device can be deployed within
cavity or vascular site with excellent locational control and with a lower
risk of vascular rupture, tissue damage or migration. The device effects a
conformal fit within the site that promotes effective embolization of body
cavities having different size and configuration.
DESCRIPTION OF DRAWING(S) - The figure shows a schematic view of
vascular embolization device
vascular embolization device 10
micropellets 12
spacers 16
microcoil segment 18
hydrogel linkage element 24
Dwg.1/44
FS CPI GMPI
FA AB; GI

MC CPI: A11-B05; A12-V02; A12-W05; D09-C01B

L44 ANSWER 2 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2004-339065 [31] WPIX

CR 2001-343247 [36]; 2002-691223 [74]; 2003-266113 [26]; 2006-492530 [50]

DNN N2004-271032 DNC C2004-128684

TI Manufacture of body cavity occlusion device for delivering therapeutic agent to patient involves coaxially encapsulating portion of carrier in expansible, hydrophilic polymer.

DC A96 B07 D22 P34

IN CONSTANT, M; COX, B J; CRUISE, G M; GREENE, G R; TRAN, T

PA (CONS-I) CONSTANT M; (COXB-I) COX B J; (CRUI-I) CRUISE G M; (GREE-I) GREENE G R; (TRAN-I) TRAN T

CYC 1

PI US--2004059370 A1 20040325 (200431)* 29 A61M-029-00 <--

ADT US--2004059370 A1 CIP of 1999US-0410970 19991004, CIP of 2000US-0542145 20000404, CIP of 2001US-0867340 20010529, Cont of 2002US-0157621 20020529, 2003US-0670142 20030924

FDT US--2004059370 A1 CIP of US-----6238403, CIP of US-----6299619, CIP of US-----6602261

PRAI 2002US-0157621 20020529; 1999US-0410970

19991004; 2000US-0542145 20000404; 2001US-0867340

20010529; 2003US-0670142 20030924

IC ICM A61M-029-00

AB US2004059370 A UPAB: 20060804

NOVELTY - A body cavity occlusion device (10) is manufactured by providing an elongated, flexible, filamentous carrier; and coaxially encapsulating a portion of the length of the carrier in an expansible, hydrophilic polymer.

USE - The invention is used for manufacture of body cavity occlusion device for delivering a therapeutic agent to a patient by disposing the agent in the axial reservoir of the device; and embolizing a body cavity of the patient with the device (claimed).

ADVANTAGE - The invented method can fill aneurysms and other body cavities of a target range of sizes, configurations and neck widths with an occlusive and/or thrombogenic medium with a minimal risk of inadvertent tissue damage, aneurysm rupture or blood vessel wall damage. It also allows for the precise locational deployment of the medium while minimizing the potential for migration away from the target location.

DESCRIPTION OF DRAWING(S) - The figure is an elevational view of a vascular embolization device.

Device(12) Micropellet 10

Spacers 16

Segment 18

Retention member 20

Dwg.1/43

FS CPI GMPI

FA AB; GI

MC CPI: A12-V03D; B11-C04; D09-C04

TECH UPTX: 20040514

TECHNOLOGY FOCUS - INSTRUMENTATION AND TESTING - Preferred Method: The carrier is encapsulated by providing an elongated member of the polymer in a softened state; and skewering the member coaxially with the carrier. The elongated member is provided by inserting the member into a tubular holder such that the member is radially confined and axially restrained in the member. An axial reservoir is formed in the lumen by inserting an elongated mandrel into the lumen of the carrier before its encapsulation; and removing the mandrel from the lumen of the carrier after its encapsulation. The polymer is dehydrated to shrink it by immersing the

device in a hygroscopic medium or by heating the device. It has a rate of hydration in an aqueous medium that is a function of a physical parameter of the medium. The rate of hydration of the polymer is set in response to the parameter and is adjusted by treating the polymer with an acid. The device is immersed for a period of time in an aqueous medium having the physical parameter. The period of time and the physical parameter of the medium are selected to soften the polymer and render it lubricious without expanding it. Preferred Component: The carrier includes an axial, lumen. Preferred Dimension: An unsupported end of a portion of the device deflects downward under the weight of the portion and relative to an opposite, supported end of the portion of 0.75 inches when: the hydrogel is in a dry state and a horizontal distance between the opposite ends of the portion is more than 2.25 inches. The hydrogel is in a moderately hydrated state and the horizontal length is 1.5-2.25 inches and the hydrogel is in a fully hydrated state and the horizontal length is less than 1.5 inches.

L44 ANSWER 3 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 AN 2003-266113 [26] WPIX
 CR 2001-343247 [36]; 2002-691223 [74]; 2004-339065 [31]; 2006-492530 [50]
 DNN N2003-211320
 TI Vascular embolization device manufacturing method involves coaxially encapsulating filamentous carrier in expansile, hydrophilic polymer.
 DC P31 P32
 IN CONSTANT, M; COX, B J; CRUISE, G M; GREENE, G R; TRAN, T
 PA (MICR-N) MICROVENTION INC; (CONS-I) CONSTANT M; (COXB-I) COX B J; (CRUI-I) CRUISE G M; (GREE-I) GREENE G R; (TRAN-I) TRAN T
 CYC 101
 PI US--2002177855 A1 20021128 (200326)* 29 A61F-011-00
 WO---200296302 A1 20021205 (200326) EN A61B-017-12
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
 NL OA PT SD SE SL SZ TR TZ UG ZB ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
 RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW
 EP-----1401338 A1 20040331 (200424) EN A61B-017-12
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI TR
 AU--2002344223 A1 20021209 (200452) A61B-017-12
 JP--2004527342 W 20040909 (200459) 93 A61B-017-12
 US-----7014645 B2 20060321 (200621) A61B-017-03 <--
 ADT US--2002177855 A1 CIP of 1999US-0410970 19991004, CIP of
 2000US-0542145 20000404, CIP of 2001US-0867340 20010529,
 2002US-0157621 20020529; WO---200296302 A1 2002WO-US16873
 20020529; EP-----1401338 A1 2002EP-0752008 20020529, 2002WO-US16873
 20020529; AU--2002344223 A1 2002AU-0344223 20020529; JP--2004527342 W
 2002JP-0592820 20020529, 2002WO-US16873 20020529; US-----7014645 B2
 CIP of 1999US-0410970 19991004, CIP of 2000US-0542145 20000404,
 CIP of 2001US-0867340 20010529, 2002US-0157621 20020529
 FDT US--2002177855 A1 CIP of US-----6238403, CIP of US-----6299619;
 EP-----1401338 A1 Based on WO---200296302; AU--2002344223 A1 Based on
 WO---200296302; JP--2004527342 W Based on WO---200296302; US-----7014645
 B2 CIP of US-----6238403, CIP of US-----6299619, CIP of US-----6602261
 PRAI 2002US-0157621 20020529; 1999US-0410970
 19991004; 2000US-0542145 20000404; 2001US-0867340
 20010529
 IC ICM A61B-017-03; A61B-017-08; A61B-017-12; A61F-011-00
 ICS B29C-070-74

AB US2002177855 A UPAB: 20060804
NOVELTY - The carrier made of thin filament of a suitable polymer is coaxially encapsulated in expansile, hydrophilic polymer such as polyvinyl alcohol (PVA).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

- (1) method for delivering therapeutic agent to patient; and
- (2) embolization device.

USE - For manufacturing vascular embolization device (claimed) used in embolization of vascular aneurysms, during treatment of vascular anomalies, such as arteriovenous malformations and arteriovenous fistulas. Also, used for occlusion of fallopian tubes for sterilization, treating cardiac defects like foramen ovale, ductus arteriosus, left-atrial-appendage and atrial-septal defects.

ADVANTAGE - The embolization device can be placed within the cavity with excellent locational control, lower risk of vascular rupture, tissue damage. Embolizes body cavities having a wide variety of sizes, configurations and neck widths.

Dwg. 0/44

FS GMPI
FA AB

L44 ANSWER 4 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2002-691223 [74] WPIX
CR 2001-343247 [36]; 2003-266113 [26]; 2004-339065 [31]; 2006-492530 [50]
DNN N2002-545343
TI Vascular embolization device has micropellets fixed at spaced intervals to exterior surface of carrier along substantial portion of length of carrier proximally from distal tip.
DC P31 P32
IN CONSTANT, M; COX, B J; CRUISE, G M; GREENE, G R; TRAN, T
PA (MICR-N) MICROVENTION INC; (CONS-I) CONSTANT M; (COXB-I) COX B J; (CRUI-I) CRUISE G M; (GREE-I) GREENE G R; (TRAN-I) TRAN T
CYC 3
PI US--2002120276 A1 20020829 (200274)* 19 A61F-002-06
US-----6602261 B2 20030805 (200353) A61F-011-00 <--
AU--2002344223 A1 20021209 (200452) A61B-017-12
JP--2004527342 W 20040909 (200459) 93 A61B-017-12
ADT US--2002120276 A1 CIP of 1999US-0410970 19991004, CIP of 2000US-0542145 20000404, 2001US-0867340 20010529; US-----6602261 B2 CIP of 1999US-0410970 19991004, CIP of 2000US-0542145 20000404, 2001US-0867340 20010529; AU--2002344223 A1 2002AU-0344223 20020529; JP--2004527342 W 2002JP-0592820 20020529, 2002WO-US16873 20020529
FDT US--2002120276 A1 CIP of US-----6238403; US-----6602261 B2 CIP of US-----6238403, CIP of US-----6299619; AU--2002344223 A1 Based on WO---200296302; JP--2004527342 W Based on WO---200296302
PRAI 2001US-0867340 20010529; 1999US-0410970 19991004; 2000US-0542145 20000404; 2002US-0157621 20020529
IC ICM A61B-017-12; A61F-002-06; A61F-011-00
ICS B29C-070-74
AB US2002120276 A UPAB: 20060804
NOVELTY - The device (10) includes a flexible, filamentous carrier having a distal tip and an exterior surface. Elongated continuous, coaxial micropellets (12) are fixed at spaced intervals to the exterior surface of the carrier along a substantial portion of the length of the carrier proximally from the distal tip.
USE - For embolizing vascular aneurysms and similar vascular abnormalities. Used for controlling vascular bleeding to occlude blood

supply to tumors.

ADVANTAGE - Provides a vascular embolization device which effects a conformal fit within the site that promotes effective embolization. Facilitates precise and highly controllable deployment of the vascular embolization device. Effectively embolizes vascular sites having a wide variety of sizes, configurations and neck widths.

DESCRIPTION OF DRAWING(S) - The figure shows the elevational view of the vascular embolization device.

Vascular embolization device 10

Micropellets 12

Dwg.1/23

FS GMPI

FA AB; GI

L44 ANSWER 5 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2001-489030 [53] WPIX

CR 2001-497158 [54]; 2001-581845 [65]; 2001-625596 [72]

DNN N2001-361798

TI Computer system, includes billing module accessible to the connect server that generates accounting data based on the provision of the content in the database to the users.

DC T01 W01 W02

IN AOKI, K; EUBANKS, G C; YUKIE, S

PA (SONY) SONY CORP AMERICA

CYC 93

PI WO---200159651 A2 20010816 (200153)* EN 22 G06F-017-60

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TR TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AU---200122934 A 20010820 (200175) G06F-011-32

AU---200124578 A 20010820 (200175) G06F-017-60

AU---200126010 A 20010820 (200175) G06F-003-00

AU---200138073 A 20010820 (200175) G06F-017-30

AU--2001222934 A8 20051006 (200612) G06F-011-32

AU--2001238073 A8 20051020 (200615) G06F-017-30

ADT WO---200159651 A2 2000WO-US035297 20001227; AU---200122934 A

2001AU-0022934 20001227; AU---200124578 A 2001AU-0024578 20001227;

AU---200126010 A 2001AU-0026010 20001227; AU---200138073 A 2001AU-0038073

20010207; AU--2001222934 A8 2001AU-0222934 20001227; AU--2001238073 A8

2001AU-0238073 20010207

FDT AU---200122934 A Based on WO---200159572; AU---200124578 A Based on

WO---200159651; AU---200126010 A Based on WO---200159551; AU---200138073 A

Based on WO---200159622; AU--2001222934 A8 Based on WO---200159572;

AU--2001238073 A8 Based on WO---200159622

PRAI 2000US-0542139 20000404; 2000US-180984P 20000208;

2000US-180985P 20000208; 2000US-180987P 20000208;

2000US-180988P 20000208; 2000US-180990P 20000208;

2000US-180991P 20000208; 2000US-180992P 20000208;

2000US-180993P 20000208; 2000US-181105P 20000208;

2000US-181127P 20000208; 2000US-181128P 20000208;

2000US-181129P 20000208; 2000US-181144P 20000208;

2000US-181145P 20000208; 2000US-181147P 20000208;

2000US-181148P 20000208; 2000US-191184P 20000322;

2000US-192264P 20000327; 2000US-0542666 20000404;

2000US-0542154 20000404; 2000US-180998P

20000208; 2000US-0542126 20000404

IC ICM G06F-003-00; G06F-011-32; G06F-017-30; G06F-017-60
 ICS G08B-025-10; H04L-012-18
 AB WO 200159651 A UPAB: 20060302
 NOVELTY - A connect server (26) receives contents requests from a user terminal (32), and accesses a publicly vended content database (14) to fulfill such requests. A billing module (30) accessible to the connect server generates accounting data based on the provision of the content in the database to the users.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a digitized content vending method.

USE - For vending digitized content over an Internet network path.

ADVANTAGE - User can be alerted to events that occur attendant to customized data e.g. when motion is sensed by an in-home security camera, when stock price in a user-customized portfolio reaches a predetermined threshold. User can select one or more channels for immediate display or for display at the time scheduled, thus user can be billed not only based on a song-by-song or program-by-program basis, but on the basis of the subscription services that are essentially defined by the user profile.

DESCRIPTION OF DRAWING(S) - The figure shows the schematic diagram of the computer system.

Publicly vended content database 14

Connect server 26

Billing module 30

User terminal 32

Dwg.1/4

FS EPI

FA AB; GI

MC EPI: T01-J05A

L44 ANSWER 6 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STM
 AN 2001-343247 [36] WPIX
 CR 2002-691223 [74]; 2003-266113 [26]; 2004-339065 [31]; 2006-492530 [50]
 DNN N2001-248588 DNC C2001-106231
 TI Embolization device for, e.g. vascular aneurysm, comprises expandable embolizing micropellet connected to filamentous carrier at fixed location.
 DC A96 P31 P32 P34
 IN COX, B J; GREENE, G R; ROSENBLUTH, R F
 PA (MICR-N) MICROVENTION INC
 CYC 95
 PI WO---200128434 A1 20010426 (200136)* EN 38 A61B-017-12
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
 NL OA PT SD SE SL SZ TZ UG ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
 DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
 LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
 SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
 US-----6238403 B1 20010529 (200138) A61F-011-00 <--
 AU---200077396 A 20010430 (200148) A61B-017-12
 US-----6299619 B1 20011009 (200162) A61F-011-00 <--
 BR---200014482 A 20020611 (200248) A61B-017-12
 EP-----1225836 A1 20020731 (200257) EN A61B-017-12
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI
 CN-----1376041 A 20021023 (200313) A61B-017-12
 JP--2003511188 W 20030325 (200330) 36 A61B-017-12
 AU-----777822 B2 20041104 (200504) A61B-017-12
 AU--2005200324 A1 20050224 (200521) A61B-017-12
 ADT WO---200128434 A1 2000WO-US026926 20000929; US-----6238403 B1
 1999US-0410970 19991004; AU---200077396 A 2000AU-0077396 20000929;

US-----6299619 B1 CIP of 1999US-0410970 19991004, 2000US-0542145
 20000404; BR---200014482 A 2000BR-0014482 20000929, 2000WO-US26926
 20000929; EP-----1225836 A1 2000EP-0967148 20000929, 2000WO-US26926
 20000929; CN-----1376041 A 2000CN-0813238 20000929; JP--2003511188 W
 2000WO-US26926 20000929, 2001JP-0531033 20000929; AU-----777822 B2
 2000AU-0077396 20000929; AU--2005200324 A1 2005AU-0200324 20050127
 FDT AU---200077396 A Based on WO---200128434; BR---200014482 A Based on
 WO---200128434; EP-----1225836 A1 Based on WO---200128434; JP--2003511188
 W Based on WO---200128434; AU-----777822 B2 Previous Publ.
 AU---200077396, Based on WO---200128434; AU--2005200324 A1 Div ex
 AU-----777822
 PRAI 2000US-0542145 20000404; 1999US-0410970
 19991004
 IC ICM A61B-017-12; A61F-011-00
 ICS A61B-017-00; A61L-029-00; A61M-025-00
 AB WO 200128434 A UPAB: 20060804
 NOVELTY - An embolization device comprises an elongate, filamentous
 carrier and an expandable embolizing micropellet non-releasably connected
 to the carrier at a fixed location.
 DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a
 method of embolizing a vascular site comprising passing a microcatheter
 intravascularly so that its distal end is in a vascular site; providing a
 vascular embolization device comprising highly expandable embolizing
 micropellet(s) mechanically connected to a flexible filamentous carrier at
 a fixed location; passing the embolization device through the
 microcatheter so that it emerges from the distal end of the microcatheter
 into the vascular site; and expanding the embolizing micropellet in situ
 to fill the site with the embolizing micropellet(s) and the carrier while
 maintaining the connection between the embolizing micropellet(s) and the
 carrier.
 USE - For embolizing vascular aneurysm and vascular anomalies, e.g.,
 arteriovenous malformations, arteriovenous fistulas.
 ADVANTAGE - The invented device can be deployed within a vascular
 site with excellent locational control and with lower risk of vascular
 rupture, tissue damage, or migration. It effects a conformal fit within
 the site to promote effective embolization and facilitates precise and
 highly controllable deployment through its ability to be delivered to the
 site through a microcatheter.
 DESCRIPTION OF DRAWING(S) - The figure shows a vascular embolization
 device of the invention.
 Embolizing micropellet 12
 Microcoil spacer 16
 Dwg.1/13
 FS CPI GMPI
 FA AB; GI
 MC CPI: A12-V03D
 TECH UPTX: 20010628
 TECHNOLOGY FOCUS - INSTRUMENTATION AND TESTING - Preferred Components: The
 embolizing micropellet (12) which has an initial diameter of not more than
 0.5 mm is expandable to at least 3 mm and to a volume which is at least 25
 times its initial volume. A second embolizing micropellet is mechanically
 connected to the carrier at a fixed location from the first expandable
 embolizing micropellet. A microcoil spacer (16) is on the carrier between
 the first and second expandable embolizing micropellets. The carrier
 includes a thin, flexible metal wire or a thin filament of polymer in a
 multi-looped configuration.
 Preferred Method: Passing the embolization device through the
 microcatheter includes injecting polyethylene glycol as biocompatible,
 non-aqueous fluid through the microcatheter to prevent the hydration of

the embolizing micropellet with the microcatheter. Expanding includes passing saline solution through the microcatheter and into the vascular site.

TECHNOLOGY FOCUS - POLYMERS - Preferred Material: The embolizing micropellet is formed of a hydrophilic hydrogen foam material. The foam material includes a water-swellaable foam matrix formed as a macroporous solid comprising a foam stabilizing agent and a (co)polymer of a free radical polymerizable hydrophilic olefin monomer cross-linked with up to 10 wt.% multiolefin-functional cross-linking agent. The embolizing micropellet is formed of polyvinyl alcohol foam, collagen foam, or poly (2-hydroxyethyl methacrylate).

TECHNOLOGY FOCUS - METALLURGY - Preferred Material: The wire is made of an alloy of nickel and titanium that exhibits good elastic memory properties.

L44 ANSWER 7 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 AN 2000-109895 [10] WPIX
 DNN N2000-084421 DNC C2000-033540
 TI Blocking of tubular cavities such as urinary tract, digestive tract for treating cancer - involves introducing a water absorbing resin having a protective layer of polylactic acid containing ultrafine ferrite or magnetite powder.
 DC A23 A96 B04 D22 E31 P31 P34
 PA (TAKE-I) TAKEUCHI Y
 CYC 1
 PI JP-----11347038 A 19991221 (200010)* 7 A61B-017-12
 ADT JP-----11347038 A 1998JP-0194944 19980605
 PRAI 1998JP-0194944 19980605
 IC ICM A61B-017-12
 ICS A61B-017-36; A61M-031-00; C08J-003-28; C08J-007-06; C08L-071-02
 AB JP 11347038 A UPAB: 20000301
 NOVELTY - A water absorbing resin having a protective layer (12) of polylactic acid containing ultrafine ferrite or magnetite powder is used for blocking peripheral blood circulation in tubular cavities. The resin at the specified space absorbs water and leads to **embolism** of the tubular cavities temporarily. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for the device used for blocking tubular cavities.
 USE - Blocking of tubular cavities such as urinary tract, digestive tract etc is useful for treating cancer. By devitalizing cancer cells, spreading of cancer to other tissues is prevented. Urinary tract blockage is useful at the time of contraception.
 ADVANTAGE - Selective blockage of tubular cavity can be carried out.
 DESCRIPTION OF DRAWING(S) - The figure shows water absorbing resin. (12) Protective layer.
 Dwg.1/4
 FS CPI GMPI
 FA AB; GI; DCN
 MC CPI: A05-E02; A12-V01; B04-C03D; B04-D02; B11-C04A; B14-H01; B14-H01B; B14-P01; D09-C01; E35-U02
 L44 ANSWER 8 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 AN 1999-312417 [26] WPIX
 DNN N1999-233329 DNC C1999-092193
 TI Hemocompatible polymers linked to pharmacological agents.
 DC A96 B04 D22 P34
 IN PLATE, N A; SINANI, V A; UZHINOVA, L D; VALUEV, L I
 PA (TOPE) TOPCHIEV PETROCHEM SYNTHESIS; (TOPE) TOPCHIEV PETROCHEM SYNTHESIS INST

CYC 79

PI WO-----9916475 A2 19990408 (199926)* EN 48 A61L-000-00
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SZ UG ZW
 W: AL AM AU AZ BA BB BG BR BY CA CN CZ EE GE HU ID IL IS JP KE KG KR
 KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK
 SL TJ TM TR TT UA UG UZ VN YU ZW
 AU-----9892788 A 19990423 (199935) A61L-000-00
 US-----5945457 A 19990831 (199942) A01N-001-00
 ADT WO-----9916475 A2 1998WO-IB001622 19981001; AU-----9892788 A
 1998AU-0092788 19981001; US-----5945457 A 1997US-0942571 19971001
 FDT AU-----9892788 A Based on WO-----9916475
 PRAI 1997US-0942571 19971001
 IC ICM A01N-001-00; A61L-000-00
 ICS A01N-001-02
 AB WO 9916475 A UPAB: 20011203

NOVELTY - Hemocompatible composition comprises a polymer containing at least one pharmacological material other than heparin, chemically bonded to a polymer backbone such that the pharmacological material retains its biological properties.

DETAILED DESCRIPTION - Hemocompatible composition containing pharmacological material or materials other than heparin, bonded chemically to a polymer backbone so that the pharmacological material or materials retain its/their biological properties; optionally with incorporation of other pharmacological material or materials into the polymer physically.

INDEPENDENT CLAIMS are also included for:

- (1) preparation of biologically active polymer compositions which retain their activity over a prolonged time period, comprising:
 - (a) functionalising pharmacological material or materials, other than heparin, by reacting with an acyl halide;
 - (b) copolymerising with a monomer or monomers to form a hydrophilic polymer, or grafting onto a hydrophobic or hydrophilic polymer to modify it; and optionally
 - (c) incorporating one or more pharmaceutical materials into the modified polymer physically; and
- (2) a medical device with one or more parts comprising the hemocompatible composition.

MECHANISM OF ACTION - Lysine and adenine favor sorption of profibrinolysin, a precursor of fibrinolysin so that there is a long term clot-dissolving activity. Salicylic acid and adenine derivatives inhibit aggregation of platelets on the surface. The optional irradiation treatment can modify polymers, which are not hemocompatible, so that they become hemocompatible, after incorporation of the pharmacological materials.

USE - The composition is used for implants, medical devices, and parts of complex apparatus coming into direct contact with blood; also for coatings for them. The implants include drug delivery systems; the medical devices include drains for body fluids, heart valves, vascular grafts, tendons, reinforcing meshes, prostheses (e.g., esophageal), or ureter or gastrointestinal segments; complex devices are those which simulate physiological organs, including artificial kidney (blood dialysis), lung (blood oxygenation), heart, and pancreas.

ADVANTAGE - The incorporated pharmacological material retains a high level of activity, and maintains it over long periods, of weeks, months, or even years. This is in contrast to some prior art solutions of the problem.

FS CPI GMPI
 FA AB; DCN

MC CPI: A12-V02; A12-V03; B06-D09; B10-B01B; B10-C03; **B11-C04A**;
B14-F04; D09-C01C; D09-C01D

ABEX UPTX: 19990707

EXAMPLE - A solution of trypsin (300 mg) in NaHCO₃ pH 8 buffer (20 ml) was treated with CH₂=CHCOCl (68.4 mg) at 0degreesC with stirring for 15 minutes, then warmed to room temperature. Acrylamide (2.97 g), N5-methacryloyl-L-lysine (30 mg), and N,N'-methylenebis-acrylamide (150 mg) in water (20 ml) were added, the mix purged with argon, and 0.03 wt.% of NH₄ persulphate and (CH₂NMe₂)₂ added. Polymerisation was for 1 hour. The resultant gel was reduced to small size particles, washed with water and saline, then allowed to swell in blood plasma for 5 hours. This material had a **blood clotting** time of 134 minutes.

TECH UPTX: 19990707

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Components: The pharmacological materials are e.g. L-lysine, adenine, salicylic acid, plasmin, enzymes or their inhibitors, antibiotics, and their combinations.

TECHNOLOGY FOCUS - POLYMERS - Preparation: The acyl halide is acyl chloride. For hydrophobic polymers, it may be necessary to irradiate the polymer before graft polymerisation with the pharmacological material or materials; the radiation dose should be sufficient to result in a graft copolymer having at least 25 weight-% of the substrate polymer grafted, but not enough to cause appreciable polymer degradation. Optionally, the materials may be hydrophilic on one surface and hydrophobic on the other.

L44 ANSWER 9 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1999-263186 [22] WPIX

CR 1997-178903 [16]

DNN N1999-196012 DNC C1999-077544

TI Improved **embolic** materials for occlusion of vascular elements and fallopian tubes by injection.

DC A18 A25 **A96** B04 D22 P32

IN GUGLIELMI, G; JI, C

PA (REGC) UNIV CALIFORNIA

CYC 1

PI US-----5894022 A 19990413 (199922)* 9 A61F-013-00

ADT US-----5894022 A CIP of 1995US-0519738 19950828, 1997US-0946608 19971007

PRAI 1997US-0946608 19971007; 1995US-0519738 19950828

IC ICM A61F-013-00

ICS A61K-009-14

AB US 5894022 A UPAB: 19990609

NOVELTY - Improved **embolic** materials for occlusion of vascular elements and fallopian tubes by injection comprise semi-solid/semi-liquid material in which a matrix base is insolubilized to entrap aqueous solution and liquid oil base.

ACTIVITY - **Embolic**.

USE - Used for endovascular occlusion of vasculature and fallopian tubes (claimed). Used for **embolization** in abnormal microvasculature beds or nidi. Used to administer hemostatics, positive electrical charge donators, sclerotic agents, anticarcinogens, radioactive agents.

ADVANTAGE - Permanently occludes the **embolized** vasculature. Prepared from aqueous solution and liquid oil, allowing inclusion of water-soluble and liposoluble medicaments as well as liposoluble modifiers (phospholipids), water-soluble modifiers (polyethylene glycol) and stabilizing agents (ascorbic acid, tocopherol) to modify the physical properties of the composition and/or protect the added medicaments. May include sclerosant to encourage formation of scar tissue in occluded lumens (claimed) e.g. tetracycline. Inclusion of radioactive agents allows

monitoring of administration by the physician. Frictional characteristics are reduced facilitating injection of the material through e.g. hollow needles and catheters. Inclusion of semi-solid particles or multipurpose particles (MPP), which are soft and flexible with excellent deformability, allows easy access into **embolizing** vascular beds or nidi and more complete **embolization** than prior art. In addition, MPP are radio-opaque and easily visible under fluoroscopic monitoring, avoiding pulmonary **embolism** and infarction, and iatrogenic or physician-induced complication or transcatheter **embolization**. The MPP slowly release included medications at the site of **embolization** to reach the highest local effects without significant systemic disturbance. Ten swine (mixed sex; 50-60 lb) were used for an in vivo test of multipurpose ointment containing sclerosing agents tetracycline and doxycycline (MPO1) compared with generic composition without sclerosing agents (MPO). Animals 1-6 underwent **embolization** of rete and ascending cervical artery using the test composition, animals 7-8 underwent **embolization** of lung and rete with test composition using MPO1 and the ascending cervical artery with MOP, and animals 9-10 underwent bilateral rete **embolization** with polyvinyl alcohol (PVA) particles as control. Angiography was performed just before and just after **embolization** and followed up at 1- and 2-week and 1-, 2-, 3-, and 6-month intervals. Animal 1 was sacrificed on day 1, animal 2 at 2 weeks following **embolization**, animals 2, 3, 4 and 7 at 2 months, animal 8 at 3 months and animals 5, 6, 9, and 10 at 6 months. All **embolized** vessels and lungs were harvested for pathology and spleen and lymph node samples collected for histology. All other organs were subjected to gross examination. No recanalization was found by angiography for up to 6 months in the MPO1 group, but occurred in all conventional PVA **embolized** retes. The degree of feeding artery reopening was 20-80% and tended to increase over time. After the main feeder pharyngeal artery and rete was **embolized** with MPO, immediate post-**embolization** angiographies showed 20-35% of the rete microvasculatures remained patent or unembolized. In MPO1-treated animals, only 0-10% of the rete remained open. Follow-up angiographies of the MOP group showed the middle meningeal branch enlarged with time and its feeding portion of the rete extended into the previously **embolized** organs. The percentage of patent vessels in the rete increased to 50-70%. In the MPO1 group, no change or very small changes in size of the collateral branch and its domain were seen.

Dwg.0/0

FS CPI GMPI

FA AB

MC CPI: A05-H03; A10-E09B2; A12-V01; **B11-C04**; B11-C09; D09-C01

ABEX UPTX: 19990609

ADMINISTRATION - Administration is by injection (claimed).

TECH UPTX: 19990609

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred materials - The liquid oil base is radio-opaque. The materials further comprise sclerosant to encourage formation of scar tissue in the occluded lumens. The semi-solid/semi-liquid material comprises water-insoluble microscopic mesh of fibrin to entrap the aqueous solution and the liquid oil.

L44 ANSWER 10 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1998-341094 [30] WPIX

DNN N1998-267239 DNC C1998-104970

TI **Embolic** material - comprises biocompatible and absorbable collagen having shape restoring property when absorbing water.

DC A96 B04 D22 P31 P34

PA (KOKE) KOKEN KK

CYC 1
 PI JP-----10127754 A 19980519 (199830)* 5 A61L-027-00
 ADT JP-----10127754 A 1996JP-0293706 19961106
 PRAI 1996JP-0293706 19961106
 IC ICM A61L-027-00
 ICS A61B-017-12; A61K-038-17
 ICA A61K-049-04
 AB JP 10127754 A UPAB: 19980730

Embolic material comprises a biocompatible and absorbable collagen having shape restoring property when absorbing water.

The original form of the **embolic** material is preferably a stick, coil, sponge or granules. The material is crosslinked. The material also contains X-ray contrast medium. The material is obtained by adding or penetrating a softening agent (especially glycerol) to a moulding.

ADVANTAGE - The **embolic** material disappears after vascular obturation, so extraction of the material is not required. The material promotes **embolisation** and leads to an early cure.

Dwg.0/0

FS CPI GMPI

FA AB

MC CPI: A03-C01; A12-V; A12-V01; B04-N02; B10-E04C; **B11-C04**;
 B14-F08; D09-C

L44 ANSWER 11 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN **1998-130442** [12] WPIX

CR 1998-130379 [12]

DNN N1998-102957 DNC C1998-043080

TI Treating aneurysm - by introducing **embolic** material permitting tissue ingrowth, material being expandable from small volume on introduction to larger volume on contact with blood.

DC A14 A25 A26 **A96** B07 P34

IN GREFF, R J; JONES, M L

PA (MICR-N) MICRO THERAPEUTICS INC

CYC 77

PI WO-----9804315 A1 19980205 (199812)* EN 19 A61M-029-00

RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT
 SD SE SZ UG ZW

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
 GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW
 MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU
 ZW

AU-----9735772 A 19980220 (199828) A61M-029-00

ADT WO-----9804315 A1 1997WO-US011003 19970618; AU-----9735772 A

1997AU-0035772 19970618

FDT AU-----9735772 A Based on WO-----9804315

PRAI 1996US-0690075 19960731

IC ICM A61M-029-00

AB WO 9804315 A UPAB: 19980323

An expandable plug (40) is used to treat a vascular aneurysm. It consists of a biocompatible material which is expandable from a first constrained volume to a second larger volume. A blood soluble agent is in contact with the expandable material to hold it in the constrained volume until contacted by blood. Also claimed is a method of delivering the expandable plug using an elongate, flexible delivery device (29), the plug in its constrained state being secured to its distal end. The plug is advanced to the treatment site where it is exposed to blood causing the material to expand.

The plug may consist of an open cell structure foam, to which cells may bind to stimulate **embolisation** and **thrombosis**.

Open cell foam is preferred. Suitable materials include cross-linked polyvinyl alcohol (PVA), polyurethane foam, polyethylene foam, silicone foams or fluorinated polyolefin foams. The plug may be attached to insertion wire (29) in various ways.

USE - The plug is inserted into an aneurysmal sac to promote **thrombus** formation to treat the aneurysm.

ADVANTAGE - The treatment minimises any interference with blood flow, can be used to treat aneurysms in small diameter vessels, and located on either straight or curved portions of the vessel. It uses the body's own healing processes to treat the aneurysm.

Dwg.6A/8

FS CPI GMPI
FA AB; GI
MC CPI: A12-V03D; B11-C04; B14-F02; B14-H01

L44 ANSWER 12 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1998-130379 [12] WPIX

CR 1998-130442 [12]

DNN N1998-102921 DNC C1998-043040

TI Expandable plug for treating aneurysm - comprises blood soluble agent in contact with expandable biocompatible material.

DC A96 B07 P31

IN GREFF, R J; JONES, M L

PA (MICR-N) MICRO THERAPEUTICS INC

CYC 76

PI WO-----9804198 A1 19980205 (199812)* EN 28 A61B-017-12

RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT
SD SE SZ UG ZW

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX
NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AU-----9736620 A 19980220 (199828) A61B-017-12

US-----5823198 A 19981020 (199849) A61B-019-00

ADT WO-----9804198 A1 1997WO-US012221 19970721; AU-----9736620 A
1997AU-0036620 19970721; US-----5823198 A 1996US-0690075 19960731

FDT AU-----9736620 A Based on WO-----9804198

PRAI 1996US-0690075 19960731

IC ICM A61B-017-12; A61B-019-00

AB WO 9804198 A UPAB: 19980323

Expandable plug (40) used to treat a vascular aneurysm comprises a biocompatible material which is expandable from a first constrained volume to a second larger volume. A blood soluble agent is in contact with the expandable material to hold it in the constrained volume until contacted by blood. Also claimed is a method of delivering the expandable plug using an elongate, flexible delivery device (29), the plug in its constrained state being secured to its distal end. The plug is advanced to the treatment site where it is exposed to blood causing the material to expand.

The plug preferably comprises an open cell structure foam, to which cells may bind to stimulate **embolisation** and **thrombosis**

. Open cell foam is preferred. Suitable materials include cross-linked polyvinyl alcohol (PVA), polyurethane foam, polyethylene foam, silicone foams or fluorinated polyolefin foams. The plug may be attached to insertion wire (29) in various ways.

USE - The plug is inserted into an aneurysmal sac to promote **thrombus** formation to treat the aneurysm.

ADVANTAGE - The treatment minimises any interference with blood flow, can be used to treat aneurysms in small diameter vessels, and located on either straight or curved portions of the vessel. It uses the body's own

healing processes to treat the aneurysm.

Dwg. 6A/8

FS CPI GMPI

FA AB; GI; DCN

MC CPI: **A12-V03D**; B04-C03B; **B11-C04**; B14-F02; B14-H01

L44 ANSWER 13 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN **1994-341506** [42] WPIX

DNN N1994-267899 DNC C1994-155535

TI Improving biocompatibility and protein binding resistance - of medical or laboratory appts., by forming hydrated polymer coating using aqueous solution of

poly isocyanate-capped oxyethylene prepolymer..

DC A25 **A96** B04 B07 D16 G02 J04 P34

IN BRAATZ, J A; CURTIN, C; CUSTER, L M; GUNTHER, V J; HEIFETZ, A H; OKKEMA, A T

PA (GRAC) GRACE & CO-CONN W R

CYC 44

PI WO-----9423771 A1 19941027 (199442)* EN 48 A61L-033-00

RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

W: AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU

LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA UZ

AU-----9463670 A 19941108 (199507) A61L-033-00

ADT WO-----9423771 A1 1994WO-US002893 19940318; AU-----9463670 A

1994AU-0063670 19940318

FDT AU-----9463670 A Based on WO-----9423771

PRAI 1993US-0046116 19930409

REP EP-----335308; EP-----355687; EP-----502591

IC ICM A61L-033-00

ICS A61L-027-00; A61L-029-00

AB WO 9423771 A UPAB: 19941212

The biocompatibility and resistance protein binding of medical or laboratory devices are increased by: (a) forming an aqueous solution of a prepolymer (I) in which at least 75% of the units consist of oxyethylene-based diols or polyols having mol. weight 7000-30000, (almost) all of the OH gps. of the diols or polyols being capped with polyisocyanates; (b) depositing the (I) solution on at least part of the device; and (c) forming a hydrated polymer coating on the device. Polymer-coated medical or laboratory devices obtd. by the process are claimed, as are haemoperfusion systems including the coated devices.

USE - The device is specifically particulate silica or charcoal, a filter or tubing (all claimed). Typically the device is tubing for use in medical devices or procedures requiring contact with blood, other protein-containing fluids or tissue, e.g. kidney dialysis or haemoperfusion appts., artificial organs or catheters. Other applications include laboratory appts., e.g. (diagnostic) assay plates, cell culture appts., blood cell storage bags, filters and appts. for mfr. and packing or pharmaceuticals or for isolation and purificn. of proteins. Coated silica or charcoal particles are used e.g. for removing toxic protein contaminants or drugs from blood; or in separation of proteins by size exclusion chromatography. Materials to be coated are e.g. glass, polystyrene, silicone, 'Teflon' (RTM), rubber, metal, wood, cloth, PVC, nylon or inorganic materials (e.g. silica gel or charcoal).

ADVANTAGE - The coatings are hydrophilic, transparent, biocompatible and non-toxic. They have long life and good resistance to protein absorption (which can cause occlusion or clogging of polymers, clouding, contamination, assay interference, irritation to adjacent body tissues, loss of tissue or body fluid protein by irreversible adsorption of denaturation, or (in blood) **thrombogenesis**, complement

activation or calcium deposition). The coatings, in dense or thin (e.g. monomolecular) form, are prepared by in situ crosslinking with water, without use of organic solvents and consequent toxicity risks.

Dwg. 0/0

FS CPI GMPI

FA AB; DCN

MC CPI: A10-E24; A11-B05D; A12-L04; **A12-V03D**; B04-C03C; B04-C03D;
B04-N02; B05-B02C; B05-C06; **B11-C04**; B11-C06; B12-K04A;
B12-M04; D05-H; G02-A05; J01-D01A